
<html lang="en"     class="pb-page"  data-request-id="bc59c7ee-a506-499c-998d-3d84c1b6f896"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/jm201758g;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2012.55.issue-6"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Synthesis and Biological Evaluation of Pyrimidine-Based Dual Inhibitors of Human Epidermal Growth Factor Receptor 1 (HER-1) and HER-2 Tyrosine Kinases" /></meta><meta name="dc.Creator" content="Mi Young  Cha" /></meta><meta name="dc.Creator" content="Kwang-Ok  Lee" /></meta><meta name="dc.Creator" content="Seok-Jong  Kang" /></meta><meta name="dc.Creator" content="Young Hee  Jung" /></meta><meta name="dc.Creator" content="Ji Yeon  Song" /></meta><meta name="dc.Creator" content="Kyung Jin  Choi" /></meta><meta name="dc.Creator" content="Joo Yun  Byun" /></meta><meta name="dc.Creator" content="Han-Jae  Lee" /></meta><meta name="dc.Creator" content="Gwan Sun  Lee" /></meta><meta name="dc.Creator" content="Seung Bum  Park" /></meta><meta name="dc.Creator" content="Maeng Sup  Kim" /></meta><meta name="dc.Description" content="A novel series of N4-(3-chlorophenyl)-5-(oxazol-2-yl)pyrimidine-4,6-diamines were synthesized and evaluated as dual inhibitors of HER-1/HER-2 tyrosine kinases. In contrast to the currently approved..." /></meta><meta name="Description" content="A novel series of N4-(3-chlorophenyl)-5-(oxazol-2-yl)pyrimidine-4,6-diamines were synthesized and evaluated as dual inhibitors of HER-1/HER-2 tyrosine kinases. In contrast to the currently approved..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 9, 2012" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm201758g" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm201758g" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm201758g" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm201758g" /></link>
        
    
    

<title>Synthesis and Biological Evaluation of Pyrimidine-Based Dual Inhibitors of Human Epidermal Growth Factor Receptor 1 (HER-1) and HER-2 Tyrosine Kinases | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm201758g" /></meta><meta property="og:title" content="Synthesis and Biological Evaluation of Pyrimidine-Based Dual Inhibitors of Human Epidermal Growth Factor Receptor 1 (HER-1) and HER-2 Tyrosine Kinases" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0014.jpeg" /></meta><meta property="og:description" content="A novel series of N4-(3-chlorophenyl)-5-(oxazol-2-yl)pyrimidine-4,6-diamines were synthesized and evaluated as dual inhibitors of HER-1/HER-2 tyrosine kinases. In contrast to the currently approved HER-2-targeted agent (lapatinib, 1), our irreversible HER-1/HER-2 inhibitors have the potential to overcome the clinically relevant and mutation-induced drug resistance. The selected compound (19a) showed excellent inhibitory activity toward HER-1/HER-2 tyrosine kinases with selectivity over 20 other kinases and inhibited the proliferation of both cancer cell types: lapatinib-sensitive cell lines (SK-Br3, MDA-MB-175, and N87) and lapatinib-resistant cell lines (MDA-MB-453, H1781, and H1975). The excellent pharmacokinetic profiles of 19a in mice and rats led us to further investigation of a novel therapeutic agent for HER-2-targeting treatment of solid tumors, especially HER-2-positive breast/gastric cancer and HER-2-mutated lung cancer." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm201758g"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm201758g">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm201758g&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm201758g&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm201758g&amp;href=/doi/10.1021/jm201758g" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 2846-2857</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm201751x" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm2017122" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthesis and Biological Evaluation of Pyrimidine-Based Dual Inhibitors of Human Epidermal Growth Factor Receptor 1 (HER-1) and HER-2 Tyrosine Kinases</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mi+Young++Cha">Mi Young Cha</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kwang-Ok++Lee">Kwang-Ok Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Seok-Jong++Kang">Seok-Jong Kang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Young+Hee++Jung">Young Hee Jung</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ji+Yeon++Song">Ji Yeon Song</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kyung+Jin++Choi">Kyung Jin Choi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joo+Yun++Byun">Joo Yun Byun</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Han-Jae++Lee">Han-Jae Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gwan+Sun++Lee">Gwan Sun Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Seung+Bum++Park">Seung Bum Park</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maeng+Sup++Kim">Maeng Sup Kim</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Department of Drug Discovery, Hanmi Research Center, 377-1 Yeongcheon-ri, Dongtan-myeon, Hwaseong, Gyeonggi-do 445-813, Korea</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Department of Chemistry, Seoul National University, Seoul 151-747, Korea</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Department of Biophysics and Chemical Biology/Bio-MAX Institute, Seoul National University, Seoul 151-747, Korea</span></div><div class="corresp-info"><strong>*</strong>For S.B.P.: phone, +82-2-880-9090; fax, +82-2-884-4025; e-mail, <a href="/cdn-cgi/l/email-protection#c4b7a6b4a5b6af84b7aab1eaa5a7eaafb6"><span class="__cf_email__" data-cfemail="b0c3d2c0d1c2dbf0c3dec59ed1d39edbc2">[email protected]</span></a>. For M.S.K.; phone, +82-31-371-5001; fax, +82-31-371-5006; e-mail, <a href="/cdn-cgi/l/email-protection#385351554b785059565551165b5716534a"><span class="__cf_email__" data-cfemail="1e7577736d5e767f707377307d7130756c">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm201758g&amp;href=/doi/10.1021%2Fjm201758g" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 2846–2857</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 28, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 December 2011</li><li><span class="item_label"><b>Published</b> online</span>9 March 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 March 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm201758g" title="DOI URL">https://doi.org/10.1021/jm201758g</a></div><div class="article_header-article-copyright"><strong>Copyright © 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2846%26pageCount%3D12%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMi%2BYoung%2BCha%252C%2BKwang-Ok%2BLee%252C%2BSeok-Jong%2BKang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D6%26contentID%3Djm201758g%26title%3DSynthesis%2Band%2BBiological%2BEvaluation%2Bof%2BPyrimidine-Based%2BDual%2BInhibitors%2Bof%2BHuman%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2B1%2B%2528HER-1%2529%2Band%2BHER-2%2BTyrosine%2BKinases%26numPages%3D12%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2857%26publicationDate%3DMarch%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm201758g"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2557</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">23</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm201758g" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthesis and Biological Evaluation of Pyrimidine-Based Dual Inhibitors of Human Epidermal Growth Factor Receptor 1 (HER-1) and HER-2 Tyrosine Kinases&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Mi&quot;,&quot;last_name&quot;:&quot;Young Cha&quot;},{&quot;first_name&quot;:&quot;Kwang-Ok&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Seok-Jong&quot;,&quot;last_name&quot;:&quot;Kang&quot;},{&quot;first_name&quot;:&quot;Young&quot;,&quot;last_name&quot;:&quot;Hee Jung&quot;},{&quot;first_name&quot;:&quot;Ji&quot;,&quot;last_name&quot;:&quot;Yeon Song&quot;},{&quot;first_name&quot;:&quot;Kyung&quot;,&quot;last_name&quot;:&quot;Jin Choi&quot;},{&quot;first_name&quot;:&quot;Joo&quot;,&quot;last_name&quot;:&quot;Yun Byun&quot;},{&quot;first_name&quot;:&quot;Han-Jae&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Gwan&quot;,&quot;last_name&quot;:&quot;Sun Lee&quot;},{&quot;first_name&quot;:&quot;Seung&quot;,&quot;last_name&quot;:&quot;Bum Park&quot;},{&quot;first_name&quot;:&quot;Maeng&quot;,&quot;last_name&quot;:&quot;Sup Kim&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;2846-2857&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm201758g&quot;},&quot;abstract&quot;:&quot;A novel series of N4-(3-chlorophenyl)-5-(oxazol-2-yl)pyrimidine-4,6-diamines were synthesized and evaluated as dual inhibitors of HER-1/HER-2 tyrosine kinases. In contrast to the currently approved HER-2-targeted agent (lapatinib, 1), our irreversible HER-1/HER-2 inhibitors have the potential to overcome the clinically relevant and mutation-induced drug resistance. The selected compound (19a) showed excellent inhibitory activity toward HER-1/HER-2 tyrosine kinases with selectivity over 20 other kinases and inhibited the proliferation of both cancer cell types: lapatinib-sensitive cell lines (SK-Br3, MDA-MB-175, and N87) and lapatinib-resistant cell lines (MDA-MB-453, H1781, and H1975). The excellent pharmacokinetic profiles of 19a in mice and rats led us to further investigation of a novel therapeutic agent for HER-2-targeting treatment of solid tumors, especially HER-2-positive breast/gastric cancer and HER-2-mutated lung cancer.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201758g&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201758g" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201758g&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201758g" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201758g&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201758g" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm201758g&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201758g&amp;href=/doi/10.1021/jm201758g" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm201758g" /></input><a href="/doi/pdf/10.1021/jm201758g" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm201758g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm201758g%26sid%3Dliteratum%253Aachs%26pmid%3D22372864%26genre%3Darticle%26aulast%3DCha%26date%3D2012%26atitle%3DSynthesis%2Band%2BBiological%2BEvaluation%2Bof%2BPyrimidine-Based%2BDual%2BInhibitors%2Bof%2BHuman%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2B1%2B%2528HER-1%2529%2Band%2BHER-2%2BTyrosine%2BKinases%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D6%26spage%3D2846%26epage%3D2857%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jmcmar.2012.55.issue-6/production/jmcmar.2012.55.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/medium/jm-2011-01758g_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201758g&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A novel series of <i>N</i><sup>4</sup>-(3-chlorophenyl)-5-(oxazol-2-yl)pyrimidine-4,6-diamines were synthesized and evaluated as dual inhibitors of HER-1/HER-2 tyrosine kinases. In contrast to the currently approved HER-2-targeted agent (lapatinib, <b>1</b>), our irreversible HER-1/HER-2 inhibitors have the potential to overcome the clinically relevant and mutation-induced drug resistance. The selected compound (<b>19a</b>) showed excellent inhibitory activity toward HER-1/HER-2 tyrosine kinases with selectivity over 20 other kinases and inhibited the proliferation of both cancer cell types: lapatinib-sensitive cell lines (SK-Br3, MDA-MB-175, and N87) and lapatinib-resistant cell lines (MDA-MB-453, H1781, and H1975). The excellent pharmacokinetic profiles of <b>19a</b> in mice and rats led us to further investigation of a novel therapeutic agent for HER-2-targeting treatment of solid tumors, especially HER-2-positive breast/gastric cancer and HER-2-mutated lung cancer.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11806" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11806" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">HER-2 is a transmembrane oncoprotein encoded by the <i>Her-2/neu</i> gene and is a member of HER/ErbB/EGFR tyrosine kinases family, which is composed of HER-1 (ErbB-1, EGFR), HER-2 (neu, ErbB-2), HER-3 (ErbB-3), and HER-4 (ErbB-4). The signaling cascade of EGFRs plays a crucial role in regulation of cell proliferation and differentiation in many tissue types, and the dysregulation of EGFR signaling pathway may contribute to malignant transformation.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> In particular, HER-2 is overexpressed in 20–25% of breast or gastric cancer, which is associated with poor prognosis.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> Therefore, HER-2 has been recognized as a therapeutic target with good clinical outcomes.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> For example, trastuzumab<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> (a humanized monoclonal antibody targeting the extracellular domain of HER-2) was approved for HER-2-positive metastatic breast cancer and gastric cancer by U.S. Food and Drug Administration (FDA). Lapatinib<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> (reversible small-molecule tyrosine kinase inhibitor of HER-1 and HER-2) was also approved for HER-2-positive metastatic breast cancer. Even though these therapeutic agents are effective for patients with HER-2-positive breast or gastric cancer, trastuzumab has potential cardiotoxicity when combined with chemotherapy (especially with anthracyclines) and lapatinib did not show the overall survival advantage in metastatic breast cancer.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> In addition, the intrinsic or acquired resistance against trastuzumab or lapatinib has been an important issue in HER-2-targeted cancer therapy.<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13-15)</a></div><div class="NLM_p">As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>, several small-molecule inhibitors of HER-2 tyrosine kinases have been developed.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a> The first HER-2-targeting small-molecule agent is lapatinib (<b>1</b>), the quinazoline-based HER-1/HER-2 dual inhibitor. Since HER-2 tyrosine kinase binds either HER-1 or HER-2 tyrosine kinases to form a hetero- or homodimer for the signal transduction of EGFR signal cascade, HER-1/HER-2 dual inhibition can be more effective than just HER-1 or HER-2 inhibition.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The next class includes the irreversible EGFR inhibitors cyanoquinoline-based pelitinib (<b>2</b>) and quinazoline-based afatinib (<b>3</b>).<a onclick="showRef(event, 'ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20">(18-20)</a> Among these HER-2 inhibitors, we focused on irreversible EGFR inhibitors because of their interesting mode of action; both HER-1 and HER-2 tyrosine kinases were inhibited by the irreversible modification of a Cys residue (Cys773 of HER-1 and Cys805 of HER-2) at their active sites. Their strong inhibitory activity toward both HER-1 and HER-2 and the unique mode of action can provide the potential to overcome the limited efficacy of current HER-2-targeted therapy. Therefore, we designed new HER-2-targeting small-molecule inhibitors with a distinct scaffold for improved antitumor efficacy to address the limited activity profile of the currently approved HER-2-targeting small molecular therapy, lapatinib.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/medium/jm-2011-01758g_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative inhibitors of HER-2 tyrosine kinase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201758g&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07813" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07813" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Chemical Design</h3><div class="NLM_p">To overcome the drug resistance and the limited activity of the current anti-HER-2 therapy, we pursued the discovery of novel HER-1/HER-2-targeting therapeutic agents with enhanced potency. We selected pyrimidine as a novel core skeleton, inspired by quinazoline- or cyanoquinoline-based irreversible EGFR inhibitors (<b>2</b>, <b>3</b>, and their general molecular framework <b>4</b> shown in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). According to previous reports,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> N1 and N3 (if Z = N; quinazoline) or 3-carbonitrile (if Z = C–CN; cyanoquinoline) in the molecular framework <b>4</b> is essential for the critical hydrogen bonding interaction with Met769 and Thr766 (or Thr830) of EGFR, respectively. In addition, the introduction of substituents at the C8 position of compound <b>4</b> resulted in the loss of EGFR inhibitory activity.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> In contrast, the aniline moiety at the C4 position of compound <b>4</b> is essential to achieve bioactive conformation. Bulky substituents such as pyridin-2-ylmethoxy or substituted benzyloxy moiety, as shown in <b>1</b>, at the R<sup>1</sup> position increase HER-2 inhibition, and small electron-withdrawing lipophilic groups such as chloride or fluoride at the R<sup>2</sup> position increase HER-1 and HER-2 inhibitory activity. On the basis of this structure–activity relationship (SAR) information, we designed pyrimidine-based analogues <b>5</b> with an <i>N</i>-acryloyl moiety at the C5 position and bulky aniline moiety at the C4 position to secure irreversible HER-2 inhibitory activity. Herein, we report the identification of <i>N</i><sup>4</sup>-(3-chlorophenyl)-5-(oxazol-2-yl)pyrimidine-4,6-diamines with <i>N</i>-acryloyl moiety as potential candidates and compound <b>19a</b> as a novel HER-1/HER-2 dual inhibitor for HER-2-targeting anticancer therapy.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/medium/jm-2011-01758g_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of novel HER-1/HER-2 dual inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201758g&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Selection of Active Scaffold</h3><div class="NLM_p">The modification at the X position of compound <b>5</b> provides the important element that can influence the orientation of <i>N</i>-acryloyl group as a Michael acceptor for the alkylation to desired cysteine residues. Therefore, we synthesized a series of <i>N</i>-4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)pyrimidin-5-linked acrylamide analogues <b>10a</b>–<b>d</b> to introduce various moieties at the X position of pyrimidine scaffold as an irreversible HER-1/HER-2 dual inhibitor. As shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>, the synthesis of analogues <b>10a</b>–<b>c</b> was initiated using 4(3<i>H</i>)-pyrimidinone <b>6</b> treated with <i>N-</i>iodosuccinimide at 100 °C in acetic acid to yield 5-iodopyrimidin-4(3<i>H</i>)-one <b>7</b>. The resulting compound <b>7</b> was chlorinated with phosphorus oxychloride under reflux conditions and subjected to substitution with aniline <b>8</b> in refluxing 2-propanol to yield <i>N</i>-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-5-iodopyrimidin-4-amine <b>9</b> as a key intermediate. This intermediate <b>9</b> was reacted with <i>N</i>-Boc-propargylamine under Sonogashira coupling conditions in the presence of bis(triphenylphosphine)palladium(II) dichloride and copper(I) iodide. Subsequently, the Boc group was removed upon treatment with 30% trifluoroacetic acid in dichloromethane, followed by amide coupling with acryloyl chloride in the presence of sodium bicarbonate at 0 °C to yield propargyl analogue <b>10a</b>. Phenyl analogue <b>10b</b> was synthesized through Suzuki coupling reaction of the key intermediate <b>9</b> with 3-aminophenylboronic acid in the presence of palladium(II) acetate, followed by N-acryloylation. For the preparation of isoxazolylmethyl analogue <b>10c</b>, the key intermediate <b>9</b> was treated with trimethylsilyl (TMS) acetylene under the identical Sonogashira coupling conditions used above. The desired analogue <b>10c</b> was synthesized through a series of reactions including TMS deprotection using tetrabutylammonium fluoride (TBAF), 1,3-dipolar cycloaddition with 2-(1,3-dioxoisoindolin-2-yl)-<i>N</i>-hydroxyacetimidoyl chloride, phthalimide deprotection using hydrazine, and subsequent N-acryloylation.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/medium/jm-2011-01758g_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201758g&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) <i>N</i>-iodosuccinimide, AcOH, 100 °C; (ii) (a) POCl<sub>3</sub>, reflux, (b) <b>8</b>, 2-propanol, reflux; (iii) (a) <i>N</i>-Boc-propargylamine, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, CuI, TEA, THF, rt; (b) TFA, DCM, rt; (c) acryloyl chloride, NaHCO<sub>3</sub>, aq THF (THF/H<sub>2</sub>O = 5:1), 0 °C; (iv) (a) 3-aminophenylboronic acid, Pd(OAc)<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, MeOH, 70 °C; (b) acryloyl chloride, NaHCO<sub>3</sub>, aq THF (THF/H<sub>2</sub>O = 5:1), 0 °C; (v) (a) trimethylsilyl acetylene, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, CuI, TEA, THF, rt; (b) TBAF, THF, 0 °C; (c) 2-(1,3-dioxoisoindolin-2-yl)-<i>N</i>-hydroxyacetimidoyl chloride, TEA, THF, reflux; (d) hydrazine monohydrate, EtOH, 65 °C; (e) acryloyl chloride, NaHCO<sub>3</sub>, aq THF (THF/H<sub>2</sub>O = 5:1), 0 °C.</p></p></figure><div class="NLM_p">For the synthesis of oxazolylmethyl analogue <b>10d</b>, ethyl 4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)pyrimidine-5-carboxylate (<b>12</b>) was prepared by condensation of diethyl ethoxymethylenemalonate (<b>11</b>) with formamidine, chlorination using thionyl chloride and phosphorus oxychloride in the presence of diisopropylethylamine, and substitution with aniline <b>8</b> in the refluxing 2-propanol (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). Then the resulting ethyl carboxylate <b>12</b> was hydrolyzed in 2 N sodium hydroxide aqueous solution and coupled with <span class="smallcaps smallerCapital">dl</span>-serine methyl ester using EDCI and HOBt to provide β-hydroxyamide <b>13</b>, which was converted to oxazole <b>14</b> via the mild cyclodehydration reaction using diethylaminosulfur trifluoride (DAST) and oxidation using bromotrichloromethane and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). Finally, oxazolylmethyl analogue <b>10d</b> was prepared by the reduction of methyl ester of oxazole <b>14</b>, substitution of hydroxyl group to azide, Staudinger reduction of azide to amine, and subsequent N-acryloylation.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/medium/jm-2011-01758g_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201758g&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) (a) formamidine hydrochloride, 160 °C; (b) POCl<sub>3</sub>, SOCl<sub>2</sub>, DIPEA, reflux; (c) <b>8</b>, 2-propanol, reflux; (ii) (a) 2 N NaOH aq solution, EtOH, 80 °C; (b) <span class="smallcaps smallerCapital">dl</span>-serine methyl ester hydrochloride, EDCI, HOBt, DIPEA, DMF, rt; (iii) (a) DAST, DCM, −78 to 0 °C; (b) DBU, CBrCl<sub>3</sub>, DCM, −40 °C to rt; (ix) (a) LAH, THF, 0 °C; (b) NaN<sub>3</sub>, PPh<sub>3</sub>, DMF/CCl<sub>4</sub> (4:1), 90 °C; (c) PPh<sub>3</sub>, H<sub>2</sub>O, THF, 60 °C; (d) acryloyl chloride, NaHCO<sub>3</sub>, aq THF (THF/H<sub>2</sub>O = 5:1), 0 °C.</p></p></figure><div class="NLM_p">All synthesized analogues <b>10a</b>–<b>d</b> were initially tested for their ability to inhibit cellular proliferation in two representative HER-1 and HER-2-positive cell lines: A431 (HER-1-overexpressing human vaginal epidermoid cancer cell line)<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and SK-Br3 (HER-2-overexpressing human breast cancer cell line).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, analogues containing <i>N</i>-acryloyl moiety with phenyl group (<b>10b</b>, IC<sub>50</sub> = 6.1 nM) or oxazolylmethyl group (<b>10d</b>, IC<sub>50</sub> = 9.7 nM) at the C5 position of pyrimidine showed stronger growth inhibition potency in SK-Br3 cell-based proliferation assay, compared to analogues with propargyl group (<b>10a</b>, IC<sub>50</sub> > 1000 nM) or isoxazolylmethyl group (<b>10c</b>, IC<sub>50</sub> = 122 nM). In addition, the oxazolylmethyl derivative <b>10d</b> (IC<sub>50</sub> = 105 nM) showed better potency compared to the phenyl derivative <b>10b</b> (IC<sub>50</sub> = 593 nM) in A431 cell lines. It was quite exciting to see that the growth inhibitory activity of analogue <b>10d</b> is comparable to that of <b>1</b>, which is an approved HER-1/HER-2 dual inhibitor for the treatment of patients with HER-2-positive metastatic breast cancer.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Cellular Activity<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> of R-Modified Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/medium/jm-2011-01758g_0008.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/medium/jm-2011-01758g_0009.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">All biological data are mean values of three independent experiments performed in duplicate.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">A431 is HER-1-overexpressing human vaginal epidermoid cancer cell line.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">SK-Br3 is HER-2-overexpressing human breast cancer cell line.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last"><b>1</b> was synthesized using the synthetic protocol reported in WO99/35146.</p></div></div><div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Optimization of Active Analogue <b>10d</b></h3><div class="NLM_p">On the basis of the results of cell-based proliferation assay against <b>10a</b>–<b>d</b>, the <i>N</i>-acryloyl moiety with oxazolylmethyl group was selected for position X of pyrimidine. For the further optimization of active analogue <b>10d</b>, we performed a series of docking studies using the EGFR crystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK">1XKK</a>) cocrystallized with <b>1</b>. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>, the modification at the Y position of compound <b>5</b> with amine group allows the additional hydrogen bonding interaction with Gly796 (Grid score, which is not considered for H-bond: −53.65 for <b>10d</b> vs −57.04 for amine (Y) containing analogue of <b>10d</b>). Therefore, we aimed to introduce the amine moiety at the Y position of pyrimidine <b>5</b> to enhance its binding affinity at the active site of EGFR. The synthesis of the amine-containing analogue of <b>10d</b> at the Y position is outlined in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. 4,6-Dichloropyrimidine-5-carbaldehyde <b>15</b> was chlorinated under radical conditions, followed by amide coupling with <span class="smallcaps smallerCapital">dl</span>-serine methyl ester to give β-hydroxyamide <b>16</b>. The C6-amine was introduced to <b>16</b> using ammonia gas in 50% ethanolic toluene in a sealed tube, followed by oxazoline formation using DAST. The C4-chloride of oxazoline <b>17</b> was substituted with various anilines (R-NH<sub>2</sub>) under acidic conditions and oxidized to oxazole using bromotrichloromethane and DBU. After the reduction of methyl ester in <b>17</b> and the substitution of alcohol to azide, the resulting azide moiety in azidomethyloxazole <b>18</b> was reduced to amine in the presence of PPh<sub>3</sub> and subsequently N-acryloylated to obtain the desired analogue <b>19</b>.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/medium/jm-2011-01758g_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Binding mode of <b>10d</b> (a) and its analogue with amine at the Y position (b) to the active site of EGFR crystal structure cocrystallized with <b>1</b> (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK">1XKK</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201758g&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/medium/jm-2011-01758g_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201758g&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) (a) SOCl<sub>2</sub>, AIBN, CCl<sub>4</sub>, 80 °C; (b) <span class="smallcaps smallerCapital">dl</span>-serine methyl ester hydrochloride, DIPEA, THF, 0 °C to rt; (ii) (a) NH<sub>3</sub> (gas), toluene/EtOH (1:1), sealed tube, 60 °C; (b) DAST, DCM, −78 to 0 °C; (iii) (a) R-NH<sub>2</sub>, 4 N HCl in 1,4-dioxane, <i>t</i>-BuOH, 60 °C; (b) DBU, CBrCl<sub>3</sub>, DCM, −40 °C to rt; (c) LAH, THF, 0 °C; (d) NaN<sub>3</sub>, PPh<sub>3</sub>, DMF/CCl<sub>4</sub> (4:1), 90 °C; (iv) (a) PPh<sub>3</sub>, H<sub>2</sub>O, THF, 60 °C; (b) acryloyl chloride, NaHCO<sub>3</sub>, aq THF (THF/H<sub>2</sub>O = 5:1), 0 °C.</p></p></figure><div class="NLM_p">Compound <b>19a</b>, an analogue of <b>10d</b> with an amine moiety at the C6 position of pyrimidine, showed 10-fold and 14-fold enhancement in its antiproliferative activity compared to <b>10d</b> in A431 (IC<sub>50</sub> of 10.8 vs 105 nM) and SK-Br3 (IC<sub>50</sub> of 0.7 vs 9.7 nM) cell lines, respectively (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Compound <b>21</b> with an amide moiety as a bioisostere of oxazole was also prepared to ensure the significance of oxazole’s conformation (see <a class="ref internalNav" href="#notes-1" aria-label="Scheme S1">Scheme S1</a>). As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, amide analogue <b>21</b> showed no antiproliferative activity in both cancer cell lines (entry 2, IC<sub>50</sub> > 1000 nM).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro Cellular Activity<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> of Analogues <b>19a</b> and <b>21</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/medium/jm-2011-01758g_0010.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/medium/jm-2011-01758g_0011.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">All biological data are mean values of three independent experiments performed in duplicate.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">A431 is HER-1-overexpressing human vaginal epidermoid cancer cell line.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">SK-Br3 is HER-2-overexpressing human breast cancer cell line.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last"><b>1</b> was synthesized using the synthetic protocol of WO99/35146.</p></div></div><div></div></div><div class="NLM_p">After significant enhancement of its antiproliferative activity via the introduction of an amine moiety at the C6 position of the pyrimidine scaffold, we turned our attention to the structure–activity relationship study of substituents (R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup> moieties) on the aryl ring of compound <b>19</b>. As stated earlier, the introduction of small electron-withdrawing lipophilic groups such as chloride or fluoride at the R<sup>2</sup> position increases HER-1/HER-2 inhibitory activity and the introduction of bulkier moieties such as pyridin-2-ylmethoxy or substituted benzyloxy at the R<sup>1</sup> position increases HER-2 inhibitory activity. In addition, we aimed to develop an orally available anticancer agent with respect to the patients’ convenience. Because the first-pass metabolism by liver is one of the major causes of poor oral bioavailability and short in vivo half-life, the in vitro metabolic stability using liver microsome is one of the efficient in vitro guidelines for the evaluation of oral bioavailability and used in a prospective manner to choose the potential candidates for further development with desirable pharmacokinetic properties including long half-life time and low oral clearance.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> Therefore, we focused on the improvement of HER-1/HER-2 potency and liver microsomal stability through the substituent modification at the R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup> positions of compound <b>19</b>. Analogues <b>19b</b>–<b>r</b> were synthesized in a similar manner as <b>19a</b> for the systematic introduction of various substituents such as halogen, alkyl, pyridylmethyloxy, benzyloxy, phenyloxy, or heteroaryloxy on phenyl moiety and subjected to the cell-based growth inhibition assay using the HER-1-positive A431 cell line and the HER-2-positive SK-Br3 cell line, along with the microsomal stability.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Cellular Activity<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> and Microsomal Stability of Analogues <b>19</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/medium/jm-2011-01758g_0012.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/medium/jm-2011-01758g_0013.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">All biological data are mean values of three independent experiments performed in duplicate.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">A431 is HER-1-overexpressing human vaginal epidermoid cancer cell line.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">SK-Br3 is HER-2-overexpressing human breast cancer cell line.</p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">Half-life (HL) of metabolism by incubation of parent molecule with liver microsomes of mouse, rat, dog, and human (duplicate).</p></div><div class="footnote" id="t3fn5"><sup>Table e</sup><p class="last">NT means “not tested”.</p></div><div class="footnote" id="t3fn6"><sup>Table f</sup><p class="last">The asterisk (∗) means very stable with a HL of >100 min.</p></div></div><div></div></div><div class="NLM_p last">As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, the HER-1/HER-2 cellular inhibitory activity was decreased by the replacement of 3-chloro (<b>19a</b>, IC<sub>50</sub> = 11 nM for A431 and IC<sub>50</sub> = 0.7 nM for SK-Br3) with 3-fluoro (<b>19b</b>, IC<sub>50</sub> = 63 nM for A431 and IC<sub>50</sub> = 6.1 nM for SK-Br3) at the R<sup>2</sup> position or the replacement of 4-(2-pyridine) (<b>19a</b>) with 4-(3-fluorophenyl) (<b>19c</b>, IC<sub>50</sub> = 63 nM for A431 and IC<sub>50</sub> = 6.1 nM for SK-Br3) at the R<sup>1</sup> position, which shares the same structure–activity relationship pattern of phenyl substituents in the case of <b>1</b>. The reduced anticancer activities were observed in a series of analogues <b>19d</b>–<b>p</b> substituted with 4-phenyloxy or 4-heteroaryloxy at the R<sup>1</sup> position. Analogue <b>19e</b> containing the 3-trifluoromethyl-1<i>H</i>-pyrazol-5-yloxy moiety had excellent microsomal stability, but this compound also showed extremely high affinity to plasma proteins (PPB = 100%, data not shown). Compound <b>19k</b> showed relatively low growth inhibitory activity in A431 cells, but it showed comparable SK-Br3 cellular activity with improved microsomal stability. Analogues <b>19q</b>–<b>r</b> with small anilines containing only fluoro or chloro substituents at the R<sup>1</sup> position showed relatively low cellular HER-2 inhibitory activity (for SK-Br3: IC<sub>50</sub>(<b>19q</b>) = 34.1 nM and IC<sub>50</sub>(<b>19r</b>) = 92.6 nM vs IC<sub>50</sub>(<b>19a</b>) = 0.7 nM). Among these analogues, <b>19a</b> showed the highest potency in growth inhibition of A431 and SK-Br3 cells with acceptable microsomal stability.</div></div><div id="sec2_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Pharmacokinetic Studies of <b>19a</b></h3><div class="NLM_p">Prior to further evaluation, our leading compound <b>19a</b> was subjected to pharmacokinetic studies in ICR (imprinting control region) mice and SD (Sprague–Dawley) rats. As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, pharmacokinetic parameters of <b>19a</b> were determined after a single oral administration (10 mg/kg for mouse and 5 mg/kg for rat) and intravenous injection (2 mg/kg for mouse and 1 mg/kg for rat). Compound <b>19a</b> demonstrated fair oral bioavailability with >20% (21.6% for mouse and 21.9% for rat) and desirable exposure levels (<i>C</i><sub>max</sub> and AUC) in mice and rats.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Pharmacokinetic Profile of <b>19a</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> in Mouse and Rat</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameters (po)</th><th class="colsep0 rowsep0" align="center">mouse<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">rat<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose (mg/kg)</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>last</sub>(ng·h/mL)</td><td class="colsep0 rowsep0" align="left">454.8</td><td class="colsep0 rowsep0" align="left">439.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub>(ng/mL)</td><td class="colsep0 rowsep0" align="left">282.5</td><td class="colsep0 rowsep0" align="left">189.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">27.7</td><td class="colsep0 rowsep0" align="left">3.23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">21.6</td><td class="colsep0 rowsep0" align="left">21.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last"><b>19a</b> was treated as HCl salt in a vehicle as a solution of 30% PEG400 and 5% ethanol in distilled water.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">The pharmacokinetic parameters were determined after a single oral administration (10 mg/kg, <i>n</i> = 3) and intravenous injection (2 mg/kg, <i>n</i> = 3) in ICR mice.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">The pharmacokinetic parameters were determined after a single oral administration (5 mg/kg, <i>n</i> = 3) and intravenous injection (1 mg/kg, <i>n</i> = 3) in SD rats.</p></div></div></div></div><div id="sec2_3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Enzymatic Activity and EGFR Irreversible Inhibition of <b>19a</b></h3><div class="NLM_p">We examined the specificity of <b>19a</b> conducting in vitro assays against purified tyrosine kinases of the EGFR family (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>) and against a panel of other protein kinases (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). <b>19a</b> effectively inhibited EGFR family kinases with IC<sub>50</sub> values of 3.3, 3.2, 22.4, and 4.0 nM against EGFR<sup>WT</sup>, EGFR<sup>T790M</sup>, HER-2, and HER-4, respectively. In particular, <b>19a</b> showed excellent inhibitory activity against mutated EGFR (EGFR<sup>T790M</sup>) and HER-4, both of which have been resistant to <b>1</b>. <b>19a</b> also showed excellent selectivity over other 20 kinases confirmed by in vitro enzymatic assays (IC<sub>50</sub> > 3 μM except for Blk).</div><div class="NLM_p"><b>19a</b> is an oxazolylpyrimidine-based HER-1/HER-2 dual inhibitor containing a functional α,β-unsaturated amide as Michael acceptor. This moiety is responsible for the irreversible inhibition of <b>19a</b> via the covalent modifications at the active site (Cys773 of EGFR and Cys805 of HER-2) of EGFR tyrosine kinase domains in a manner similar to that with other irreversible EGFR inhibitors, such as <b>2</b> and <b>3</b>. To validate this hypothesis, the phosphorylation levels (% relative to positive control) of EGFR tyrosine kinases (EGFR and HER-2) in EGFR-overexpressing A431 and HER-2-overexpressing SK-Br3 cells were measured immediately or in 8 h after the removal of <b>19a</b> from the medium. We observed the prolonged inhibitory effect on the phosphorylation of EGFR (97.5% inhibition at 0 h and 87.5% at 8 h after medium washing) and HER-2 (87.2% inhibition at 0 h and 68.2% at 8 h after medium washing) upon treatment of <b>19a</b> in both A431 and SK-Br3 cells, which might be caused by the irreversible modification of <b>19a</b> to EGFR and HER-2 (see <a class="ref internalNav" href="#notes-1" aria-label="Figure S1">Figure S1</a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vitro Enzymatic Activity<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> of <b>19a</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">enzyme assay, IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">EGFR</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">WT</th><th class="colsep0 rowsep0" align="center">T790M</th><th class="colsep0 rowsep0" align="center">HER-2</th><th class="colsep0 rowsep0" align="center">HER-4</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19a</b></td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">3.2</td><td class="colsep0 rowsep0" align="left">22.4</td><td class="colsep0 rowsep0" align="left">4.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">52.2</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">36.3</td><td class="colsep0 rowsep0" align="left">>1000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">All biological data are mean values of three independent experiments performed in duplicate.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last"><b>1</b> was synthesized using the synthetic protocol of WO99/35146.</p></div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Selectivity Profile of <b>19a</b> against 20 Kinases<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">% inhibition at 3 μM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Abl</td><td class="colsep0 rowsep0" align="char" char=".">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AMPKα1</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aurora-A</td><td class="colsep0 rowsep0" align="char" char=".">42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Blk</td><td class="colsep0 rowsep0" align="char" char=".">77</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK1/cyclinB</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cKIT</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FAK</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR1</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt1</td><td class="colsep0 rowsep0" align="char" char=".">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt3</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IGF-1R</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IR</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK2</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LKB1</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MEK1</td><td class="colsep0 rowsep0" align="char" char=".">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Met</td><td class="colsep0 rowsep0" align="char" char=".">13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFRα</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFRβ</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pim-1</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Syk</td><td class="colsep0 rowsep0" align="char" char=".">15</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">This test was conducted by Millipore Kinase Profiling Service.</p></div></div></div></div><div id="sec2_3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Cellular Activity of <b>19a</b></h3><div class="NLM_p">On the basis of the results of the cellular growth inhibition assays in A431 and SK-Br3 cell lines along with in vitro/in vivo pharmacokinetic study, we selected compound <b>19a</b> for further biological evaluation as a potential HER-1/HER-2-targeting therapeutic agent. The effects of <b>19a</b> were evaluated using a panel of cancer cell lines, which express various levels of HER-2 and other genetic information with sensitivity or resistance to <b>1</b>. <b>19a</b> showed excellent growth inhibitory activity in lapatinib-sensitive breast (MDA-MB-175, IC<sub>50</sub> = 1.6 nM) and gastric (NCI-N87, IC<sub>50</sub> = 3.0 nM) cancer cell lines with 12- to 27-fold superiority to <b>1</b>.</div><div class="NLM_p">HER-2-directed therapy including <b>1</b> is an important treatment for breast cancer. However, some tumors do not respond or develop resistance to this agent.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Although the overexpression of HER-2 correlates with sensitivity to the growth inhibition by <b>1</b>, some cancer cells that overexpress HER-2 do not respond to <b>1</b>.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Even though the factors that confer primary or acquired resistance to <b>1</b> are not well characterized, several hypotheses including low PTEN expression, <i>PIK3CA</i> mutations, or ER (estrogen receptor) activation are reported to be associated with resistance in HER-2-positive breast cancer. Analogue <b>19a</b> showed excellent growth inhibitory activity with IC<sub>50</sub> of 5.0 nM in lapatinib-resistant MDA-MB-453 cell line (IC<sub>50</sub>(<b>1</b>) = 555 nM) (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>), which is conferred by low PTEN expression and <i>PIK3CA</i> mutations with high expression of HER-2. But <b>19a</b> did not induce the growth inhibitory effect in JIMT-1 cells with low HER-2 expression level (IC<sub>50</sub>(<b>19a</b>) = 1880 nM and IC<sub>50</sub>(<b>1</b>) > 10000 nM) and MDA-MB-361 cells with ER activation (IC<sub>50</sub>(<b>19a</b>) = 562 nM and IC<sub>50</sub>(<b>1</b>) = 1029 nM). In addition, analogue <b>19a</b> induced the growth inhibition in HER-2-mutated (G776insV_G/C, NCI-H1781, IC<sub>50</sub> = 22 nM) and EGFR-mutated (L858R/T790M, NCI-H1975, IC<sub>50</sub> = 40 nM) NSCLC cell lines with resistance to <b>1</b> (IC<sub>50</sub>(NCI-H1781) = 3047 nM and IC<sub>50</sub>(NCI-H1975) > 1000 nM).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. In Vitro Cellular Activities<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> of <b>19a</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">tissue</th><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">character</th><th class="colsep0 rowsep0" align="center"><b>19a</b></th><th class="colsep0 rowsep0" align="center"><b>1</b><a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">breast cancer</td><td class="colsep0 rowsep0" align="left">MDA-MB-175</td><td class="colsep0 rowsep0" align="left">Src++,Ret+++, low HER-2</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">44.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MDA-MB-361</td><td class="colsep0 rowsep0" align="left">Her-2++,Src+++,<i>PIK3CA</i> mutation, ER activation</td><td class="colsep0 rowsep0" align="left">562.0</td><td class="colsep0 rowsep0" align="left">1029</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MDA-MB-453</td><td class="colsep0 rowsep0" align="left">HER-2++, PTEN deficiency, <i>PIK3CA</i> mutation</td><td class="colsep0 rowsep0" align="left">5.0</td><td class="colsep0 rowsep0" align="left">555.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">JIMT-1</td><td class="colsep0 rowsep0" align="left">low HER-2</td><td class="colsep0 rowsep0" align="left">1,880</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gastric cancer</td><td class="colsep0 rowsep0" align="left">N87</td><td class="colsep0 rowsep0" align="left">HER-2+++</td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="left">36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NSCLC<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">H1781</td><td class="colsep0 rowsep0" align="left">HER-2 G776insV_G/C</td><td class="colsep0 rowsep0" align="left">22.0</td><td class="colsep0 rowsep0" align="left">3047</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">H1975</td><td class="colsep0 rowsep0" align="left">EGFR L858R/T790M</td><td class="colsep0 rowsep0" align="left">40.0</td><td class="colsep0 rowsep0" align="left">>1000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">All biological data are mean values of three independent experiments performed in duplicate.</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last"><b>1</b> was synthesized using the synthetic protocol of WO99/35146.</p></div><div class="footnote" id="t7fn3"><sup>c</sup><p class="last">NSCLC: non-small-cell lung cancer.</p></div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Summary</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84422" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84422" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">HER-2 is overexpressed in 20–25% of metastatic breast or gastric cancers and is associated with an aggressive tumor type and reduced survival rate. Therefore, HER-2-targeted therapy such as trastuzumab or lapatinib is beneficial for cancer patients with high HER-2 expression level. However, most cancers that initially respond to HER-2-targeted therapy begin to progress again within 1 year. The several mechanisms by HER-2 therapy contribute to address this resistance. Herein, we have described the synthesis of a novel series of <i>N</i><sup>4</sup>-(3-chlorophenyl)-5-(oxazol-2-yl)pyrimidine-4,6-diamines which are explored as HER-1/HER-2 dual inhibitors for the treatment of resistant patients to the current HER-2-targeted therapy, lapatinib. The selected compound (<b>19a</b>) showed excellent HER-1 and HER-2 inhibition activity and also showed excellent selectivity in an enzyme-based inhibition assay with a panel of 20 kinases. We confirmed that our leading HER-1/HER-2 dual inhibitor (<b>19a</b>) has an irreversible binding mode to HER-1 and HER-2 confirmed by a cell washout test in A431 and SK-Br3 cell lines. In contrast to the currently approved HER-2-targeted agent, our selected compound (<b>19a</b>) is an irreversible small-molecule inhibitor of HER-1 and HER-2 tyrosine kinases with the potential to overcome clinically relevant, mutation-induced drug resistance. <b>19a</b> showed excellent inhibitory activity toward cellular growth of lapatinib-sensitive or resistant cancer cells. The excellent pharmacokinetic profiles of <b>19a</b> in rats and mice clearly demonstrate its merit for further investigation as a novel therapeutic agent for HER-2-targeting treatment of solid tumors, especially HER-2-positive breast or gastric cancer.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73063" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73063" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Chemistry. General Information</h3><div class="NLM_p last">All commercial chemicals and solvents were reagent grade and were used without further purification unless otherwise specified. All reported yields are isolated yields after flash column chromatography or crystallization. <sup>1</sup>H spectra were recorded on a Bruker DRX-300 [Bruker Biospin, Germany]. Chemical shifts are reported in ppm relative to the residual solvent peak (CDCl<sub>3</sub>, TMS: 0.00). Multiplicity was indicated as follows: s (singlet); d (doublet); t (triplet); q (quartet); m (multiplet); dd (doublet of doublet); dt (triplet of doublet); td (doublet of triplet); br s (broad singlet); etc. Products were purified by flash column chromatography on silica gel (230–400 mesh). The eluent used for purification is reported in parentheses. The purity of all synthesized compounds (>95% area) was analyzed by high performance liquid chromatography using a Shimadzu HPLC instrument equipped with a reverse phase column (XDB C18, 5 μm, 4.6 mm × 150 mm) and a UV detector (254 nm). HPLC column was equilibrated with 5% acetonitrile (CAN) in H<sub>2</sub>O (0.1% trifluoroacetic acid, TFA) for 5 min. After the injection of 10 μL of individual samples, the eluent was changed from 5% ACN in H<sub>2</sub>O (0.1% TFA) to 100% ACN (0.1% TFA) over 45 min with a flow rate of 1.0 mL/min. Thin-layer chromatography (TLC) was performed on precoated glass-backed plates (silica gel 60 F<sub>254</sub>, 0.25 mm), and the components were visualized under UV light (254 and 365 nm) or by treating the plates with anisaldehyde, KMnO<sub>4</sub>, and phosphomolybdic acid, followed by heating. Distilled water was treated using ion exchange and filtration.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> <i>N</i>-(3-(4-((3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)pyrimidin-5-yl)prop-2-yn-1-yl)acrylamide (<b>10a</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.95 (s, 1H), 8.83 (s, 1H), 8.62–8.60 (m, 1H), 7.79–7.76 (m, 1H), 7.68–7.65 (m, 1H), 7.47–7.46 (m, 1H), 7.17–7.14 (m, 1H), 6.62 (s, 1H), 6.31–6.25 (m, 1H), 6.11–6.07 (m, 1H), 5.75 (m, 1H), 5.71–5.68 (m, 1H), 5.36 (s, 2H), 4.59–4.57 (d, 2H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 420.7 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> <i>N</i>-(3-(4-(3-Chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidin-5-yl)phenyl)acrylamide (<b>10b</b>)</h3><div id="sec4_1_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Step 1. Preparation of 5-(3-Aminophenyl)-<i>N</i>-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)pyrimidin-4-amine</h4><div class="NLM_p last">300 mg of compound <b>9</b> and 142 mg of 3-aminophenylboronic acid hydrochloride were dissolved in 6 mL of methanol, and 7.7 mg of palladium acetate and 284 mg of potassium carbonate were added thereto. The mixture was stirred at 70 °C for 2 h. After the reaction was completed, the reaction mixture was condensed under a reduced pressure, and the resulting residue was subjected to flash column chromatography (CHCl<sub>3</sub>/CH<sub>3</sub>OH = 15: 1) to obtain the title compound (120 mg, yield 44%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.70 (s, 1H), 8.60 (d, 1H), 8.21 (s, 1H), 7.76 (t, 2H), 7.69 (d, 1H), 7.65 (d, 1H), 7.34 (m, 2H), 7.24 (d, 1H), 6.97 (d, 1H), 6.80 (m, 1H), 6.73 (s, 1H), 5.28 (s, 2H), 3.88 (s, 2H).</div></div><div id="sec4_1_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Step 2. Preparation of <i>N</i>-(3-(4-(3-Chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidin-5-yl)phenyl)acrylamide (<b>10b</b>)</h4><div class="NLM_p last">51 mg of the compound obtained in step 1 and 32 mg of sodium bicarbonate were dissolved in a mixture of 2 mL of tetrahydrofuran (THF) and 0.5 mL of distilled water at 0 °C. Then 10 μL of acryloyl chloride was added to the mixture and stirred for 30 min. After the reaction was completed, the resulting mixture was added to a saturated aqueous solution of sodium bicarbonate and extracted twice with chloroform. The separated organic layer was washed with water and saturated saline, dried over anhydrous sodium sulfate, filtered, and distilled under a reduced pressure. The resulting residue was subjected to flash column chromatography (CHCl<sub>3</sub>/CH<sub>3</sub>OH = 15: 1) to obtain the title compound (12 mg, yield 21%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.68 (s, 1H), 8.59 (d, 1H), 8.19 (s, 1H), 8.13 (s, 1H), 7.74 (m, 3H), 7.65 (t, 2H), 7.50 (t, 1H), 7.35 (m, 1H), 7.22 (m, 2H), 6.95 (s, 1H), 6.94 (d, 1H), 6.48 (d, 1H), 6.33 (m, 1H), 5.82 (d, 2H), 5.26 (s, 2H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 458.1 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> <i>N</i>-((5-(4-(3-Chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidin-5-yl)isooxazol-3-yl)methyl)acrylamide (<b>10c</b>)</h3><div id="sec4_1_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Step 1. Preparation of <i>N</i>-(3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)-5-((trimethylsilyl)ethinyl)pyrimidin-4-amine</h4><div class="NLM_p last">5.67 g of the compound <b>9</b>, 181 mg of dichlorobis(triphenylphosphine)palladium(II), and 98 mg of copper(I) iodide were dissolved in 60 mL of THF, and 7.2 mL of triethylamine and 2.15 mL of trimethylsilylacetylene were added to the mixture. The mixture was stirred at room temperature for 24 h. After the reaction was completed, a saturated aqueous solution of sodium bicarbonate was added thereto, and the resulting mixture was extracted twice with ethyl acetate. The separated organic layer was washed with water and saturated saline, dried over anhydrous sodium sulfate, filtered, and distilled under a reduced pressure. The resulting residue was subjected to column chromatography (ethyl acetate/hexanes = 1:10) to obtain the title compound (1.8 g, yield 34%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.62 (s, 1H), 8.60 (d, 1H), 8.41 (s, 1H), 7.80 (d, 1H), 7.75 (m, 1H), 7.65 (d, 1H), 7.37 (m, 1H), 7.23 (m, 2H), 7.00 (d, 1H), 5.29 (s, 2H), 1.77 (s, 1H), 0.32 (s, 9H).</div></div><div id="secz" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Step 2. Preparation of <i>N</i>-(3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)-5-ethinyl pyrimidin-4-amine</h4><div class="NLM_p last"> 1.8 g of the compound obtained in step 1 was dissolved in 30 mL of THF, and 8.8 mL of 1.0 M tetrabutylammonium fluoride solution in THF was added thereto. The mixture was stirred at room temperature for 1 h. After the reaction completion monitored by TLC, the reaction was quenched by the addition of saturated aqueous solution of sodium bicarbonate. The reaction mixture was extracted twice with ethyl acetate, and the combined organic layer was dried over anhydrous sodium sulfate, filtered, and distilled under a reduced pressure. The resulting residue was subjected to flash column chromatography (ethyl acetate/hexanes = 1:1) to obtain the title compound (1.4 g, yield 94%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.65 (s, 1H), 8.60 (m, 1H), 8.45 (s, 1H), 7.76 (m, 2H), 7.64 (d, 1H), 7.41 (m, 1H), 7.24 (m, 2H), 6.99 (d, 1H), 5.29 (s, 2H), 3.67 (s, 1H).</div></div><div id="sec4_1_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Step 3. Preparation of 2-((5-(4-(3-Chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidin-5-yl)isooxazol-3-yl)methyl)isoindoline-1,3-dione</h4><div class="NLM_p last">6.8 mL of oxalylchloride was dissolved in 250 mL of CH<sub>2</sub>Cl<sub>2</sub>, and the mixture was cooled to −78 °C. Then 8.9 mL of dimethyl sulfoxide was added to the mixture. The mixture was stirred for 10 min. 10 g of <i>N</i>-(2-hydroxyethyl)phthalimide was gradually added to the mixture, and the mixture was stirred for 30 min, and 36.5 mL of triethylamine was added thereto. The resulting mixture was heated to 0 °C and stirred for 1 h. After the reaction was completed, the resulting mixture was added to a saturated aqueous solution of NH<sub>4</sub>Cl and extracted twice with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layer was dried over anhydrous sodium sulfate, filtered, and condensed under a reduced pressure. 5.5 g of the solid thus obtained was dissolved in 50 mL of pyridine, and 6.1 g of hydroxylamine hydrochloride was added thereto, followed by stirring at 65 °C for 5 h. After the reaction was completed, the reaction mixture was condensed under a reduced pressure, ethyl acetate was added thereto, and the mixture was washed three times with water. The combined organic layer was dried over anhydrous sodium sulfate, filtered, and condensed under a reduced pressure. The resulting residue was crystallized in diethyl ether. The obtained solid was filtered, washed with diethyl ether, and dried under a reduced pressure. 588 mg of the solid was dissolved in 10 mL of THF, and 595 mg of <i>N</i>-chlorosuccinimide and 36 μL of pyridine were added thereto, followed by stirring at 70 °C for 2 h. 500 mg of the compound obtained in step 2 and 621 μL of triethylamine were added to the mixture, and the mixture was stirred at 70 °C for 12 h. After the reaction completion monitored by TLC, the reaction mixture was condensed under a reduced pressure and the resulting residue was subjected to flash column chromatography (ethyl acetate/hexanes = 1:1) to obtain the desired compound (450 mg, yield 56%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.84 (s, 1H), 8.61 (s, 1H), 8.59 (s, 1H), 8.56 (d, 1H), 7.90 (m, 5H), 7.67 (d, 1H), 7.54 (d, 1H), 7.40 (m, 1H), 7.35 (m, 1H), 7.18 (d, 1H), 7.05 (s, 1H), 5.25 (d, 2H), 4.92 (d, 2H).</div></div><div id="sec4_1_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Step 4. Preparation of 5-(3-(Aminomethyl)isooxazol-5-yl)-<i>N</i>-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)pyrimidin-4-amine</h4><div class="NLM_p last">450 mg of the compound obtained in step 3 was dissolved in 10 mL of ethanol, and 203 μL of hydrazine hydrate was added thereto, followed by stirring at 70 °C for 1 h. After the reaction completion monitored by TLC, the reaction mixture was cooled to 0 °C and the solid thus obtained was filtered and washed with chloroform. The filtrate therefrom was condensed under a reduced pressure. The resulting residue was subjected to flash column chromatography (CHCl<sub>3</sub>/CH<sub>3</sub>OH = 15:1) to obtain the title compound (200 mg, yield 59%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.79 (m, 1H), 8.61 (s, 1H), 8.57 (d, 1H), 7.86 (t, 1H), 7.71 (d, 1H), 7.55 (d, 1H), 7.45 (m, 1H), 7.35 (t, 1H), 7.20 (d, 1H), 7.04 (s, 1H), 5.26 (d, 2H), 3.79 (s, 2H).</div></div><div id="sec4_1_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Step 5. Preparation of <i>N</i>-((5-(4-(3-Chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidin-5-yl)isooxazol-3-yl)methyl)acrylamide (<b>10c</b>)</h4><div class="NLM_p last">42 mg of acrylic acid was dissolved in 10 mL of CH<sub>2</sub>Cl<sub>2</sub>, and 140 mg of <i>N</i>-(3-dimethylaminopropyl)-<i>N</i>′-ethylcarbodiimide hydrochloride, 20 mg of <i>N</i>-hydroxybenzotriazole, and 255 μL of <i>N</i>,<i>N</i>-diisopropylethylamine were added thereto, followed by stirring at room temperature for 10 min. 200 mg of the compound obtained in step 4 was added to the mixture, and the mixture was stirred at room temperature for 3 h. After the reaction completion monitored by TLC, the resulting mixture was added to a saturated aqueous solution of sodium bicarbonate and extracted twice with chloroform. The combined organic layer was dried over anhydrous sodium sulfate, filtered, and condensed under a reduced pressure. The resulting residue was subjected to silica gel flash column chromatography (CHCl<sub>3</sub>/CH<sub>3</sub>OH = 50:1) to obtain the title compound (86 mg, yield 38%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.67 (s, 1H), 8.59 (s, 1H), 8.57 (s, 1H), 7.74 (m, 2H), 7.67 (d, 1H), 7.38 (m, 1H), 7.27 (m, 1H), 7.01 (m, 2H), 6.71 (s, 1H), 6.37 (m, 1H), 6.20 (m, 1H), 5.74 (m, 1H), 5.28 (s, 2H), 4.64 (d, 2H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 463.1 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>N</i>-((2-(4-(3-Chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide (<b>10d</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 10.56 (s, 1H), 8.95 (s, 1H), 8.72 (s, 1H), 8.59 (d, 1H), 7.86 (s, 1H), 7.76–7.67 (m, 3H), 7.53 (dd, 1H), 7.00 (d, 1H), 6.40 (s, 1H), 6.19 (s, 1H), 5.73 (d, 1H), 5.30 (s, 2H), 4.56 (d, 2H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 463.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Methyl 2-(4,6-Dichloropyrimidin-5-carboxamido)-3-hydroxypropanoate (<b>16</b>)</h3><div class="NLM_p last">4,6-Dichloropyrimidin-5-carbaldehyde <b>15</b> (10 g) was dissolved in 100 mL of carbon tetrachloride, and 7.8 mL of sulfuryl chloride and 0.51 g of 2,2-azobis(2-methylpropionitrile) were added thereto, followed by stirring under reflux conditions at 80 °C for 1.5 h. After the reaction completion monitored by TLC, the reaction mixture was cooled to room temperature and filtered under a reduced pressure. The filtrate was condensed under a reduced pressure to obtain 4,6-dichloropyrimidin-5-carbonyl chloride without further purification (11.4 g, yield 95%). The resulting 4,6-dichloropyrimidin-5-carbonyl chloride (8.6 g) and <span class="smallcaps smallerCapital">dl</span>-serine methyl ester (12.6 g) were dissolved in 100 mL of THF, and 14.2 mL of <i>N</i>,<i>N</i>-diisopropylethylamine was added thereto dropwise at 0 °C. Then the reaction mixture was heated to room temperature, followed by stirring for 30 min. After the reaction completion monitored by TLC, the reaction mixture was added to water and extracted twice with chloroform. The combined organic layer was washed with water and saturated saline and dried over anhydrous sodium sulfate, followed by filtration and condensation under a reduced pressure. The obtained residue was subjected to silica gel flash column chromatography (ethyl acetate/CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH = 30:30:1) to obtain the title compound (10.2 g, yield 85%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 9.31 (d, 1H), 8.96 (s, 1H), 5.15 (s, 1H), 4.58 (m, 1H), 3.85 (m, 1H), 3.68 (s, 3H), 3.67 (m, 1H).</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Methyl 2-(4-Amino-6-chloropyrimidin-5-yl)-4,5-dihydrooxazol-4-carboxylate (<b>17</b>)</h3><div class="NLM_p last">Compound <b>16</b> (7.0 g) was dissolved in 50 mL of toluene and 50 mL of ethanol in a sealed tube, and ammonia gas was bubbled through the solution, followed by stirring at 60 °C for 2 h. Ammonia gas was further bubbled into the solution until the reaction was substantially completed, and the reaction mixture continued to be stirred at the same temperature for an additional 1 h. After the reaction completion monitored by TLC, the reaction mixture was condensed under a reduced pressure to obtain methyl 2-(4-amino-6-chloropyrimidin-5-carboxamido)-3-hydroxypropanoate (6.54 g). The resulting compound (5.0 g) was dissolved in 50 mL of CH<sub>2</sub>Cl<sub>2</sub>, and 2.65 mL of (diethylamino)sulfur trifluoride was added thereto dropwise at −78 °C. The reaction mixture was slowly warmed up to 0 °C and stirred for 2.5 h. After the reaction was completed, the reaction mixture was basificated (pH 8) with a saturated aqueous solution of sodium bicarbonate and extracted twice with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layer was dried over anhydrous sodium sulfate, filtered, and condensed under a reduced pressure. The obtained residue was crystallized with a mixed solvent of ethyl acetate and diethyl ether (v/v, 3:1), followed by filtering and drying under a reduced pressure to obtain the desired compound (2.38 g, yield 51%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.70 (s, 1H), 8.30 (s, 1H), 6.10 (s, 1H), 4.97 (m, 1H), 4.63 (m, 2H), 3.82 (s, 3H).</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>N</i>-((2-(4-Amino-6-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide (<b>19a</b>)</h3><div id="sec4_1_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Step 1. Preparation of Methyl 2-(4-Amino-6-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidin-5-yl)-4,5-dihydrooxazol-4-carboxylate</h4><div class="NLM_p last">Compound <b>17</b> (1.5 g) and 3-chloro-4-(pyridin-2-ylmethoxy)benzenamine <b>8</b> (1.37 g) were dissolved in 25 mL of <i>tert</i>-butanol, and 0.73 mL of 4 N hydrochloric acid solution in 1,4-dioxane was added thereto dropwise. The mixture was heated to 70 °C and stirred for 1.5 h, followed by condensation under a reduced pressure when the reaction was completed. After removal of solvents, 25 mL of 2-propanol was added thereto, followed by stirring at 0 °C for 2 h. The resulting solid was washed with 2-propanol, followed by filtering and drying under a reduced pressure to obtain the title compound (2.10 g, yield 79%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.24 (s, 1H), 8.63 (d, 1H), 8.26 (s, 1H), 8.10 (m, 1H), 7.95 (m, 1H), 7.75 (d, 1H), 7.61 (d, 1H), 7.43 (m, 1H), 7.32 (m, 1H), 7.25 (d, 1H), 5.31 (s, 2H), 5.05 (m, 1H), 4.63 (m, 2H), 3.71 (s, 3H).</div></div><div id="sec4_1_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Step 2. Preparation of Methyl 2-(4-Amino-6-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidin-5-yl)oxazol-4-carboxylate</h4><div class="NLM_p last">2.0 g of the compound obtained in step 1 was dissolved in 40 mL of dichloromethane, and 1.9 mL of 1,8-diazabicyclo[5.4.0]undec-7-ene was added thereto at −40 °C, followed by adding thereto 1.3 mL of bromotrichloromethane dropwise for 20 min. The mixture was warmed to room temperature and stirred for 2 h. After the reaction completion monitored by TLC, the reaction mixture was condensed under a reduced pressure and then crystallized with ethyl acetate. The resulting solid was washed with ethyl acetate, followed by filtering and drying under a reduced pressure to obtain the desired compound (0.4 g, yield 20%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.16 (s, 1H), 8.88 (s, 1H), 8.58 (m, 1H), 8.11 (m, 1H), 7.85 (m, 2H), 7.54 (m, 3H), 7.37 (m, 2H), 7.22 (d, 1H), 5.26 (s, 2H), 3.87 (s, 3H).</div></div><div id="sec4_1_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Step 3. Preparation of (2-(4-Amino-6-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methanol</h4><div class="NLM_p last">0.35 g of the compound obtained in step 2 was dissolved in 10 mL of dichloromethane at 0 °C, and 1.6 mL of 1.0 M lithium aluminum hydride ether solution was added dropwise thereto. The reaction mixture was stirred at the same temperature for 1 h. After the reaction completion monitored by TLC, an aqueous solution of Rochelle salt (potassium sodium tartrate, NaKC<sub>4</sub>H<sub>4</sub>O<sub>6</sub>) was added thereto. The resulting mixture was stirred for 1 h and extracted twice with a mixed solvent of chloroform and 2-propanol (v/v, 3:1). The combined organic layer was washed with distilled water and saturated saline and dried over anhydrous sodium sulfate, followed by filtering and distilling under a reduced pressure. The obtained residue was subjected to silica gel flash column chromatography (ethyl acetate/CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH = 10:10:1) to obtain the title compound (0.27 g, yield 82%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 10.70 (s, 1H), 8.58 (d, 1H), 8.15 (s, 1H), 7.72 (m, 3H), 7.64 (d, 1H), 7.33 (m, 1H), 7.26 (m, 1H), 6.92 (d, 1H), 5.25 (s, 2H), 4.72 (s, 2H).</div></div><div id="sec4_1_8_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Step 4. Preparation of (5-(4-(Aminomethyl)oxazol-2-yl)-<i>N</i>4-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)pyrimidin-4,6-diamine</h4><div class="NLM_p last">0.27 g of the compound obtained in step 3 was dissolved in 10 mL of <i>N</i>,<i>N</i>-dimethylformamide and 2 mL of carbon tetrachloride, and 50 mg of sodium azide and 400 mg of triphenylphosphine were added thereto. The reaction mixture was heated to 90 °C and stirred for 30 min. Subsequently, the mixture was condensed under a reduced pressure to remove carbon tetrachloride, and distilled water was added thereto, followed by the extraction twice with ethyl acetate. The combined organic layer was washed with water and saturated saline and dried over anhydrous sodium sulfate, followed by filtering and condensing under a reduced pressure. The obtained residue was dried under a reduced pressure, dissolved in 10 mL of THF, and 437 mg of triphenylphosphine and 0.1 mL of distilled water were added thereto, followed by stirring at 60 °C for 2 h. After the reaction completion monitored by TLC, the reaction mixture was condensed under a reduced pressure and then subjected to silica gel flash column chromatography (CHCl<sub>3</sub>/CH<sub>3</sub>OH = 1:1) to obtain the desired compound (50 mg, yield 19%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 10.71 (s, 1H), 8.58 (d, 1H), 8.19 (s, 1H), 7.72 (m, 2H), 7.64 (d, 2H), 7.41 (m, 1H), 7.24 (m, 1H), 6.98 (d, 1H), 5.28 (s, 2H), 3.90 (s, 2H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 424.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Step 5. Preparation of <i>N</i>-((2-(4-Amino-6-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide (<b>19a</b>)</h4><div class="NLM_p last">45 mg of the compound obtained in step 4 and 27 mg of sodium bicarbonate were dissolved in 2 mL of THF and 0.5 mL of distilled water at 0 °C, and 8.6 μL of acryloyl chloride was added thereto, followed by stirring at the same temperature for 10 min. After the reaction was completed, a saturated aqueous solution of sodium bicarbonate was added thereto and the mixture was extracted twice with chloroform. The isolated layer was washed with water and saturated saline, dried over anhydrous sodium sulfate, followed by filtering and condensing under a reduced pressure. The resulting residue was subjected to silica gel flash column chromatography (CHCl<sub>3</sub>/CH<sub>3</sub>OH = 15:1) to obtain the desired compound <b>19a</b> (20 mg, yield 39%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 10.65 (s, 1H), 8.59 (d, 1H), 8.18 (s, 1H), 7.72 (m, 3H), 7.65 (d, 1H), 7.41 (m, 1H), 7.24 (m, 1H), 6.96 (d, 1H), 6.35 (m, 1H), 6.13 (m, 2H), 5.70 (m, 2H), 5.27 (s, 2H), 4.53 (d, 2H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 478.2 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>N</i>-((2-(4-Amino-6-(3-fluoro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide (<b>19b</b>)</h3><div class="NLM_p last">The similar procedure of <b>19a</b> was repeated to obtain the compound <b>19b</b> (40 mg, final yield 51%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 10.69 (s, 1H), 8.59 (d, 1H), 8.20 (s, 1H), 7.74 (m, 1H), 7.71 (s, 1H), 7.64 (m, 2H), 7.22 (m, 2H), 6.99 (t, 1H), 6.36 (m, 1H), 6.14 (m, 1H), 6.00 (m, 1H), 5.71 (m, 1H), 5.27 (s, 2H), 4.54 (m, 2H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 462.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> <i>N</i>-((2-(4-Amino-6-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide (<b>19c</b>)</h3><div class="NLM_p last">The similar procedure of <b>19a</b> was repeated to obtain the compound <b>19c</b> (9 mg, final yield 47%). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 8.04 (s, 1H), 7.88 (m, 1H), 7.80–7.79 (d, 1H), 7.64–7.03 (m, 6H), 6.30 (s, 1H), 6.28–6.27 (d, 1H), 5.70–5.66 (m, 1H), 5.18 (s, 2H), 4.48 (s, 2H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 495.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> <i>N</i>-((2-(4-Amino-6-(3-chloro-4-(1-methyl-1<i>H</i>-pyrazol-5-yloxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide (<b>19d</b>)</h3><div class="NLM_p last">The similar procedure of <b>19a</b> was repeated to obtain the compound <b>19d</b> (68 mg, final yield 31%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 10.96 (bs, 1H), 8.21 (s, 1H), 7.93–7.91 (m, 1H), 7.74 (s, 1H), 7.57–7.53 (m, 1H), 7.14–7.11 (d, 1H), 6.50 (m, 1H), 6.40–6.33 (m, 1H), 6.20–6.11 (m, 1H), 5.73–5.69 (m, 1H), 5.52 (m, 1H), 4.54 (d, 2H), 3.80 (s, 3H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 467.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> <i>N</i>-((2-(4-Amino-6-(3-chloro-4-(1-methyl-3-(trifluoromethyl)-1<i>H</i>-pyrazol-5-yloxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide (<b>19e</b>)</h3><div class="NLM_p last">The similar procedure of <b>19a</b> was repeated to obtain the compound <b>19e</b> (25 mg, final yield 67%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.12 (s, 1H), 8.64 (t, 1H), 8.19 (d, 1H), 8.16 (s, 1H), 8.05 (s, 1H), 7.72 (m, 1H), 7.49 (s, 2H), 7.41 (d, 1H), 6.25 (m, 2H), 6.02 (s, 1H), 5.62 (m, 1H), 4.39 (d, 2H), 3.84 (s, 3H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 535.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> <i>N</i>-((2-(4-Amino-6-(3-chloro-4-phenoxyphenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide (<b>19f</b>)</h3><div class="NLM_p last">The similar procedure of <b>19a</b> was repeated to obtain the compound <b>19f</b> (29 mg, final yield 67%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 10.86 (bs, 1H), 8.25 (s, 1H), 7.92 (d, 1H), 7.74 (s, 1H), 7.55–7.52 (m, 1H), 7.37–7.31 (m, 2H), 7.10–6.97 (m, 4H), 6.41–6.35 (m, 1H), 6.19 (m, 1H), 5.73 (m, 1H), 4.57 (d, 2H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 463.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> <i>N</i>-((2-(4-Amino-6-(3-chloro-4-(2,5-dichlorophenoxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide (<b>19g</b>)</h3><div class="NLM_p last">The similar procedure of <b>19a</b> was repeated to obtain the compound <b>19g</b> (14 mg, final yield 40%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 8.37 (s, 1H), 7.97 (m, 1H), 7.75 (s, 1H), 7.50 (m, 1H), 7.40–7.37 (m, 1H), 7.05–6.75 (m, 2H), 6.60 (m, 1H), 6.17 (m, 1H), 5.73 (m, 1H), 4.55 (m, 2H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 531.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> <i>N</i>-((2-(4-Amino-6-(3-chloro-4-(2,4-dichlorophenoxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide (<b>19h</b>)</h3><div class="NLM_p last">The similar procedure of <b>19a</b> was repeated to obtain the compound <b>19h</b> (14 mg, final yield 41%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 8.24 (s, 1H), 7.96 (m, 1H), 7.75 (s, 1H), 7.55 (m, 1H), 7.49 (m, 1H), 7.18–7.14 (m, 1H), 6.98–6.95 (d, 1H), 6.78–6.75 (d, 1H), 6.41–6.35 (m, 1H), 6.20–6.17 (m, 1H), 5.75–5.71 (m, 1H), 4.58–4.56 (m, 2H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 531.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> <i>N</i>-((2-(4-Amino-6-(3-chloro-4-(2,3-dichlorophenoxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide (<b>19i</b>)</h3><div class="NLM_p last">The similar procedure of <b>19a</b> was repeated to obtain the compound <b>19i</b> (11 mg, final yield 39%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>+CD<sub>3</sub>OD) δ 8.20 (s, 1H), 7.94–7.93 (m, 1H), 7.40 (m, 1H), 7.20 (m, 1H), 7.10 (m, 1H), 6.98 (m, 1H), 6.60 (m, 1H), 6.34 (m, 1H), 6.10 (m, 1H), 5.80 (m, 1H), 4.56–4.54 (m, 2H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 531.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> <i>N</i>-((2-(4-Amino-6-(3-chloro-4-(2-fluorophenoxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide (<b>19j</b>)</h3><div class="NLM_p last">The similar procedure of <b>19a</b> was repeated to obtain the compound <b>19j</b> (7 mg, final yield 21%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 8.20 (s, 1H), 7.87 (m, 1H), 7.73 (s, 1H), 7.49 (m, 1H), 7.19 (m, 1H), 7.07 (m, 2H), 6.94 (m, 2H), 6.36 (m, 2H), 6.16 (m, 1H), 5.70 (m, 1H), 4.53 (d, 2H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 481.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> <i>N</i>-((2-(4-Amino-6-(3-chloro-4-(3-fluorophenoxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide (<b>19k</b>)</h3><div class="NLM_p last">The similar procedure of <b>19a</b> was repeated to obtain the compound <b>19k</b> (14 mg, final yield 38%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.24 (s, 1H), 7.95 (m, 1H), 7.72 (s, 1H), 7.59–7.56 (m, 1H), 7.25 (m, 1H), 7.09–7.06 (m, 1H), 6.77–6.71 (m, 2H), 6.67–6.64 (m, 1H), 6.63 (m, 1H), 6.19–6.15 (m, 1H), 5.73–5.69 (m, 1H), 4.56 (s, 2H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 481.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> <i>N</i>-((2-(4-Amino-6-(3-chloro-4-(3-fluorophenoxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide (<b>19l</b>)</h3><div class="NLM_p last">The similar procedure of <b>19a</b> was repeated to obtain the compound <b>19l</b> (21 mg, final yield 44%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.24 (s, 1H), 7.90 (m, 1H), 7.73 (s, 1H), 7.51 (m, 1H), 7.02–6.93 (m, 5H), 6.40–6.34 (m, 1H), 6.19–6.10 (m, 1H), 5.74–5.70 (m, 1H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 481.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> <i>N</i>-((2-(4-Amino-6-(3-chloro-4-(pyridin-2-yloxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide (<b>19m</b>)</h3><div class="NLM_p last">The similar procedure of <b>19a</b> was repeated to obtain the compound <b>19m</b> (7 mg, final yield 30%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD) δ 10.93 (s, 1H), 8.20 (s, 1H), 7.90 (s, 1H), 7.73–7.71 (m, 2H), 7.54 (dd, 1H), 7.18 (d, 2H), 7.01–6.96 (m, 2H), 6.37 (d, 1H), 6.18 (t, 1H), 5.68 (d, 1H), 4.53 (d, 2H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 464.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> <i>N</i>-((2-(4-Amino-6-(3-chloro-4-(pyridin-3-yloxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide (<b>19n</b>)</h3><div class="NLM_p last">The similar procedure of <b>19a</b> was repeated to obtain the compound <b>19n</b> (20 mg, final yield 44%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 11.10 (s, 1H), 8.64 (t, 1H), 8.33 (m, 2H), 8.17 (m, 2H), 8.05 (s, 1H), 7.70 (m, 1H), 7.49 (s, 1H), 7.39 (m, 1H), 7.25 (m, 2H), 6.20 (m, 2H), 5.62 (m, 2H), 4.39 (d, 2H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 464.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> <i>N</i>-((2-(4-Amino-6-(3-chloro-4-(6-methylpyridin-3-yloxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide (<b>19o</b>)</h3><div class="NLM_p last">The similar procedure of <b>19a</b> was repeated to obtain the compound <b>19o</b> (1 mg, final yield 2%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.23 (d, 1H), 8.21 (s, 1H), 7.92 (d, 1H), 7.75 (s, 1H), 7.55 (m, 1H), 7.16 (m, 2H), 7.02 (m, 2H), 6.50 (m, 1H), 6.37 (m, 1H), 6.15 (m, 1H), 5.71 (m, 1H), 4.55 (d, 2H), 2.54 (s, 3H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 478.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> <i>N</i>-((2-(4-Amino-6-(3-methyl-4-(6-methylpyridin-3-yloxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide (<b>19p</b>)</h3><div class="NLM_p last">The similar procedure of <b>19a</b> was repeated to obtain the compound <b>19p</b> (34 mg, final yield 76%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 10.65 (bs, 1H), 8.28–8.27 (d, 1H), 8.23 (s, 1H), 7.74 (s, 1H), 7.53 (d, 1H), 7.48–7.44 (m, 1H), 7.10 (m, 2H), 6.92–6.89 (d, 1H), 6.40–6.34 (m, 1H), 6.20–6.11 (m,1H), 5.74–5.70 (m, 1H), 4.57 (d, 2H), 2.54 (s, 3H), 2.28 (s, 3H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 458.4 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> <i>N</i>-((2-(4-Amino-6-(3-chloro-4-fluorophenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide (<b>19q</b>)</h3><div class="NLM_p last">The similar procedure of <b>19a</b> was repeated to obtain the compound <b>19q</b> (19 mg, final yield 16%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.07 (s, 1H), 7.75 (dd, 1H), 7.69 (s, 1H), 7.42–7.37 (m, 1H), 7.06 (t, 1H), 6.28 (d, 1H), 6.20 (d, 1H), 5.63 (d, 1H), 4.42 (s, 2H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 389.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> <i>N</i>-((2-(4-Amino-6-(3,4-dichloro-2-fluorophenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide (<b>19r</b>)</h3><div class="NLM_p last">The similar procedure of <b>19a</b> was repeated to obtain the compound <b>19r</b> (26 mg, final yield 45%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.38–8.30 (m, 1H), 8.13 (s, 1H), 8.04 (s, 1H), 7.61–7.48 (m, 3H), 6.32–6.23 (m, 1H), 6.16–6.09 (m, 1H), 4.35 (s, 2H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 423.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> <i>N</i>-(2-Acrylamidoethyl)-4-amino-6-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)pyrimidine-5-carboxamide (<b>21</b>)</h3><div class="NLM_p last">Compound <b>21</b> was synthesized in 14.4% yield over three steps from <b>20</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.58 (s, 1H), 8.56 (s, 1H), 8.08–7.87 (m, 1H), 7.75–7.69 (m, 2H), 7.38–7.32 (m, 2H), 7.02 (d, 1H), 6.23 (dd, 2H), 5.68 (d, 1H), 5.28 (s, 2H), 3.43 (t, 2H), 3.36 (t, 2H). MS (ESI<sup>+</sup>): <i>m</i>/<i>z</i> = 468.8 [M + H]<sup>+</sup>.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> General Procedures for the Cell Growth Inhibitory Assay</h3><div class="NLM_p last">A human vaginal epidermoid cancer cell line A431 (ATCC, CRL-1555) and a human breast cancer cell line SK-Br3 (ATCC, HTB-30) were used to measure the inhibitory activities of synthesized compounds toward cancer cell growth. Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 4.5 g/L glucose and 1.5 g/L sodium bicarbonate and were supplemented with 10% fetal bovine serum (FBS). In addition, MDA-MB-175, MDA-MB-361, MDA-MB-453, NCI-N87, NCI-H1781, and NCI-H1975 cells were purchased from the American Type Culture Collection (ATCC). JIMT-1 cell line was purchased from DSMZ (Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH) and was incubated in the same conditions as above. MDA-MB-175, MDA-MB-361, and MDA-MB-453 cells were incubated in L-15 medium, and NCI-N87, NCI-H1781, and NCI-H1975 cells were incubated in RPMI medium containing 1 mM sodium pyruvate. All culture media were supplemented with 1% penicillin–streptomycin and 10% fetal bovine serum (FBS). Cells were incubated in a humidified atmosphere under 5% CO<sub>2</sub> except for MDA-MB-175, MDA-MB-361, and MDA-MB-453 cells (CO<sub>2</sub> free) at 37 °C. Cell growth inhibition assays and GI<sub>50</sub> determinations were performed as previously described.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> General Procedures for the Microsomal Stability Assay</h3><div class="NLM_p last">All assays were conducted in duplicate. The incubation mixtures were prepared in E-tube and were contained with 5 μM synthesized analogue, 1 mg/mL liver microsomes (from mouse, rat, dog, and human), and NADPH regeneration solution (1.3 mM NADP<sup>+</sup>, 3.3 mM glucose 6-phosphate, 3.3 mM MgCl<sub>2</sub>, and 0.4 U/mL glucose 6-phosphate dehydrogenase) in 100 mM potassium phosphate buffer solution. Reactions were initiated by the addition of NADPH and kept in a shaking water bath at 37 °C. At the each sampling time, aliquots were removed and added to termination solvent (acetonitrile). The samples were centrifuged for 4–5 min at 13 000 rpm, and the supernatant was subjected to HPLC analysis (HPLC/Agilent 1200 series). In the determination of the in vitro <i>t</i><sub>1/2</sub> (half-life, HL), the analyte peak areas were converted to percentage of drug remaining, using the <i>T</i> = 0 peak area values as 100%. The slope of the linear regression from log percentage remaining versus incubation time relationships (−<i>k</i>) was used in the conversion to the in vitro <i>t</i><sub>1/2</sub>, values by the in vitro <i>t</i><sub>1/2</sub>= −0.693/<i>k</i>. The percent remaining of test compound is calculated compared to the initial quantity at 0 time.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Pharmacokinetic Studies</h3><div class="NLM_p last">Male mice (imprinting control region mice, body-weight range of 27 ± 5 g, iv, <i>n</i> = 3, po, <i>n</i> = 3) and male rats (Sprague–Dawley rats, body-weight range of 250 ± 10 g, iv, <i>n</i> = 3, po, <i>n</i> = 3) were administered analogue <b>19a</b> intravenously via the tail vein at 2 and 1 mg/kg, respectively, or orally at 10 and 5 mg/kg, respectively, by gavage in a solution of 30% PEG400 and 5% ethanol in distilled water. For the in vivo study, <b>19a</b> was prepared as HCl salt. At predetermined times 24 h or more after dosing, 0.3 mL blood was collected from the jugular vein using a tube containing anticoagulant (1000 IU/mL, heparin, 3 μL). The plasma was separated by centrifugation (12 000 rpm, 2 min, Eppendorf). The concentrations of the compound were measured in the plasma using LC/MS/MS after protein precipitation with acetonitrile. The relevant estimated pharmacokinetic parameters for plasma were derived using WinNonlin, version 5.2 (Pharsight).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> General Procedures for the EGFR Enzyme Assay</h3><div class="NLM_p last">An amunt of 10 μL of EGFR enzyme (EGFR<sup>WT</sup>, EGFR<sup>T790M</sup>, HER-2, or HER-4 kinase, Upstate) was added to each well of a 96-well microplate. As an EGFR inhibitor, 10 μL of serially diluted solution of synthesized compounds was added to the individual wells, and the plate was incubated at room temperature for 10 min. Then 10 μL of Poly (Glu, Tyr 4:1, Sigma) and 10 μL of ATP were successively added to initiate a kinase reaction, and the resulting mixture was incubated at room temperature for 1 h. 10 μL of 100 mM EDTA was added to each well, and the mixture was stirred for 5 min to terminate the kinase reaction. Then 10 μL of 10× anti-phosphotyrosine antibody (Pan Vera), 10 μL of 10× protein tyrosine kinase (PTK) green tracer (Pan Vera), and 30 μL of fluorescence polarization (FP)-diluted buffer were added to the reacted mixture, followed by incubation in the dark at room temperature for 30 min. The FP value of each well was determined using a VICTORIII fluorescence meter (Perkin-Elmer) at 488 nm. The IC<sub>50</sub>, i.e., the concentration at which 50% inhibition was observed, was determined by setting the maximum value (0% inhibition) to the polarized light value for a well untreated with EGFR inhibitor and the minimum value (100% inhibition). IC<sub>50</sub> calculations and analysis were carried out using Microsoft Excel.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Prolongation of Phosphorylation Inhibition</h3><div class="NLM_p last">Cells were plated at a density of 5 × 10<sup>5</sup>/well in six-well plates under normal culture conditions (10% FBS and 1% penicillin–streptomycin). After 24 h, the medium was changed to 0.1% FBS medium and cells were incubated for 16 h. Cells were then treated with 1 μM analogue <b>19a</b> for 4 h. Each set was washed 4 times with warmed compound-free medium and incubated for 0 and 8 h. Each set was stimulated with EGF (100 ng/mL) for 5 min. The phosphorylation rates of EGFR or HER-2 were measured by Western blotting.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i61"><a href="/doi/suppl/10.1021/jm201758g">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42024" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42024" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Scheme showing the synthesis of compound <b>21</b> and figure showing prolonged inhibitory results on the phosphorylation of EGFR for compound <b>19a</b>. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm201758g/suppl_file/jm201758g_si_001.pdf">jm201758g_si_001.pdf (114.27 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm201758g" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11355" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11355" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Seung Bum Park</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry, Seoul National University, Seoul 151-747, Korea</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Biophysics and Chemical Biology/Bio-MAX Institute, Seoul National University, Seoul 151-747, Korea</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3447564455465f74475a411a55571a5f46145f5d5947745c555a595d1a575b1a5f46"><span class="__cf_email__" data-cfemail="d3a0b1a3b2a1b893a0bda6fdb2b0fdb8a1">[email protected]</span> <span class="__cf_email__" data-cfemail="c7acaeaab487afa6a9aaaee9a4a8e9acb5">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maeng Sup Kim</span> - <span class="hlFld-Affiliation affiliation">Department of Drug Discovery, Hanmi Research Center, 377-1 Yeongcheon-ri, Dongtan-myeon,
Hwaseong, Gyeonggi-do 445-813, Korea</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5d2e3f2d3c2f361d2e3328733c3e73362f7d3634302e1d353c333034733e3273362f"><span class="__cf_email__" data-cfemail="6310011302110823100d164d02004d0811">[email protected]</span> <span class="__cf_email__" data-cfemail="8ee5e7e3fdcee6efe0e3e7a0ede1a0e5fc">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mi Young Cha</span> - <span class="hlFld-Affiliation affiliation">Department of Drug Discovery, Hanmi Research Center, 377-1 Yeongcheon-ri, Dongtan-myeon,
Hwaseong, Gyeonggi-do 445-813, Korea</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Chemistry, Seoul National University, Seoul 151-747, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kwang-Ok Lee</span> - <span class="hlFld-Affiliation affiliation">Department of Drug Discovery, Hanmi Research Center, 377-1 Yeongcheon-ri, Dongtan-myeon,
Hwaseong, Gyeonggi-do 445-813, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Seok-Jong Kang</span> - <span class="hlFld-Affiliation affiliation">Department of Drug Discovery, Hanmi Research Center, 377-1 Yeongcheon-ri, Dongtan-myeon,
Hwaseong, Gyeonggi-do 445-813, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Young Hee Jung</span> - <span class="hlFld-Affiliation affiliation">Department of Drug Discovery, Hanmi Research Center, 377-1 Yeongcheon-ri, Dongtan-myeon,
Hwaseong, Gyeonggi-do 445-813, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ji Yeon Song</span> - <span class="hlFld-Affiliation affiliation">Department of Drug Discovery, Hanmi Research Center, 377-1 Yeongcheon-ri, Dongtan-myeon,
Hwaseong, Gyeonggi-do 445-813, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kyung Jin Choi</span> - <span class="hlFld-Affiliation affiliation">Department of Drug Discovery, Hanmi Research Center, 377-1 Yeongcheon-ri, Dongtan-myeon,
Hwaseong, Gyeonggi-do 445-813, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joo Yun Byun</span> - <span class="hlFld-Affiliation affiliation">Department of Drug Discovery, Hanmi Research Center, 377-1 Yeongcheon-ri, Dongtan-myeon,
Hwaseong, Gyeonggi-do 445-813, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Han-Jae Lee</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry, Seoul National University, Seoul 151-747, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gwan Sun Lee</span> - <span class="hlFld-Affiliation affiliation">Department of Drug Discovery, Hanmi Research Center, 377-1 Yeongcheon-ri, Dongtan-myeon,
Hwaseong, Gyeonggi-do 445-813, Korea</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i62" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i62"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i63" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i63"> Abbreviations Used</h2><tr><td class="NLM_term">HER</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal inhibitory concentration</p></td></tr><tr><td class="NLM_term">po</td><td class="NLM_def"><p class="first last">per os</p></td></tr><tr><td class="NLM_term">AUC<sub>last</sub></td><td class="NLM_def"><p class="first last">area under the curve from 0 h to last time</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum plasma concentration</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">drug half-life</p></td></tr><tr><td class="NLM_term"><i>F</i></td><td class="NLM_def"><p class="first last">oral bioavailability</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i64">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76637" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76637" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 28 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">Cell signaling by receptor tyrosine kinases</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1016%2FS0092-8674%2800%2900114-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=11057895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2000&pages=211-225&author=J.+Schlessinger&title=Cell+signaling+by+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-225</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review, with 109 refs.  The purpose of this review is to describe general concepts underlying the mechanism of action of RTKs and the signaling pathways that they regulate, while attempting to shed light on the question of how specificity is defined by the action of RTKs, and how a specific biol. response can be generated by the diverse array of signaling pathways activated by all RTKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0AvjN2PpaVbVg90H21EOLACvtfcHk0lgAqDBzvrzvpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D&md5=7b4cacd2513290f3b3e6120b58647654</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900114-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900114-8%26sid%3Dliteratum%253Aachs%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2000%26volume%3D103%26spage%3D211%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Hynes, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span> </span><span class="NLM_article-title">ERBB receptors and cancer: the complexity of targeted inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1038%2Fnrc1609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=15864276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=341-354&author=N.+E.+Hynesauthor=H.+A.+Lane&title=ERBB+receptors+and+cancer%3A+the+complexity+of+targeted+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">ERBB receptors and cancer: the complexity of targeted inhibitors</span></div><div class="casAuthors">Hynes, Nancy E.; Lane, Heidi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  ERBB receptor tyrosine kinases have important roles in human cancer.  In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumors, and clin. studies indicate that they have important roles in tumor etiol. and progression.  Accordingly, these receptors have been intensely studied to understand their importance in cancer biol. and as therapeutic targets, and many ERBB inhibitors are now used in the clinic.  We will discuss the significance of these receptors as clin. targets, in particular the mol. mechanisms underlying response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrimBiy4bn4LrVg90H21EOLACvtfcHk0lgAqDBzvrzvpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D&md5=54a45e004711da7017ee0f016696a36e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1609%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DLane%26aufirst%3DH.%2BA.%26atitle%3DERBB%2520receptors%2520and%2520cancer%253A%2520the%2520complexity%2520of%2520targeted%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D341%26epage%3D354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Yarden, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Untangling the ErbB signaling network</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1038%2F35052073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=11252954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=127-137&author=Y.+Yardenauthor=M.+X.+Sliwkowski&title=Untangling+the+ErbB+signaling+network"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Untangling the ErbB signalling network</span></div><div class="casAuthors">Yarden, Yosef; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-137</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 112 refs.  When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signaling pathways, culminating in responses ranging from cell division to death, motility to adhesion.  The network is often dysregulated in cancer and lends credence to the mantra that mol. understanding yields clin. benefit: over 25,000 women with breast cancer have now been treated with Herceptin, a recombinant antibody designed to block the receptor ErbB2.  Likewise, small-mol. enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clin. testing.  What can this pathway teach us about translating basic science into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhWL1HObvNrVg90H21EOLACvtfcHk0licyDCfv0XTcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D&md5=1561a9666f77fce888be821399870cd6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2F35052073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35052073%26sid%3Dliteratum%253Aachs%26aulast%3DYarden%26aufirst%3DY.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DUntangling%2520the%2520ErbB%2520signaling%2520network%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D127%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuire, W. L.</span><span> </span><span class="NLM_article-title">Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">235</span><span class="NLM_x">, </span> <span class="NLM_fpage">177</span><span class="NLM_x">–</span> <span class="NLM_lpage">182</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1126%2Fscience.3798106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=3798106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADyaL2sXhtVSht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=235&publication_year=1987&pages=177-182&author=D.+J.+Slamonauthor=G.+M.+Clarkauthor=S.+G.+Wongauthor=W.+J.+Levinauthor=A.+Ullrichauthor=W.+L.+McGuire&title=Human+breast+cancer%3A+correlation+of+relapse+and+survival+with+amplification+of+the+HER-2%2Fneu+oncogene"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Human breast cancer:  correlation of relapse and survival with amplification of the HER-2/neu oncogene</span></div><div class="casAuthors">Slamon, Dennis J.; Clark, Gary M.; Wong, Steven G.; Levin, Wendy J.; Ullrich, Axel; McGuire, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">235</span>
        (<span class="NLM_cas:issue">4785</span>),
    <span class="NLM_cas:pages">177-82</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The HER-2/neu oncogene is a member of the erbB-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor.  This gene has been shown to be amplified in human breast cancer cell lines.  In the current study, alterations of the gene in 189 primary human breast cancers were investigated.  HER-2/neu was found to be amplified from 2- to >20-fold in 30% of the tumors.  Correlation of gene amplification with several disease parameters was evaluated.  Amplification of the HER-2neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer.  It retained its significance even when adjustments were made for other known prognostic factors.  Moreover, HER-2/neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-pos. disease.  These data indicate that this gene may play a role in the biol. behavior and(or) pathogenesis of human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWPpNbN8S_QrVg90H21EOLACvtfcHk0licyDCfv0XTcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXhtVSht7s%253D&md5=0889410d6e47651de4d8085e9bbd70d9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.3798106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.3798106%26sid%3Dliteratum%253Aachs%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DClark%26aufirst%3DG.%2BM.%26aulast%3DWong%26aufirst%3DS.%2BG.%26aulast%3DLevin%26aufirst%3DW.%2BJ.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DMcGuire%26aufirst%3DW.%2BL.%26atitle%3DHuman%2520breast%2520cancer%253A%2520correlation%2520of%2520relapse%2520and%2520survival%2520with%2520amplification%2520of%2520the%2520HER-2%252Fneu%2520oncogene%26jtitle%3DScience%26date%3D1987%26volume%3D235%26spage%3D177%26epage%3D182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godolphin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holt, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Udove, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Press, M. F.</span><span> </span><span class="NLM_article-title">Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">244</span><span class="NLM_x">, </span> <span class="NLM_fpage">707</span><span class="NLM_x">–</span> <span class="NLM_lpage">712</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=244&publication_year=1989&pages=707-712&author=D.+J.+Slamonauthor=W.+Godolphinauthor=L.+A.+Jonesauthor=J.+A.+Holtauthor=S.+G.+Wongauthor=D.+E.+Keithauthor=W.+J.+Levinauthor=S.+G.+Stuartauthor=J.+Udoveauthor=A.+Ullrichauthor=M.+F.+Press&title=Studies+of+the+HER-2%2Fneu+proto-oncogene+in+human+breast+and+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DGodolphin%26aufirst%3DW.%26aulast%3DJones%26aufirst%3DL.%2BA.%26aulast%3DHolt%26aufirst%3DJ.%2BA.%26aulast%3DWong%26aufirst%3DS.%2BG.%26aulast%3DKeith%26aufirst%3DD.%2BE.%26aulast%3DLevin%26aufirst%3DW.%2BJ.%26aulast%3DStuart%26aufirst%3DS.%2BG.%26aulast%3DUdove%26aufirst%3DJ.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DPress%26aufirst%3DM.%2BF.%26atitle%3DStudies%2520of%2520the%2520HER-2%252Fneu%2520proto-oncogene%2520in%2520human%2520breast%2520and%2520ovarian%2520cancer%26jtitle%3DScience%26date%3D1989%26volume%3D244%26spage%3D707%26epage%3D712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Nahta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shabaya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozbay, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowe, D. L.</span><span> </span><span class="NLM_article-title">Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens</span> <span class="citation_source-journal">Curr. Pharm. Pharmacogenomics Pers. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="NLM_x">–</span> <span class="NLM_lpage">274</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.2174%2F187569209790112337" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=263-274&author=R.+Nahtaauthor=S.+Shabayaauthor=T.+Ozbayauthor=D.+L.+Rowe&title=Personalizing+HER2-targeted+therapy+in+metastatic+breast+cancer+beyond+HER2+status%3A+what+we+have+learned+from+clinical+specimens"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2174%2F187569209790112337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187569209790112337%26sid%3Dliteratum%253Aachs%26aulast%3DNahta%26aufirst%3DR.%26aulast%3DShabaya%26aufirst%3DS.%26aulast%3DOzbay%26aufirst%3DT.%26aulast%3DRowe%26aufirst%3DD.%2BL.%26atitle%3DPersonalizing%2520HER2-targeted%2520therapy%2520in%2520metastatic%2520breast%2520cancer%2520beyond%2520HER2%2520status%253A%2520what%2520we%2520have%2520learned%2520from%2520clinical%2520specimens%26jtitle%3DCurr.%2520Pharm.%2520Pharmacogenomics%2520Pers.%2520Med.%26date%3D2009%26volume%3D7%26spage%3D263%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Vogel, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cobleigh, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripathy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutheil, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fehrenbacher, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novotny, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burchmore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Press, M.</span><span> </span><span class="NLM_article-title">Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">719</span><span class="NLM_x">–</span> <span class="NLM_lpage">726</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1200%2FJCO.20.3.719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=11821453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsVGmt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=719-726&author=C.+L.+Vogelauthor=M.+A.+Cobleighauthor=D.+Tripathyauthor=J.+C.+Gutheilauthor=L.+N.+Harrisauthor=L.+Fehrenbacherauthor=D.+J.+Slamonauthor=M.+Murphyauthor=W.+F.+Novotnyauthor=M.+Burchmoreauthor=S.+Shakauthor=S.+J.+Stewartauthor=M.+Press&title=Efficacy+and+safety+of+trastuzumab+as+a+single+agent+in+first-line+treatment+of+HER2-overexpressing+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer</span></div><div class="casAuthors">Vogel, Charles L.; Cobleigh, Melody A.; Tripathy, Debu; Gutheil, John C.; Harris, Lyndsay N.; Fehrenbacher, Louis; Slamon, Dennis J.; Murphy, Maureen; Novotny, William F.; Burchmore, Michael; Shak, Steven; Stewart, Stanford J.; Press, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">719-726</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose: To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer.  Patients and Methods: One hundred fourteen women with HER2-overexpressing metastatic breast cancer were randomized to receive first-line treatment with trastuzumab 4 mg/kg loading dose, followed by 2 mg/kg weekly, or a higher 8 mg/kg loading dose, followed by 4 mg/kg weekly.  Results: The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses.  Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochem. (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), resp.  The clin. benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7% resp.  The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) anal. were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), resp.  Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clin. benefit had not experienced disease progression at follow-up at 12 mo or later.  The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%).  Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require addnl. intervention after discontinuation of trastuzumab.  There was no clear evidence of a dose-response relationship for response, survival, or adverse events.  Conclusion: Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4PRsjPrY4wLVg90H21EOLACvtfcHk0lgKgIPySFb3cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsVGmt7o%253D&md5=c29c4d7958fd6d7434c48c63cc58d81d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1200%2FJCO.20.3.719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.20.3.719%26sid%3Dliteratum%253Aachs%26aulast%3DVogel%26aufirst%3DC.%2BL.%26aulast%3DCobleigh%26aufirst%3DM.%2BA.%26aulast%3DTripathy%26aufirst%3DD.%26aulast%3DGutheil%26aufirst%3DJ.%2BC.%26aulast%3DHarris%26aufirst%3DL.%2BN.%26aulast%3DFehrenbacher%26aufirst%3DL.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DMurphy%26aufirst%3DM.%26aulast%3DNovotny%26aufirst%3DW.%2BF.%26aulast%3DBurchmore%26aufirst%3DM.%26aulast%3DShak%26aufirst%3DS.%26aulast%3DStewart%26aufirst%3DS.%2BJ.%26aulast%3DPress%26aufirst%3DM.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520trastuzumab%2520as%2520a%2520single%2520agent%2520in%2520first-line%2520treatment%2520of%2520HER2-overexpressing%2520metastatic%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D719%26epage%3D726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leyland-Jones, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuchs, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paton, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajamonde, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, L.</span><span> </span><span class="NLM_article-title">Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">783</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1056%2FNEJM200103153441101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=11248153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADC%252BD3MXisVGktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=783-792&author=D.+J.+Slamonauthor=B.+Leyland-Jonesauthor=S.+Shakauthor=H.+Fuchsauthor=V.+Patonauthor=A.+Bajamondeauthor=T.+Flemingauthor=W.+Eiermannauthor=J.+Wolterauthor=M.+Pegramauthor=J.+Baselgaauthor=L.+Norton&title=Use+of+chemotherapy+plus+a+monoclonal+antibody+against+HER2+for+metastatic+breast+cancer+that+overexpresses+HER2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</span></div><div class="casAuthors">Slamon, Dennis J.; Leyland-Jones, Brian; Shak, Steven; Fuchs, Hank; Paton, Virginia; Bajamonde, Alex; Fleming, Thomas; Eiermann, Wolfgang; Wolter, Janet; Pegram, Mark; Baselga, Jose; Norton, Larry</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">783-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 % of breast cancers, increasing the aggressiveness of the tumor.  We evaluated the efficacy and safety of trastuzumab, a recombinant monoclonal antibody against HER2, in women with metastatic breast cancer that overexpressed HER2.  We randomly assigned 234 patients to receive std. chemotherapy plus trastuzumab.  Patients who had not previously received adjuvant (postoperative) therapy with an anthracycline were treated with doxorubicin (or epirubicin in the case of 36 women) and cyclophosphamide with (143 women) or without trastuzumab (138 women).  Patients who had previously received adjuvant anthracycline were treated with paclitaxel alone (96 women) or paclitaxel with trastuzumab (92 women).  The addn. of trastuzumab to chemotherapy was assocd. with a longer time to disease progression (median, 7.4 vs. 4.6 mo; P<0.001), a higher rate of objective response (50 % vs. 32 %, P<0.001), a longer duration of response (median, 9.1 vs. 6.1 mo; P<0.001), a lower rate of death at 1 yr (22 % vs. 33 %, P=0.008), longer survival (median survival, 25.1 vs. 20.3 mo; P=0.046), and a 20 % redn. in the risk of death.  The most important adverse event was cardiac dysfunction, which occurred in 27 % of the group given an anthracycline, cyclophosphamide, and trastuzumab; 8 % of the group given an anthracycline and cyclophosphamide alone; 13 % of the group given paclitaxel and trastuzumab; and 1 % of the group given paclitaxel alone.  Although the cardiotoxicity was potentially severe and, in some cases, life-threatening, the symptoms generally improved with std. medical management.  Trastuzumab increases the clin. benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGK_4WWRZLKLVg90H21EOLACvtfcHk0lgKgIPySFb3cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXisVGktrc%253D&md5=81112f11ffc66fc3a898b61e104322b6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJM200103153441101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200103153441101%26sid%3Dliteratum%253Aachs%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DLeyland-Jones%26aufirst%3DB.%26aulast%3DShak%26aufirst%3DS.%26aulast%3DFuchs%26aufirst%3DH.%26aulast%3DPaton%26aufirst%3DV.%26aulast%3DBajamonde%26aufirst%3DA.%26aulast%3DFleming%26aufirst%3DT.%26aulast%3DEiermann%26aufirst%3DW.%26aulast%3DWolter%26aufirst%3DJ.%26aulast%3DPegram%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DNorton%26aufirst%3DL.%26atitle%3DUse%2520of%2520chemotherapy%2520plus%2520a%2520monoclonal%2520antibody%2520against%2520HER2%2520for%2520metastatic%2520breast%2520cancer%2520that%2520overexpresses%2520HER2%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D783%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Wenle, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spector, N. L.</span><span> </span><span class="NLM_article-title">Anti-tumor activity of GW-572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6255</span><span class="NLM_x">–</span> <span class="NLM_lpage">6263</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=6255-6263&author=X.+Wenleauthor=R.+J.+Mullinauthor=B.+R.+Keithauthor=L.+H.+Liuauthor=H.+Maauthor=D.+W.+Rusnakauthor=G.+Owensauthor=K.+J.+Alligoodauthor=N.+L.+Spector&title=Anti-tumor+activity+of+GW-572016%3A+a+dual+tyrosine+kinase+inhibitor+blocks+EGF+activation+of+EGFR%2FerbB2+and+downstream+Erk1%2F2+and+AKT+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWenle%26aufirst%3DX.%26aulast%3DMullin%26aufirst%3DR.%2BJ.%26aulast%3DKeith%26aufirst%3DB.%2BR.%26aulast%3DLiu%26aufirst%3DL.%2BH.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DOwens%26aufirst%3DG.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DSpector%26aufirst%3DN.%2BL.%26atitle%3DAnti-tumor%2520activity%2520of%2520GW-572016%253A%2520a%2520dual%2520tyrosine%2520kinase%2520inhibitor%2520blocks%2520EGF%2520activation%2520of%2520EGFR%252FerbB2%2520and%2520downstream%2520Erk1%252F2%2520and%2520AKT%2520pathways%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26spage%3D6255%26epage%3D6263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Johnston, S. R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leary, A.</span><span> </span><span class="NLM_article-title">Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">453</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1358%2Fdot.2006.42.7.985637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFamsLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=441-453&author=S.+R.+D.+Johnstonauthor=A.+Leary&title=Lapatinib%3A+a+novel+EGFR%2FHER2+tyrosine+kinase+inhibitor+for+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer</span></div><div class="casAuthors">Johnston, Stephen R. D.; Leary, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of Today</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">441-453</span>CODEN:
                <span class="NLM_cas:coden">MDACAP</span>;
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Lapatinib is an oral dual tyrosine kinase inhibitor that targets epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2), both frequently overexpressed in human cancer.  Preclin. data have shown that lapatinib is a potent and selective inhibitor of the tyrosine kinase domain of EGFR and HER2, and tumor cells that overexpress these receptors are growth inhibited by lapatinib both in vitro and in vivo.  Phase I clin. trials have shown that lapatinib is well tolerated, with mild diarrhea and rash the most frequent toxicities, and early evidence of clin. efficacy has been reported esp. in HER2-pos. breast cancer.  Phase II studies have shown activity for lapatinib in trastuzumab-refractory breast cancer either alone or in combination with trastuzumab.  When used as first-line monotherapy for advanced breast cancer, objective tumor responses have been seen in 28% of patients with untreated HER2-pos. advanced breast cancer.  An extensive phase III program in advanced breast cancer is now in progress both for refractory disease and as first-line therapy in combination with chemotherapy with and without trastuzumab, and with endocrine therapy.  Phase II studies have also been conducted in a variety of other tumors, including renal cell cancer.  Parallel biomarker studies are starting to elucidate predictive mol. phenotypes that may indicate likelihood of response to lapatinib, and these may direct future trials with this oral tyrosine kinase inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC9Obf0OXhBLVg90H21EOLACvtfcHk0lhO2nHL8sc39g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFamsLzO&md5=a1ebcf51ffa841d1fe058eebcc1e05fa</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1358%2Fdot.2006.42.7.985637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2006.42.7.985637%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DS.%2BR.%2BD.%26aulast%3DLeary%26aufirst%3DA.%26atitle%3DLapatinib%253A%2520a%2520novel%2520EGFR%252FHER2%2520tyrosine%2520kinase%2520inhibitor%2520for%2520cancer%26jtitle%3DDrugs%2520Today%26date%3D2006%26volume%3D42%26spage%3D441%26epage%3D453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Speyer, J.</span><span> </span><span class="NLM_article-title">Cardiac dysfunction in the trastuzumab clinical experience</span> <span class="citation_source-journal">J. Clin.Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1156</span><span class="NLM_x">–</span> <span class="NLM_lpage">1157</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=11870153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A280%3ADC%252BD387jsFShsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=1156-1157&author=J.+Speyer&title=Cardiac+dysfunction+in+the+trastuzumab+clinical+experience"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac dysfunction in the trastuzumab clinical experience</span></div><div class="casAuthors">Speyer James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1156-7</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTVQSbk-JXyK5ggzHGM8X5CfW6udTcc2eYv0DJlOuVvN7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387jsFShsA%253D%253D&md5=183c1cd38a341395dc7e419ebc4ca089</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSpeyer%26aufirst%3DJ.%26atitle%3DCardiac%2520dysfunction%2520in%2520the%2520trastuzumab%2520clinical%2520experience%26jtitle%3DJ.%2520Clin.Oncol.%26date%3D2002%26volume%3D20%26spage%3D1156%26epage%3D1157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Abraham, J.</span><span> </span><span class="NLM_article-title">Dual HER1/HER2 inhibitor lapatinib in advanced/metastatic breast cancer</span> <span class="citation_source-journal">Commun. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1016%2FS1548-5315%2811%2970050-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=73-78&author=J.+Abraham&title=Dual+HER1%2FHER2+inhibitor+lapatinib+in+advanced%2Fmetastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS1548-5315%2811%2970050-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1548-5315%252811%252970050-X%26sid%3Dliteratum%253Aachs%26aulast%3DAbraham%26aufirst%3DJ.%26atitle%3DDual%2520HER1%252FHER2%2520inhibitor%2520lapatinib%2520in%2520advanced%252Fmetastatic%2520breast%2520cancer%26jtitle%3DCommun.%2520Oncol.%26date%3D2007%26volume%3D4%26spage%3D73%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Nahta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteva, F. J.</span><span> </span><span class="NLM_article-title">Herceptin: mechanisms of action and resistance</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">232</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">138</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1016%2Fj.canlet.2005.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=16458110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWhurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2006&pages=123-138&author=R.+Nahtaauthor=F.+J.+Esteva&title=Herceptin%3A+mechanisms+of+action+and+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Herceptin: mechanisms of action and resistance</span></div><div class="casAuthors">Nahta, Rita; Esteva, Francisco J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-138</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  HER-2 is overexpressed in 20-25% of invasive breast cancers and is assocd. with an aggressive tumor phenotype and reduced survival rate.  The HER-2 status of a tumor is the crit. determinant of response to the HER-2-targeted antibody Herceptin.  Thus, accurate assessment of HER-2 expression levels is essential for identifying breast cancer patients who will benefit from HER-2-targeted therapy.  Herceptin combined with chemotherapy increases response rates, time to disease progression, and survival.  However, the majority of cancers that initially respond to Herceptin begin to progress again within 1 yr.  This review describes mechanisms by which Herceptin inhibits cell growth in breast cancers that overexpress HER-2 and highlights possible mechanisms contributing to Herceptin resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW9LNMTGjHbLVg90H21EOLACvtfcHk0li6GNqpuKvIrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWhurg%253D&md5=39a03694b92804ff42924c1b85a584b5</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2005.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2005.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DNahta%26aufirst%3DR.%26aulast%3DEsteva%26aufirst%3DF.%2BJ.%26atitle%3DHerceptin%253A%2520mechanisms%2520of%2520action%2520and%2520resistance%26jtitle%3DCancer%2520Lett.%26date%3D2006%26volume%3D232%26spage%3D123%26epage%3D138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">O’Brien, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browne, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginther, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arboleda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffy, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donovan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span> </span><span class="NLM_article-title">Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1489</span><span class="NLM_x">–</span> <span class="NLM_lpage">1502</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1158%2F1535-7163.MCT-09-1171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=20501798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFGgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1489-1502&author=N.+A.+O%E2%80%99Brienauthor=B.+C.+Browneauthor=L.+Chowauthor=Y.+Wangauthor=C.+Gintherauthor=J.+Arboledaauthor=M.+J.+Duffyauthor=J.+Crownauthor=N.+O%E2%80%99Donovanauthor=D.+J.+Slamon&title=Activated+phosphoinositide+3-kinase%2FAKT+signaling+confers+resistance+to+trastuzumab+but+not+lapatinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib</span></div><div class="casAuthors">O'Brien, Neil A.; Browne, Brigid C.; Chow, Lucy; Wang, Yuhua; Ginther, Charles; Arboleda, Jane; Duffy, Michael J.; Crown, John; O'Donovan, Norma; Slamon, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1489-1502</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Trastuzumab and lapatinib provide clin. benefit to women with human epidermal growth factor receptor 2 (HER)-pos. breast cancer.  However, not all patients whose tumors contain the HER2 alteration respond.  Consequently, there is an urgent need to identify new predictive factors for these agents.  The aim of this study was to investigate the role of receptor tyrosine kinase signaling and phosphoinositide 3-kinase (PI3K)/AKT pathway activation in conferring resistance to trastuzumab and lapatinib.  To address this question, we evaluated response to trastuzumab and lapatinib in a panel of 18 HER2-amplified cell lines, using both two- and three-dimensional culture.  The SUM-225, HCC-1419, HCC-1954, UACC-893, HCC-1569, UACC-732, JIMT-1, and MDA-453 cell lines were found to be innately resistant to trastuzumab, whereas the MDA-361, MDA-453, HCC-1569, UACC-732, JIMT-1, HCC-202, and UACC-893 cells are innately lapatinib resistant.  Lapatinib was active in de novo (SUM-225, HCC-1419, and HCC-1954) and in a BT-474 cell line with acquired resistance to trastuzumab.  In these cells, trastuzumab had little effect on AKT phosphorylation, whereas lapatinib retained activity through the dephosphorylation of AKT.  Increased phosphorylation of HER2, epidermal growth factor receptor, HER3, and insulin-like growth factor IR correlated with response to lapatinib but not trastuzumab.  Loss of PTEN or the presence of activating mutations in PI3K marked resistance to trastuzumab, but lapatinib response was independent of these factors.  Thus, increased activation of the PI3K/AKT pathway correlates with resistance to trastuzumab, which can be overcome by lapatinib.  In conclusion, pharmacol. targeting of the PI3K/AKT pathway may provide benefit to HER2-pos. breast cancer patients who are resistant to trastuzumab therapy.  Mol Cancer Ther; 9(6); 1489-502.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDln4KA1Sy-LVg90H21EOLACvtfcHk0li6GNqpuKvIrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFGgsrk%253D&md5=b28273c73db0d89ce83e92827d62bbb7</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-1171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-1171%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DN.%2BA.%26aulast%3DBrowne%26aufirst%3DB.%2BC.%26aulast%3DChow%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DArboleda%26aufirst%3DJ.%26aulast%3DDuffy%26aufirst%3DM.%2BJ.%26aulast%3DCrown%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DN.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26atitle%3DActivated%2520phosphoinositide%25203-kinase%252FAKT%2520signaling%2520confers%2520resistance%2520to%2520trastuzumab%2520but%2520not%2520lapatinib%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1489%26epage%3D1502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Köninki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barok, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitkänen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemmilä, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ilvesaro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isola, J.</span><span> </span><span class="NLM_article-title">Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">294</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1016%2Fj.canlet.2010.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=20193978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A280%3ADC%252BC3cvpt1ylsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2010&pages=211-219&author=K.+K%C3%B6ninkiauthor=M.+Barokauthor=M.+Tannerauthor=S.+Staffauthor=J.+Pitk%C3%A4nenauthor=P.+Hemmil%C3%A4author=J.+Ilvesaroauthor=J.+Isola&title=Multiple+molecular+mechanisms+underlying+trastuzumab+and+lapatinib+resistance+in+JIMT-1+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells</span></div><div class="casAuthors">Koninki Katri; Barok Mark; Tanner Minna; Staff Synnove; Pitkanen Jukka; Hemmila Paivikki; Ilvesaro Joanna; Isola Jorma</div><div class="citationInfo"><span class="NLM_cas:title">Cancer letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Trastuzumab plays an important role in breast cancer therapy.  However, a significant fraction of patients do not respond to therapy or they tend to develop resistance shortly after beginning therapy.  Although some resistance mechanisms have been described, it is unclear whether these mechanisms can coexist.  In this study, we analyzed the resistance mechanisms in the breast cancer cell line JIMT-1, a model of intrinsic trastuzumab resistance.  We compared the JIMT-1 cell line with a panel of eight HER-2 positive breast cancer cell lines.  All cell lines were characterized for the phosphatidylinositol 3-kinase (PIK3CA) mutation status, expression levels of the phosphatase and tensin homolog on chromosome 10 (PTEN) and neuregulin-1 (NRG1) mRNA, HER-2 gene copy number, and protein expression.  The results were correlated to the sensitivity to trastuzumab and lapatinib as well as the potency of trastuzumab-mediated antibody-dependent cellular cytotoxicity (ADCC) evoked by trastuzumab.  JIMT-1 cells showed several co-existing drug resistance mechanisms, including an activating mutation of the PIK3CA gene, low expression of PTEN, high expression of NRG1, and relatively low expression of HER-2 receptor protein (despite gene amplification).  All these features were present at variable levels in other cell lines, whereas JIMT-1 was unique in displaying all these factors at the same time.  Unexpectedly, ADCC reaction by normal lymphocytes was equally strong in all HER-2 positive cell lines, without any correlation to molecular markers or direct sensitivity to the drugs.  Resistance to trastuzumab and lapatinib is probably caused by several co-existing molecular mechanisms.  Direct sensitivity to trastuzumab and lapatinib was not correlated with ADCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR84Wu3NDh-W0loaUqgkFHkfW6udTcc2eYAazGoY_Davrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cvpt1ylsQ%253D%253D&md5=ffd542be1a5448568c3ddfcf50f73ccc</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2010.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2010.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6ninki%26aufirst%3DK.%26aulast%3DBarok%26aufirst%3DM.%26aulast%3DTanner%26aufirst%3DM.%26aulast%3DStaff%26aufirst%3DS.%26aulast%3DPitk%25C3%25A4nen%26aufirst%3DJ.%26aulast%3DHemmil%25C3%25A4%26aufirst%3DP.%26aulast%3DIlvesaro%26aufirst%3DJ.%26aulast%3DIsola%26aufirst%3DJ.%26atitle%3DMultiple%2520molecular%2520mechanisms%2520underlying%2520trastuzumab%2520and%2520lapatinib%2520resistance%2520in%2520JIMT-1%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Lett.%26date%3D2010%26volume%3D294%26spage%3D211%26epage%3D219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1087</span><span class="NLM_x">–</span> <span class="NLM_lpage">1092</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1358%2Fdof.2001.026.11.858717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsVyltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2001&pages=1087-1092&author=A.+A.+Adjei&title=Epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy</span></div><div class="casAuthors">Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1087-1092</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases are transmembrane proteins involved in signal transduction.  They propagate growth factor signals from the cell surface to intracellular processes that control crit. functions such as growth, differentiation, angiogenesis and inhibition of apoptosis.  In malignancies, these signaling pathways are often exploited to optimize tumor growth and metastasis.  One such family of receptor tyrosine kinases is the epidermal growth factor receptor (EGFR) tyrosine kinase.  These receptors are overexpressed in a wide variety of epithelial cancers and have been implicated in tumor aggressiveness.  Thus, targeting the EGFR tyrosine kinase has attracted considerable attention.  This review will summarize current preclin. and clin. knowledge of the small-mol. oral inhibitors of the EGFR tyrosine kinase, which include ZD-1839, OSI-774, CI-1033, EKB-569, PKI-166, GW-2016 and BIBX-1382.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfB_TYrS4ANrVg90H21EOLACvtfcHk0liQFXgzbmzQqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsVyltg%253D%253D&md5=1c66b23e86d02cfaa5e719f5c0fcd53e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1358%2Fdof.2001.026.11.858717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2001.026.11.858717%26sid%3Dliteratum%253Aachs%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DDrugs%2520Future%26date%3D2001%26volume%3D26%26spage%3D1087%26epage%3D1092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Renhowe, P. A.</span><span> </span><span class="NLM_article-title">Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy-clinical progress</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">214</span><span class="NLM_x">–</span> <span class="NLM_lpage">224</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2002&pages=214-224&author=P.+A.+Renhowe&title=Inhibitors+of+growth+factor+receptor+kinase-dependent+signaling+pathways+in+anticancer+chemotherapy-clinical+progress"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26atitle%3DInhibitors%2520of%2520growth%2520factor%2520receptor%2520kinase-dependent%2520signaling%2520pathways%2520in%2520anticancer%2520chemotherapy-clinical%2520progress%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2002%26volume%3D5%26spage%3D214%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H.</span><span> </span><span class="NLM_article-title">Synthesis and structure–activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles: the design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020241c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=49-63&author=A.+Wissnerauthor=E.+Overbeekauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=N.+Mamuyaauthor=E.+C.+Rosfjordauthor=C.+Discafaniauthor=R.+Davisauthor=X.+Shiauthor=S.+K.+Rabindranauthor=B.+C.+Gruberauthor=F.+Yeauthor=W.+A.+Hallettauthor=R.+Nilakantanauthor=R.+Shenauthor=Y.+Wangauthor=L.+M.+Greenbergerauthor=H.+Tsou&title=Synthesis+and+structure%E2%80%93activity+relationships+of+6%2C7-disubstituted+4-anilinoquinoline-3-carbonitriles%3A+the+design+of+an+orally+active%2C+irreversible+inhibitor+of+the+tyrosine+kinase+activity+of+the+epidermal+growth+factor+receptor+%28EGFR%29+and+the+human+epidermal+growth+factor+receptor-2+%28HER-2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm020241c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020241c%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DTsou%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%25206%252C7-disubstituted%25204-anilinoquinoline-3-carbonitriles%253A%2520the%2520design%2520of%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520tyrosine%2520kinase%2520activity%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520the%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520%2528HER-2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D49%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Tsou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek-Klumpers, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.+R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Shenauthor=X.+Shiauthor=Y.+F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrogio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himmelsbach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span> </span><span class="NLM_article-title">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4702</span><span class="NLM_x">–</span> <span class="NLM_lpage">4711</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4702-4711&author=D.+Liauthor=L.+Ambrogioauthor=T.+Shimamuraauthor=S.+Kuboauthor=M.+Takahashiauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=G.+I.+Shapiroauthor=A.+Baumauthor=F.+Himmelsbachauthor=W.+J.+Rettigauthor=M.+Meyersonauthor=F.+Solcaauthor=H.+Greulichauthor=K.+K.+Wong&title=BIBW2992%2C+an+irreversible+EGFR%2FHER2+inhibitor+highly+effective+in+preclinical+lung+cancer+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DAmbrogio%26aufirst%3DL.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DBIBW2992%252C%2520an%2520irreversible%2520EGFR%252FHER2%2520inhibitor%2520highly%2520effective%2520in%2520preclinical%2520lung%2520cancer%2520models%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D4702%26epage%3D4711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Kamath, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buolamwini, J. K.</span><span> </span><span class="NLM_article-title">Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=16283677" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=1-26&author=S.+Kamathauthor=J.+K.+Buolamwini&title=Targeting+EGFR+and+HER-2+receptor+tyrosine+kinases+for+cancer+drug+discovery+and+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKamath%26aufirst%3DS.%26aulast%3DBuolamwini%26aufirst%3DJ.%2BK.%26atitle%3DTargeting%2520EGFR%2520and%2520HER-2%2520receptor%2520tyrosine%2520kinases%2520for%2520cancer%2520drug%2520discovery%2520and%2520development%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2006%26spage%3D1%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Shintani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crohin, C. C.</span><span> </span><span class="NLM_article-title">Intragenic mutation analysis of the human epidermal growth factor receptor (EGFR) gene in malignant human oral keratinocytes</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">4142</span><span class="NLM_x">–</span> <span class="NLM_lpage">4147</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=4142-4147&author=S.+Shintaniauthor=K.+Matsuoauthor=C.+C.+Crohin&title=Intragenic+mutation+analysis+of+the+human+epidermal+growth+factor+receptor+%28EGFR%29+gene+in+malignant+human+oral+keratinocytes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShintani%26aufirst%3DS.%26aulast%3DMatsuo%26aufirst%3DK.%26aulast%3DCrohin%26aufirst%3DC.%2BC.%26atitle%3DIntragenic%2520mutation%2520analysis%2520of%2520the%2520human%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520gene%2520in%2520malignant%2520human%2520oral%2520keratinocytes%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D4142%26epage%3D4147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Wildenhain, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackstein, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrulis, I. L.</span><span> </span><span class="NLM_article-title">p185neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">879</span><span class="NLM_x">–</span> <span class="NLM_lpage">883</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1990&pages=879-883&author=Y.+Wildenhainauthor=T.+Pawsonauthor=M.+E.+Blacksteinauthor=I.+L.+Andrulis&title=p185neu+is+phosphorylated+on+tyrosine+in+human+primary+breast+tumors+which+overexpress+neu%2FerbB-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWildenhain%26aufirst%3DY.%26aulast%3DPawson%26aufirst%3DT.%26aulast%3DBlackstein%26aufirst%3DM.%2BE.%26aulast%3DAndrulis%26aufirst%3DI.%2BL.%26atitle%3Dp185neu%2520is%2520phosphorylated%2520on%2520tyrosine%2520in%2520human%2520primary%2520breast%2520tumors%2520which%2520overexpress%2520neu%252FerbB-2%26jtitle%3DOncogene%26date%3D1990%26volume%3D5%26spage%3D879%26epage%3D883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerns, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleintop, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McConnell, O. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huryn, D. M.</span><span> </span><span class="NLM_article-title">Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">453</span><span class="NLM_x">–</span> <span class="NLM_lpage">462</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1177%2F1087057103255988" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=14567798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntlWrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=453-462&author=L.+Diauthor=E.+H.+Kernsauthor=Y.+Hongauthor=T.+A.+Kleintopauthor=O.+J.+McConnellauthor=D.+M.+Huryn&title=Optimization+of+a+higher+throughput+microsomal+stability+screening+assay+for+profiling+drug+discovery+candidates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates</span></div><div class="casAuthors">Di, Li; Kerns, Edward H.; Hong, Yan; Kleintop, Teresa A.; McConnell, Oliver J.; Huryn, Donna M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">453-462</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Metabolic stability plays an important role in the success of drug candidates.  First-pass metab. is one of the major causes of poor oral bioavailability and short half-life.  Traditionally, metabolic stability was evaluated at a later stage of drug discovery and required laborious manual manipulations.  With the advance of high-throughput screening, combinatorial chem., and early profiling of drug-like properties, automated and rapid stability assays are needed to meet the increasing demand of throughput, speed, and reproducibility at earlier stages of drug discovery.  The authors describe optimization of a simple, robust, high-throughput microsomal stability assay developed in a 96-well format.  The assay consists of 2 automated components: robotic sample prepn. for incubation and cleanup and rapid liq. chromatog./mass spectrometry/mass spectrometry (LC/MS/MS) anal. to det. percent remaining of the parent compd.  The reagent solns. and procedural steps were optimized for automation.  Variables affecting assay results were investigated.  The variability introduced by microsome prepns. from different sources (various vendors and batches) was studied and indicates the need for careful control.  Quality control and normalization of the stability results are crit. when applying the screening data, generated at different times or research sites, to discovery projects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZEmYcLkKCtrVg90H21EOLACvtfcHk0lgmf6nWVtoS-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntlWrtbo%253D&md5=0a576434f52b90073d67b81aa4dd3b92</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1177%2F1087057103255988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057103255988%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26aulast%3DHong%26aufirst%3DY.%26aulast%3DKleintop%26aufirst%3DT.%2BA.%26aulast%3DMcConnell%26aufirst%3DO.%2BJ.%26aulast%3DHuryn%26aufirst%3DD.%2BM.%26atitle%3DOptimization%2520of%2520a%2520higher%2520throughput%2520microsomal%2520stability%2520screening%2520assay%2520for%2520profiling%2520drug%2520discovery%2520candidates%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2003%26volume%3D8%26spage%3D453%26epage%3D462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1350</span><span class="NLM_x">–</span> <span class="NLM_lpage">1359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=10534321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1350-1359&issue=11&author=R.+S.+Obach&title=Prediction+of+human+clearance+of+twenty-nine+drugs+from+hepatic+microsomal+intrinsic+clearance+data%3A+an+examination+of+in+vitro+half-life+approach+and+nonspecific+binding+to+microsomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1350-1359</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Twenty-nine drugs of disparate structures and physicochem. properties were used in an examn. of the capability of human liver microsomal lability data ("in vitro T1/2" approach) to be useful in the prediction of human clearance.  Addnl., the potential importance of nonspecific binding to microsomes in the in vitro incubation milieu for the accurate prediction of human clearance was investigated.  The compds. examd. demonstrated a wide range of microsomal metabolic labilities with scaled intrinsic clearance values ranging from less than 0.5 mL/min/kg to 189 mL/min/kg.  Microsomal binding was detd. at microsomal protein concns. used in the lability incubations.  For the 29 compds. studied, unbound fractions in microsomes ranged from 0.11 to 1.0.  Generally, basic compds. demonstrated the greatest extent of binding and neutral and acidic compds. the least extent of binding.  In the projection of human clearance values, basic and neutral compds. were well predicted when all binding considerations (blood and microsome) were disregarded, however, including both binding considerations also yielded reasonable predictions.  Including only blood binding yielded very poor projections of human clearance for these two types of compds.  However, for acidic compds., disregarding all binding considerations yielded poor predictions of human clearance.  It was generally most difficult to accurately predict clearance for this class of compds.; however the accuracy was best when all binding considerations were included.  Overall, inclusion of both blood and microsome binding values gave the best agreement between in vivo clearance values and clearance values projected from in vitro intrinsic clearance data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWp2hUTOxyubVg90H21EOLACvtfcHk0ljoc1sBTNgA_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D&md5=7804cd4dfb131caac45aff9b7a1df901</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DPrediction%2520of%2520human%2520clearance%2520of%2520twenty-nine%2520drugs%2520from%2520hepatic%2520microsomal%2520intrinsic%2520clearance%2520data%253A%2520an%2520examination%2520of%2520in%2520vitro%2520half-life%2520approach%2520and%2520nonspecific%2520binding%2520to%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1999%26volume%3D27%26issue%3D11%26spage%3D1350%26epage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greshock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Annan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halsey, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sathe, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span> </span><span class="NLM_article-title">Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">6871</span><span class="NLM_x">–</span> <span class="NLM_lpage">6878</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=6871-6878&author=L.+Liuauthor=J.+Gregerauthor=H.+Shiauthor=Y.+Liuauthor=J.+Greshockauthor=R.+Annanauthor=W.+Halseyauthor=G.+M.+Satheauthor=A.+Martinauthor=T.+M.+Gilmer&title=Novel+mechanism+of+lapatinib+resistance+in+HER2-positive+breast+tumor+cells%3A+activation+of+AXL"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DGreger%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGreshock%26aufirst%3DJ.%26aulast%3DAnnan%26aufirst%3DR.%26aulast%3DHalsey%26aufirst%3DW.%26aulast%3DSathe%26aufirst%3DG.%2BM.%26aulast%3DMartin%26aufirst%3DA.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26atitle%3DNovel%2520mechanism%2520of%2520lapatinib%2520resistance%2520in%2520HER2-positive%2520breast%2520tumor%2520cells%253A%2520activation%2520of%2520AXL%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D6871%26epage%3D6878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spehar, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arenas-Elliott, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degenhardt, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haws, T. F.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudson-Curtis, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span> </span><span class="NLM_article-title">Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines</span> <span class="citation_source-journal">Cell Proliferation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">580</span><span class="NLM_x">–</span> <span class="NLM_lpage">594</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=580-594&author=D.+W.+Rusnakauthor=K.+J.+Alligoodauthor=R.+J.+Mullinauthor=G.+M.+Speharauthor=C.+Arenas-Elliottauthor=A.+M.+Martinauthor=Y.+Degenhardtauthor=S.+K.+Rudolphauthor=T.+F.+Hawsauthor=B.+L.+Hudson-Curtisauthor=T.+M.+Gilmer&title=Assessment+of+epidermal+growth+factor+receptor+%28EGFR%2C+ErbB1%29+and+HER2+%28ErbB2%29+protein+expression+levels+and+response+to+lapatinib+%28Tykerb%2C+GW572016%29+in+an+expanded+panel+of+human+normal+and+tumour+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DMullin%26aufirst%3DR.%2BJ.%26aulast%3DSpehar%26aufirst%3DG.%2BM.%26aulast%3DArenas-Elliott%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DDegenhardt%26aufirst%3DY.%26aulast%3DRudolph%26aufirst%3DS.%2BK.%26aulast%3DHaws%26aufirst%3DT.%2BF.%26aulast%3DHudson-Curtis%26aufirst%3DB.%2BL.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26atitle%3DAssessment%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%252C%2520ErbB1%2529%2520and%2520HER2%2520%2528ErbB2%2529%2520protein%2520expression%2520levels%2520and%2520response%2520to%2520lapatinib%2520%2528Tykerb%252C%2520GW572016%2529%2520in%2520an%2520expanded%2520panel%2520of%2520human%2520normal%2520and%2520tumour%2520cell%2520lines%26jtitle%3DCell%2520Proliferation%26date%3D2007%26volume%3D40%26spage%3D580%26epage%3D594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Cha, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.-O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. S.</span><span> </span><span class="NLM_article-title">Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6880</span><span class="NLM_x">–</span> <span class="NLM_lpage">6888</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901146p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6880-6888&author=M.+Y.+Chaauthor=K.-O.+Leeauthor=J.+W.+Kimauthor=C.+G.+Leeauthor=J.+Y.+Songauthor=Y.+H.+Kimauthor=G.+S.+Leeauthor=S.+B.+Parkauthor=M.+S.+Kim&title=Discovery+of+a+novel+Her-1%2FHer-2+dual+tyrosine+kinase+inhibitor+for+the+treatment+of+Her-1+selective+inhibitor-resistant+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm901146p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901146p%26sid%3Dliteratum%253Aachs%26aulast%3DCha%26aufirst%3DM.%2BY.%26aulast%3DLee%26aufirst%3DK.-O.%26aulast%3DKim%26aufirst%3DJ.%2BW.%26aulast%3DLee%26aufirst%3DC.%2BG.%26aulast%3DSong%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DLee%26aufirst%3DG.%2BS.%26aulast%3DPark%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DM.%2BS.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520Her-1%252FHer-2%2520dual%2520tyrosine%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520Her-1%2520selective%2520inhibitor-resistant%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6880%26epage%3D6888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 23 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting  Guo</span>, <span class="hlFld-ContribAuthor ">Shutao  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (4)
                                     , 600-620. <a href="https://doi.org/10.1002/cmdc.202000658" title="DOI URL">https://doi.org/10.1002/cmdc.202000658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000658%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDiscovery%252Bof%252BMultitargeted%252BTyrosine%252BKinase%252BInhibitors%252Bas%252BAnticancer%252BAgents%26aulast%3DGuo%26aufirst%3DTing%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D4%26spage%3D600%26epage%3D620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinjia  Yan</span>, <span class="hlFld-ContribAuthor ">Jing  Wen</span>, <span class="hlFld-ContribAuthor ">Lin  Zhou</span>, <span class="hlFld-ContribAuthor ">Lei  Fan</span>, <span class="hlFld-ContribAuthor ">Xiaobo  Wang</span>, <span class="hlFld-ContribAuthor ">Zhi  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Current Scenario of 1,3-oxazole Derivatives for Anticancer Activity. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (21)
                                     , 1916-1937. <a href="https://doi.org/10.2174/1568026620666200624161151" title="DOI URL">https://doi.org/10.2174/1568026620666200624161151</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026620666200624161151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026620666200624161151%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DCurrent%252BScenario%252Bof%252B1%25252C3-oxazole%252BDerivatives%252Bfor%252BAnticancer%252BActivity%26aulast%3DYan%26aufirst%3DXinjia%26date%3D2020%26volume%3D20%26issue%3D21%26spage%3D1916%26epage%3D1937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Supaphorn  Seetaha</span>, <span class="hlFld-ContribAuthor ">Siriluk  Ratanabanyong</span>, <span class="hlFld-ContribAuthor ">Kiattawee  Choowongkomon</span>. </span><span class="cited-content_cbyCitation_article-title">Expression, purification, and characterization of the native intracellular domain of human epidermal growth factor receptors 1 and 2 in Escherichia coli. </span><span class="cited-content_cbyCitation_journal-name">Applied Microbiology and Biotechnology</span><span> <strong>2019,</strong> <em>103 </em>
                                    (20)
                                     , 8427-8438. <a href="https://doi.org/10.1007/s00253-019-10116-6" title="DOI URL">https://doi.org/10.1007/s00253-019-10116-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00253-019-10116-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00253-019-10116-6%26sid%3Dliteratum%253Aachs%26jtitle%3DApplied%2520Microbiology%2520and%2520Biotechnology%26atitle%3DExpression%25252C%252Bpurification%25252C%252Band%252Bcharacterization%252Bof%252Bthe%252Bnative%252Bintracellular%252Bdomain%252Bof%252Bhuman%252Bepidermal%252Bgrowth%252Bfactor%252Breceptors%252B1%252Band%252B2%252Bin%252BEscherichia%252Bcoli%26aulast%3DSeetaha%26aufirst%3DSupaphorn%26date%3D2019%26date%3D2019%26volume%3D103%26issue%3D20%26spage%3D8427%26epage%3D8438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harun M.  Patel</span>, <span class="hlFld-ContribAuthor ">Rahul  Pawara</span>, <span class="hlFld-ContribAuthor ">Sanjay J.  Surana</span>. </span><span class="cited-content_cbyCitation_article-title">Current Approaches in the Development of Covalent Irreversible EGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 45-128. <a href="https://doi.org/10.1016/B978-0-08-102661-8.00003-2" title="DOI URL">https://doi.org/10.1016/B978-0-08-102661-8.00003-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102661-8.00003-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102661-8.00003-2%26sid%3Dliteratum%253Aachs%26atitle%3DCurrent%252BApproaches%252Bin%252Bthe%252BDevelopment%252Bof%252BCovalent%252BIrreversible%252BEGFR%252BInhibitors%26aulast%3DPatel%26aufirst%3DHarun%2BM.%26date%3D2019%26spage%3D45%26epage%3D128%26pub%3DElsevier%26atitle%3DThird%252BGeneration%252BEGFR%252BInhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Viktor  Kolman</span>, <span class="hlFld-ContribAuthor ">Filip  Kalčic</span>, <span class="hlFld-ContribAuthor ">Petr  Jansa</span>, <span class="hlFld-ContribAuthor ">Zdeněk  Zídek</span>, <span class="hlFld-ContribAuthor ">Zlatko  Janeba</span>. </span><span class="cited-content_cbyCitation_article-title">Influence of the C-5 substitution in polysubstituted pyrimidines on inhibition of prostaglandin E2 production. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>156 </em>, 295-301. <a href="https://doi.org/10.1016/j.ejmech.2018.07.010" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.07.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.07.010%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DInfluence%252Bof%252Bthe%252BC-5%252Bsubstitution%252Bin%252Bpolysubstituted%252Bpyrimidines%252Bon%252Binhibition%252Bof%252Bprostaglandin%252BE2%252Bproduction%26aulast%3DKolman%26aufirst%3DViktor%26date%3D2018%26volume%3D156%26spage%3D295%26epage%3D301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huiyan  Deng</span>, <span class="hlFld-ContribAuthor ">Junying  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaojin  Duan</span>, <span class="hlFld-ContribAuthor ">Yueping  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">The relationship between EGFR mutation status and clinic-pathologic features in pulmonary adenocarcinoma. </span><span class="cited-content_cbyCitation_journal-name">Pathology - Research and Practice</span><span> <strong>2018,</strong> <em>214 </em>
                                    (3)
                                     , 450-454. <a href="https://doi.org/10.1016/j.prp.2017.09.008" title="DOI URL">https://doi.org/10.1016/j.prp.2017.09.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.prp.2017.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.prp.2017.09.008%26sid%3Dliteratum%253Aachs%26jtitle%3DPathology%2520-%2520Research%2520and%2520Practice%26atitle%3DThe%252Brelationship%252Bbetween%252BEGFR%252Bmutation%252Bstatus%252Band%252Bclinic-pathologic%252Bfeatures%252Bin%252Bpulmonary%252Badenocarcinoma%26aulast%3DDeng%26aufirst%3DHuiyan%26date%3D2018%26volume%3D214%26issue%3D3%26spage%3D450%26epage%3D454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nulgumnalli Manjunathaiah  Raghavendra</span>, <span class="hlFld-ContribAuthor ">Divya  Pingili</span>, <span class="hlFld-ContribAuthor ">Sundeep  Kadasi</span>, <span class="hlFld-ContribAuthor ">Akhila  Mettu</span>, <span class="hlFld-ContribAuthor ">S.V.U.M.  Prasad</span>. </span><span class="cited-content_cbyCitation_article-title">Dual or multi-targeting inhibitors: The next generation anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 1277-1300. <a href="https://doi.org/10.1016/j.ejmech.2017.10.021" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.10.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.10.021%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual%252Bor%252Bmulti-targeting%252Binhibitors%25253A%252BThe%252Bnext%252Bgeneration%252Banticancer%252Bagents%26aulast%3DRaghavendra%26aufirst%3DNulgumnalli%2BManjunathaiah%26date%3D2018%26volume%3D143%26spage%3D1277%26epage%3D1300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed  Elkamhawy</span>, <span class="hlFld-ContribAuthor ">Sora  Paik</span>, <span class="hlFld-ContribAuthor ">Ahmed H.E.  Hassan</span>, <span class="hlFld-ContribAuthor ">Yong Sup  Lee</span>, <span class="hlFld-ContribAuthor ">Eun Joo  Roh</span>. </span><span class="cited-content_cbyCitation_article-title">Hit discovery of 4-amino- N -(4-(3-(trifluoromethyl)phenoxy)pyrimidin-5-yl)benzamide: A novel EGFR inhibitor from a designed small library. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2017,</strong> <em>75 </em>, 393-405. <a href="https://doi.org/10.1016/j.bioorg.2017.10.009" title="DOI URL">https://doi.org/10.1016/j.bioorg.2017.10.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2017.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2017.10.009%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DHit%252Bdiscovery%252Bof%252B4-amino-%252BN%252B-%2525284-%2525283-%252528trifluoromethyl%252529phenoxy%252529pyrimidin-5-yl%252529benzamide%25253A%252BA%252Bnovel%252BEGFR%252Binhibitor%252Bfrom%252Ba%252Bdesigned%252Bsmall%252Blibrary%26aulast%3DElkamhawy%26aufirst%3DAhmed%26date%3D2017%26volume%3D75%26spage%3D393%26epage%3D405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandra N.  Milik</span>, <span class="hlFld-ContribAuthor ">Deena S.  Lasheen</span>, <span class="hlFld-ContribAuthor ">Rabah A.T.  Serya</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>142 </em>, 131-151. <a href="https://doi.org/10.1016/j.ejmech.2017.07.023" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.07.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.07.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.07.023%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHow%252Bto%252Btrain%252Byour%252Binhibitor%25253A%252BDesign%252Bstrategies%252Bto%252Bovercome%252Bresistance%252Bto%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252Binhibitors%26aulast%3DMilik%26aufirst%3DSandra%2BN.%26date%3D2017%26volume%3D142%26spage%3D131%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weiwei  Han</span>, <span class="hlFld-ContribAuthor ">Yongli  Du</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemistry & Biodiversity</span><span> <strong>2017,</strong> <em>14 </em>
                                    (7)
                                     , e1600372. <a href="https://doi.org/10.1002/cbdv.201600372" title="DOI URL">https://doi.org/10.1002/cbdv.201600372</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbdv.201600372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbdv.201600372%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%2526%2520Biodiversity%26atitle%3DRecent%252BDevelopment%252Bof%252Bthe%252BSecond%252Band%252BThird%252BGeneration%252BIrreversible%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitors%26aulast%3DHan%26aufirst%3DWeiwei%26date%3D2017%26date%3D2017%26volume%3D14%26issue%3D7%26spage%3De1600372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Viktor  Kolman</span>, <span class="hlFld-ContribAuthor ">Petr  Jansa</span>, <span class="hlFld-ContribAuthor ">Filip  Kalčic</span>, <span class="hlFld-ContribAuthor ">Zlatko  Janeba</span>, <span class="hlFld-ContribAuthor ">Zdeněk  Zídek</span>. </span><span class="cited-content_cbyCitation_article-title">Polysubstituted 4,6-bis(hetero)arylpyrimidines as dual inhibitors of nitric oxide and prostaglandin E 2 production. </span><span class="cited-content_cbyCitation_journal-name">Nitric Oxide</span><span> <strong>2017,</strong> <em>67 </em>, 53-57. <a href="https://doi.org/10.1016/j.niox.2017.05.001" title="DOI URL">https://doi.org/10.1016/j.niox.2017.05.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.niox.2017.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.niox.2017.05.001%26sid%3Dliteratum%253Aachs%26jtitle%3DNitric%2520Oxide%26atitle%3DPolysubstituted%252B4%25252C6-bis%252528hetero%252529arylpyrimidines%252Bas%252Bdual%252Binhibitors%252Bof%252Bnitric%252Boxide%252Band%252Bprostaglandin%252BE%252B2%252Bproduction%26aulast%3DKolman%26aufirst%3DViktor%26date%3D2017%26volume%3D67%26spage%3D53%26epage%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D.  Qu</span>, <span class="hlFld-ContribAuthor ">A.  Yan</span>, <span class="hlFld-ContribAuthor ">J. S.  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">SAR and QSAR study on the bioactivities of human epidermal growth factor receptor-2 (HER2) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">SAR and QSAR in Environmental Research</span><span> <strong>2017,</strong> <em>28 </em>
                                    (2)
                                     , 111-132. <a href="https://doi.org/10.1080/1062936X.2017.1284898" title="DOI URL">https://doi.org/10.1080/1062936X.2017.1284898</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1062936X.2017.1284898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1062936X.2017.1284898%26sid%3Dliteratum%253Aachs%26jtitle%3DSAR%2520and%2520QSAR%2520in%2520Environmental%2520Research%26atitle%3DSAR%252Band%252BQSAR%252Bstudy%252Bon%252Bthe%252Bbioactivities%252Bof%252Bhuman%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor-2%252B%252528HER2%252529%252Binhibitors%26aulast%3DQu%26aufirst%3DD.%26date%3D2017%26date%3D2017%26volume%3D28%26issue%3D2%26spage%3D111%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiang-Xiang  Tao</span>, <span class="hlFld-ContribAuthor ">Yong-Tao  Duan</span>, <span class="hlFld-ContribAuthor ">Long-Wang  Chen</span>, <span class="hlFld-ContribAuthor ">Dan-Jie  Tang</span>, <span class="hlFld-ContribAuthor ">Meng-Ru  Yang</span>, <span class="hlFld-ContribAuthor ">Peng-Fei  Wang</span>, <span class="hlFld-ContribAuthor ">Chen  Xu</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of pyrazolyl-nitroimidazole derivatives as potential EGFR/HER-2 kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (2)
                                     , 677-683. <a href="https://doi.org/10.1016/j.bmcl.2015.11.040" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.11.040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.11.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.11.040%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bpyrazolyl-nitroimidazole%252Bderivatives%252Bas%252Bpotential%252BEGFR%25252FHER-2%252Bkinase%252Binhibitors%26aulast%3DTao%26aufirst%3DXiang-Xiang%26date%3D2016%26volume%3D26%26issue%3D2%26spage%3D677%26epage%3D683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hae-Sun  Park</span>, <span class="hlFld-ContribAuthor ">Chaewon  Kim</span>, <span class="hlFld-ContribAuthor ">Myung-Sook  Park</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and synthesis of novel allylthioaralkylthiopyridazines: their antiproliferative activity against MCF-7 and Hep3B cells. </span><span class="cited-content_cbyCitation_journal-name">Archives of Pharmacal Research</span><span> <strong>2015,</strong> <em>38 </em>
                                    (5)
                                     , 791-800. <a href="https://doi.org/10.1007/s12272-014-0416-3" title="DOI URL">https://doi.org/10.1007/s12272-014-0416-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12272-014-0416-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12272-014-0416-3%26sid%3Dliteratum%253Aachs%26jtitle%3DArchives%2520of%2520Pharmacal%2520Research%26atitle%3DDiscovery%252Band%252Bsynthesis%252Bof%252Bnovel%252Ballylthioaralkylthiopyridazines%25253A%252Btheir%252Bantiproliferative%252Bactivity%252Bagainst%252BMCF-7%252Band%252BHep3B%252Bcells%26aulast%3DPark%26aufirst%3DHae-Sun%26date%3D2015%26date%3D2014%26volume%3D38%26issue%3D5%26spage%3D791%26epage%3D800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A V  Galenko</span>, <span class="hlFld-ContribAuthor ">A F  Khlebnikov</span>, <span class="hlFld-ContribAuthor ">M S  Novikov</span>, <span class="hlFld-ContribAuthor ">V V  Pakalnis</span>, <span class="hlFld-ContribAuthor ">N V  Rostovskii</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in isoxazole chemistry. </span><span class="cited-content_cbyCitation_journal-name">Russian Chemical Reviews</span><span> <strong>2015,</strong> <em>84 </em>
                                    (4)
                                     , 335-377. <a href="https://doi.org/10.1070/RCR4503" title="DOI URL">https://doi.org/10.1070/RCR4503</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1070/RCR4503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1070%2FRCR4503%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Chemical%2520Reviews%26atitle%3DRecent%252Badvances%252Bin%252Bisoxazole%252Bchemistry%26aulast%3DGalenko%26aufirst%3DA%2BV%26date%3D2015%26date%3D2015%26volume%3D84%26issue%3D4%26spage%3D335%26epage%3D377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chaewon  Kim</span>, <span class="hlFld-ContribAuthor ">Saet-Byeul  Kim</span>, <span class="hlFld-ContribAuthor ">Myung-Sook  Park</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of novel 3-allylseleno-6-alkylthiopyridazines: their anticancer activity against MCF-7 cells. </span><span class="cited-content_cbyCitation_journal-name">Archives of Pharmacal Research</span><span> <strong>2014,</strong> <em>37 </em>
                                    (4)
                                     , 452-458. <a href="https://doi.org/10.1007/s12272-013-0244-x" title="DOI URL">https://doi.org/10.1007/s12272-013-0244-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12272-013-0244-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12272-013-0244-x%26sid%3Dliteratum%253Aachs%26jtitle%3DArchives%2520of%2520Pharmacal%2520Research%26atitle%3DSynthesis%252Bof%252Bnovel%252B3-allylseleno-6-alkylthiopyridazines%25253A%252Btheir%252Banticancer%252Bactivity%252Bagainst%252BMCF-7%252Bcells%26aulast%3DKim%26aufirst%3DChaewon%26date%3D2014%26date%3D2013%26volume%3D37%26issue%3D4%26spage%3D452%26epage%3D458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rui  Wang</span>, <span class="hlFld-ContribAuthor ">Zai-Qun  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Ferrocene as a functional group enhances the inhibitive effect of dihydropyrimidine on radical-induced oxidation of DNA. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2014,</strong> <em>1 </em>
                                    (7)
                                     , 792. <a href="https://doi.org/10.1039/C4QO00150H" title="DOI URL">https://doi.org/10.1039/C4QO00150H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4QO00150H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4QO00150H%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DFerrocene%252Bas%252Ba%252Bfunctional%252Bgroup%252Benhances%252Bthe%252Binhibitive%252Beffect%252Bof%252Bdihydropyrimidine%252Bon%252Bradical-induced%252Boxidation%252Bof%252BDNA%26aulast%3DWang%26aufirst%3DRui%26date%3D2014%26date%3D2014%26volume%3D1%26issue%3D7%26spage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dong-Dong  Li</span>, <span class="hlFld-ContribAuthor ">Ya-Juan  Qin</span>, <span class="hlFld-ContribAuthor ">Jian  Sun</span>, <span class="hlFld-ContribAuthor ">Jing-Ran  Li</span>, <span class="hlFld-ContribAuthor ">Fei  Fang</span>, <span class="hlFld-ContribAuthor ">Qian-Ru  Du</span>, <span class="hlFld-ContribAuthor ">Yong  Qian</span>, <span class="hlFld-ContribAuthor ">Hai-Bin  Gong</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>, . </span><span class="cited-content_cbyCitation_article-title">Optimization of Substituted 6-Salicyl-4-Anilinoquinazoline Derivatives as Dual EGFR/HER2 Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">PLoS ONE</span><span> <strong>2013,</strong> <em>8 </em>
                                    (8)
                                     , e69427. <a href="https://doi.org/10.1371/journal.pone.0069427" title="DOI URL">https://doi.org/10.1371/journal.pone.0069427</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0069427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0069427%26sid%3Dliteratum%253Aachs%26jtitle%3DPLoS%2520ONE%26atitle%3DOptimization%252Bof%252BSubstituted%252B6-Salicyl-4-Anilinoquinazoline%252BDerivatives%252Bas%252BDual%252BEGFR%25252FHER2%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DLi%26aufirst%3DDong-Dong%26date%3D2013%26date%3D2013%26volume%3D8%26issue%3D8%26spage%3De69427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yongjun  Mao</span>, <span class="hlFld-ContribAuthor ">Wenxiu  Zhu</span>, <span class="hlFld-ContribAuthor ">Xiaoguang  Kong</span>, <span class="hlFld-ContribAuthor ">Zhen  Wang</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Nicholas Kenneth  Terrett</span>, <span class="hlFld-ContribAuthor ">Jingkang  Shen</span>, <span class="hlFld-ContribAuthor ">Jingshan  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel pyrimidine, 3-cyanopyridine and m-amino-N-phenylbenzamide based monocyclic EGFR tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2013,</strong> <em>21 </em>
                                    (11)
                                     , 3090-3104. <a href="https://doi.org/10.1016/j.bmc.2013.03.053" title="DOI URL">https://doi.org/10.1016/j.bmc.2013.03.053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2013.03.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2013.03.053%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bpyrimidine%25252C%252B3-cyanopyridine%252Band%252Bm-amino-N-phenylbenzamide%252Bbased%252Bmonocyclic%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DMao%26aufirst%3DYongjun%26date%3D2013%26volume%3D21%26issue%3D11%26spage%3D3090%26epage%3D3104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nan  Li</span>, <span class="hlFld-ContribAuthor ">Yue  Jin</span>, <span class="hlFld-ContribAuthor ">Li-zhe  Xue</span>, <span class="hlFld-ContribAuthor ">Pei-yong  Li</span>, <span class="hlFld-ContribAuthor ">De-yue  Yan</span>, <span class="hlFld-ContribAuthor ">Xin-yuan  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">188Re-labeled hyperbranched polysulfonamine as a robust tool for targeted cancer diagnosis and radioimmunotherapy. </span><span class="cited-content_cbyCitation_journal-name">Chinese Journal of Polymer Science</span><span> <strong>2013,</strong> <em>31 </em>
                                    (3)
                                     , 530-540. <a href="https://doi.org/10.1007/s10118-013-1242-7" title="DOI URL">https://doi.org/10.1007/s10118-013-1242-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10118-013-1242-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10118-013-1242-7%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Journal%2520of%2520Polymer%2520Science%26atitle%3D188Re-labeled%252Bhyperbranched%252Bpolysulfonamine%252Bas%252Ba%252Brobust%252Btool%252Bfor%252Btargeted%252Bcancer%252Bdiagnosis%252Band%252Bradioimmunotherapy%26aulast%3DLi%26aufirst%3DNan%26date%3D2013%26date%3D2013%26volume%3D31%26issue%3D3%26spage%3D530%26epage%3D540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sanjay  Saha</span>, <span class="hlFld-ContribAuthor ">Ch.  Venkata Ramana Reddy</span>, <span class="hlFld-ContribAuthor ">T.  Chiranjeevi</span>, <span class="hlFld-ContribAuthor ">Uma  Addepally</span>, <span class="hlFld-ContribAuthor ">T.S.  Chinta Rao</span>, <span class="hlFld-ContribAuthor ">Balaram  Patro</span>. </span><span class="cited-content_cbyCitation_article-title">The first total synthesis and biological evaluation of marine natural products ma’edamines A and B. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>23 </em>
                                    (4)
                                     , 1013-1016. <a href="https://doi.org/10.1016/j.bmcl.2012.12.033" title="DOI URL">https://doi.org/10.1016/j.bmcl.2012.12.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2012.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2012.12.033%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DThe%252Bfirst%252Btotal%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bmarine%252Bnatural%252Bproducts%252Bma%2525E2%252580%252599edamines%252BA%252Band%252BB%26aulast%3DSaha%26aufirst%3DSanjay%26date%3D2013%26volume%3D23%26issue%3D4%26spage%3D1013%26epage%3D1016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Caterina  Carmi</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>, <span class="hlFld-ContribAuthor ">Pier Giorgio  Petronini</span>, <span class="hlFld-ContribAuthor ">Roberta R.  Alfieri</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2012,</strong> <em>84 </em>
                                    (11)
                                     , 1388-1399. <a href="https://doi.org/10.1016/j.bcp.2012.07.031" title="DOI URL">https://doi.org/10.1016/j.bcp.2012.07.031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2012.07.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2012.07.031%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DClinical%252Bperspectives%252Bfor%252Birreversible%252Btyrosine%252Bkinase%252Binhibitors%252Bin%252Bcancer%26aulast%3DCarmi%26aufirst%3DCaterina%26date%3D2012%26volume%3D84%26issue%3D11%26spage%3D1388%26epage%3D1399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shilin  Xu</span>, <span class="hlFld-ContribAuthor ">Lianwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Shaohua  Chang</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Yingxue  Liu</span>, <span class="hlFld-ContribAuthor ">Zhang  zhang</span>, <span class="hlFld-ContribAuthor ">Yong  Xu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of new molecules inhibiting epidermal growth factor receptor threonine790→ methionine790 mutant. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2012,</strong> <em>3 </em>
                                    (9)
                                     , 1155. <a href="https://doi.org/10.1039/c2md20078c" title="DOI URL">https://doi.org/10.1039/c2md20078c</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/c2md20078c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2Fc2md20078c%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnew%252Bmolecules%252Binhibiting%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Bthreonine790%2525E2%252586%252592%252Bmethionine790%252Bmutant%26aulast%3DXu%26aufirst%3DShilin%26date%3D2012%26volume%3D3%26issue%3D9%26spage%3D1155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/medium/jm-2011-01758g_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201758g&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/medium/jm-2011-01758g_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative inhibitors of HER-2 tyrosine kinase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201758g&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/medium/jm-2011-01758g_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of novel HER-1/HER-2 dual inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201758g&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/medium/jm-2011-01758g_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201758g&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) <i>N</i>-iodosuccinimide, AcOH, 100 °C; (ii) (a) POCl<sub>3</sub>, reflux, (b) <b>8</b>, 2-propanol, reflux; (iii) (a) <i>N</i>-Boc-propargylamine, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, CuI, TEA, THF, rt; (b) TFA, DCM, rt; (c) acryloyl chloride, NaHCO<sub>3</sub>, aq THF (THF/H<sub>2</sub>O = 5:1), 0 °C; (iv) (a) 3-aminophenylboronic acid, Pd(OAc)<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, MeOH, 70 °C; (b) acryloyl chloride, NaHCO<sub>3</sub>, aq THF (THF/H<sub>2</sub>O = 5:1), 0 °C; (v) (a) trimethylsilyl acetylene, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, CuI, TEA, THF, rt; (b) TBAF, THF, 0 °C; (c) 2-(1,3-dioxoisoindolin-2-yl)-<i>N</i>-hydroxyacetimidoyl chloride, TEA, THF, reflux; (d) hydrazine monohydrate, EtOH, 65 °C; (e) acryloyl chloride, NaHCO<sub>3</sub>, aq THF (THF/H<sub>2</sub>O = 5:1), 0 °C.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/medium/jm-2011-01758g_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201758g&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) (a) formamidine hydrochloride, 160 °C; (b) POCl<sub>3</sub>, SOCl<sub>2</sub>, DIPEA, reflux; (c) <b>8</b>, 2-propanol, reflux; (ii) (a) 2 N NaOH aq solution, EtOH, 80 °C; (b) <span class="smallcaps smallerCapital">dl</span>-serine methyl ester hydrochloride, EDCI, HOBt, DIPEA, DMF, rt; (iii) (a) DAST, DCM, −78 to 0 °C; (b) DBU, CBrCl<sub>3</sub>, DCM, −40 °C to rt; (ix) (a) LAH, THF, 0 °C; (b) NaN<sub>3</sub>, PPh<sub>3</sub>, DMF/CCl<sub>4</sub> (4:1), 90 °C; (c) PPh<sub>3</sub>, H<sub>2</sub>O, THF, 60 °C; (d) acryloyl chloride, NaHCO<sub>3</sub>, aq THF (THF/H<sub>2</sub>O = 5:1), 0 °C.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/medium/jm-2011-01758g_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Binding mode of <b>10d</b> (a) and its analogue with amine at the Y position (b) to the active site of EGFR crystal structure cocrystallized with <b>1</b> (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK">1XKK</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201758g&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/medium/jm-2011-01758g_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-6/jm201758g/production/images/large/jm-2011-01758g_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201758g&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) (a) SOCl<sub>2</sub>, AIBN, CCl<sub>4</sub>, 80 °C; (b) <span class="smallcaps smallerCapital">dl</span>-serine methyl ester hydrochloride, DIPEA, THF, 0 °C to rt; (ii) (a) NH<sub>3</sub> (gas), toluene/EtOH (1:1), sealed tube, 60 °C; (b) DAST, DCM, −78 to 0 °C; (iii) (a) R-NH<sub>2</sub>, 4 N HCl in 1,4-dioxane, <i>t</i>-BuOH, 60 °C; (b) DBU, CBrCl<sub>3</sub>, DCM, −40 °C to rt; (c) LAH, THF, 0 °C; (d) NaN<sub>3</sub>, PPh<sub>3</sub>, DMF/CCl<sub>4</sub> (4:1), 90 °C; (iv) (a) PPh<sub>3</sub>, H<sub>2</sub>O, THF, 60 °C; (b) acryloyl chloride, NaHCO<sub>3</sub>, aq THF (THF/H<sub>2</sub>O = 5:1), 0 °C.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i64">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60640" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60640" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 28 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">Cell signaling by receptor tyrosine kinases</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1016%2FS0092-8674%2800%2900114-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=11057895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2000&pages=211-225&author=J.+Schlessinger&title=Cell+signaling+by+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-225</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review, with 109 refs.  The purpose of this review is to describe general concepts underlying the mechanism of action of RTKs and the signaling pathways that they regulate, while attempting to shed light on the question of how specificity is defined by the action of RTKs, and how a specific biol. response can be generated by the diverse array of signaling pathways activated by all RTKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0AvjN2PpaVbVg90H21EOLACvtfcHk0ljjyigeMjsK8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D&md5=7b4cacd2513290f3b3e6120b58647654</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900114-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900114-8%26sid%3Dliteratum%253Aachs%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2000%26volume%3D103%26spage%3D211%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Hynes, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span> </span><span class="NLM_article-title">ERBB receptors and cancer: the complexity of targeted inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1038%2Fnrc1609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=15864276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=341-354&author=N.+E.+Hynesauthor=H.+A.+Lane&title=ERBB+receptors+and+cancer%3A+the+complexity+of+targeted+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">ERBB receptors and cancer: the complexity of targeted inhibitors</span></div><div class="casAuthors">Hynes, Nancy E.; Lane, Heidi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  ERBB receptor tyrosine kinases have important roles in human cancer.  In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumors, and clin. studies indicate that they have important roles in tumor etiol. and progression.  Accordingly, these receptors have been intensely studied to understand their importance in cancer biol. and as therapeutic targets, and many ERBB inhibitors are now used in the clinic.  We will discuss the significance of these receptors as clin. targets, in particular the mol. mechanisms underlying response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrimBiy4bn4LrVg90H21EOLACvtfcHk0ljjyigeMjsK8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D&md5=54a45e004711da7017ee0f016696a36e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1609%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DLane%26aufirst%3DH.%2BA.%26atitle%3DERBB%2520receptors%2520and%2520cancer%253A%2520the%2520complexity%2520of%2520targeted%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D341%26epage%3D354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Yarden, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Untangling the ErbB signaling network</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1038%2F35052073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=11252954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=127-137&author=Y.+Yardenauthor=M.+X.+Sliwkowski&title=Untangling+the+ErbB+signaling+network"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Untangling the ErbB signalling network</span></div><div class="casAuthors">Yarden, Yosef; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-137</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 112 refs.  When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signaling pathways, culminating in responses ranging from cell division to death, motility to adhesion.  The network is often dysregulated in cancer and lends credence to the mantra that mol. understanding yields clin. benefit: over 25,000 women with breast cancer have now been treated with Herceptin, a recombinant antibody designed to block the receptor ErbB2.  Likewise, small-mol. enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clin. testing.  What can this pathway teach us about translating basic science into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhWL1HObvNrVg90H21EOLACvtfcHk0ljjyigeMjsK8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D&md5=1561a9666f77fce888be821399870cd6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2F35052073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35052073%26sid%3Dliteratum%253Aachs%26aulast%3DYarden%26aufirst%3DY.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DUntangling%2520the%2520ErbB%2520signaling%2520network%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D127%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuire, W. L.</span><span> </span><span class="NLM_article-title">Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">235</span><span class="NLM_x">, </span> <span class="NLM_fpage">177</span><span class="NLM_x">–</span> <span class="NLM_lpage">182</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1126%2Fscience.3798106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=3798106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADyaL2sXhtVSht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=235&publication_year=1987&pages=177-182&author=D.+J.+Slamonauthor=G.+M.+Clarkauthor=S.+G.+Wongauthor=W.+J.+Levinauthor=A.+Ullrichauthor=W.+L.+McGuire&title=Human+breast+cancer%3A+correlation+of+relapse+and+survival+with+amplification+of+the+HER-2%2Fneu+oncogene"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Human breast cancer:  correlation of relapse and survival with amplification of the HER-2/neu oncogene</span></div><div class="casAuthors">Slamon, Dennis J.; Clark, Gary M.; Wong, Steven G.; Levin, Wendy J.; Ullrich, Axel; McGuire, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">235</span>
        (<span class="NLM_cas:issue">4785</span>),
    <span class="NLM_cas:pages">177-82</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The HER-2/neu oncogene is a member of the erbB-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor.  This gene has been shown to be amplified in human breast cancer cell lines.  In the current study, alterations of the gene in 189 primary human breast cancers were investigated.  HER-2/neu was found to be amplified from 2- to >20-fold in 30% of the tumors.  Correlation of gene amplification with several disease parameters was evaluated.  Amplification of the HER-2neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer.  It retained its significance even when adjustments were made for other known prognostic factors.  Moreover, HER-2/neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-pos. disease.  These data indicate that this gene may play a role in the biol. behavior and(or) pathogenesis of human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWPpNbN8S_QrVg90H21EOLACvtfcHk0liZfEUyiXMXxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXhtVSht7s%253D&md5=0889410d6e47651de4d8085e9bbd70d9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.3798106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.3798106%26sid%3Dliteratum%253Aachs%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DClark%26aufirst%3DG.%2BM.%26aulast%3DWong%26aufirst%3DS.%2BG.%26aulast%3DLevin%26aufirst%3DW.%2BJ.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DMcGuire%26aufirst%3DW.%2BL.%26atitle%3DHuman%2520breast%2520cancer%253A%2520correlation%2520of%2520relapse%2520and%2520survival%2520with%2520amplification%2520of%2520the%2520HER-2%252Fneu%2520oncogene%26jtitle%3DScience%26date%3D1987%26volume%3D235%26spage%3D177%26epage%3D182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godolphin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holt, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Udove, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Press, M. F.</span><span> </span><span class="NLM_article-title">Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">244</span><span class="NLM_x">, </span> <span class="NLM_fpage">707</span><span class="NLM_x">–</span> <span class="NLM_lpage">712</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=244&publication_year=1989&pages=707-712&author=D.+J.+Slamonauthor=W.+Godolphinauthor=L.+A.+Jonesauthor=J.+A.+Holtauthor=S.+G.+Wongauthor=D.+E.+Keithauthor=W.+J.+Levinauthor=S.+G.+Stuartauthor=J.+Udoveauthor=A.+Ullrichauthor=M.+F.+Press&title=Studies+of+the+HER-2%2Fneu+proto-oncogene+in+human+breast+and+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DGodolphin%26aufirst%3DW.%26aulast%3DJones%26aufirst%3DL.%2BA.%26aulast%3DHolt%26aufirst%3DJ.%2BA.%26aulast%3DWong%26aufirst%3DS.%2BG.%26aulast%3DKeith%26aufirst%3DD.%2BE.%26aulast%3DLevin%26aufirst%3DW.%2BJ.%26aulast%3DStuart%26aufirst%3DS.%2BG.%26aulast%3DUdove%26aufirst%3DJ.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DPress%26aufirst%3DM.%2BF.%26atitle%3DStudies%2520of%2520the%2520HER-2%252Fneu%2520proto-oncogene%2520in%2520human%2520breast%2520and%2520ovarian%2520cancer%26jtitle%3DScience%26date%3D1989%26volume%3D244%26spage%3D707%26epage%3D712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Nahta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shabaya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozbay, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowe, D. L.</span><span> </span><span class="NLM_article-title">Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens</span> <span class="citation_source-journal">Curr. Pharm. Pharmacogenomics Pers. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="NLM_x">–</span> <span class="NLM_lpage">274</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.2174%2F187569209790112337" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=263-274&author=R.+Nahtaauthor=S.+Shabayaauthor=T.+Ozbayauthor=D.+L.+Rowe&title=Personalizing+HER2-targeted+therapy+in+metastatic+breast+cancer+beyond+HER2+status%3A+what+we+have+learned+from+clinical+specimens"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2174%2F187569209790112337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187569209790112337%26sid%3Dliteratum%253Aachs%26aulast%3DNahta%26aufirst%3DR.%26aulast%3DShabaya%26aufirst%3DS.%26aulast%3DOzbay%26aufirst%3DT.%26aulast%3DRowe%26aufirst%3DD.%2BL.%26atitle%3DPersonalizing%2520HER2-targeted%2520therapy%2520in%2520metastatic%2520breast%2520cancer%2520beyond%2520HER2%2520status%253A%2520what%2520we%2520have%2520learned%2520from%2520clinical%2520specimens%26jtitle%3DCurr.%2520Pharm.%2520Pharmacogenomics%2520Pers.%2520Med.%26date%3D2009%26volume%3D7%26spage%3D263%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Vogel, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cobleigh, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripathy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutheil, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fehrenbacher, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novotny, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burchmore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Press, M.</span><span> </span><span class="NLM_article-title">Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">719</span><span class="NLM_x">–</span> <span class="NLM_lpage">726</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1200%2FJCO.20.3.719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=11821453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsVGmt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=719-726&author=C.+L.+Vogelauthor=M.+A.+Cobleighauthor=D.+Tripathyauthor=J.+C.+Gutheilauthor=L.+N.+Harrisauthor=L.+Fehrenbacherauthor=D.+J.+Slamonauthor=M.+Murphyauthor=W.+F.+Novotnyauthor=M.+Burchmoreauthor=S.+Shakauthor=S.+J.+Stewartauthor=M.+Press&title=Efficacy+and+safety+of+trastuzumab+as+a+single+agent+in+first-line+treatment+of+HER2-overexpressing+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer</span></div><div class="casAuthors">Vogel, Charles L.; Cobleigh, Melody A.; Tripathy, Debu; Gutheil, John C.; Harris, Lyndsay N.; Fehrenbacher, Louis; Slamon, Dennis J.; Murphy, Maureen; Novotny, William F.; Burchmore, Michael; Shak, Steven; Stewart, Stanford J.; Press, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">719-726</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose: To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer.  Patients and Methods: One hundred fourteen women with HER2-overexpressing metastatic breast cancer were randomized to receive first-line treatment with trastuzumab 4 mg/kg loading dose, followed by 2 mg/kg weekly, or a higher 8 mg/kg loading dose, followed by 4 mg/kg weekly.  Results: The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses.  Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochem. (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), resp.  The clin. benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7% resp.  The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) anal. were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), resp.  Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clin. benefit had not experienced disease progression at follow-up at 12 mo or later.  The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%).  Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require addnl. intervention after discontinuation of trastuzumab.  There was no clear evidence of a dose-response relationship for response, survival, or adverse events.  Conclusion: Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4PRsjPrY4wLVg90H21EOLACvtfcHk0liZfEUyiXMXxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsVGmt7o%253D&md5=c29c4d7958fd6d7434c48c63cc58d81d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1200%2FJCO.20.3.719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.20.3.719%26sid%3Dliteratum%253Aachs%26aulast%3DVogel%26aufirst%3DC.%2BL.%26aulast%3DCobleigh%26aufirst%3DM.%2BA.%26aulast%3DTripathy%26aufirst%3DD.%26aulast%3DGutheil%26aufirst%3DJ.%2BC.%26aulast%3DHarris%26aufirst%3DL.%2BN.%26aulast%3DFehrenbacher%26aufirst%3DL.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DMurphy%26aufirst%3DM.%26aulast%3DNovotny%26aufirst%3DW.%2BF.%26aulast%3DBurchmore%26aufirst%3DM.%26aulast%3DShak%26aufirst%3DS.%26aulast%3DStewart%26aufirst%3DS.%2BJ.%26aulast%3DPress%26aufirst%3DM.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520trastuzumab%2520as%2520a%2520single%2520agent%2520in%2520first-line%2520treatment%2520of%2520HER2-overexpressing%2520metastatic%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D719%26epage%3D726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leyland-Jones, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuchs, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paton, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajamonde, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, L.</span><span> </span><span class="NLM_article-title">Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">783</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1056%2FNEJM200103153441101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=11248153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADC%252BD3MXisVGktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=783-792&author=D.+J.+Slamonauthor=B.+Leyland-Jonesauthor=S.+Shakauthor=H.+Fuchsauthor=V.+Patonauthor=A.+Bajamondeauthor=T.+Flemingauthor=W.+Eiermannauthor=J.+Wolterauthor=M.+Pegramauthor=J.+Baselgaauthor=L.+Norton&title=Use+of+chemotherapy+plus+a+monoclonal+antibody+against+HER2+for+metastatic+breast+cancer+that+overexpresses+HER2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</span></div><div class="casAuthors">Slamon, Dennis J.; Leyland-Jones, Brian; Shak, Steven; Fuchs, Hank; Paton, Virginia; Bajamonde, Alex; Fleming, Thomas; Eiermann, Wolfgang; Wolter, Janet; Pegram, Mark; Baselga, Jose; Norton, Larry</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">783-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 % of breast cancers, increasing the aggressiveness of the tumor.  We evaluated the efficacy and safety of trastuzumab, a recombinant monoclonal antibody against HER2, in women with metastatic breast cancer that overexpressed HER2.  We randomly assigned 234 patients to receive std. chemotherapy plus trastuzumab.  Patients who had not previously received adjuvant (postoperative) therapy with an anthracycline were treated with doxorubicin (or epirubicin in the case of 36 women) and cyclophosphamide with (143 women) or without trastuzumab (138 women).  Patients who had previously received adjuvant anthracycline were treated with paclitaxel alone (96 women) or paclitaxel with trastuzumab (92 women).  The addn. of trastuzumab to chemotherapy was assocd. with a longer time to disease progression (median, 7.4 vs. 4.6 mo; P<0.001), a higher rate of objective response (50 % vs. 32 %, P<0.001), a longer duration of response (median, 9.1 vs. 6.1 mo; P<0.001), a lower rate of death at 1 yr (22 % vs. 33 %, P=0.008), longer survival (median survival, 25.1 vs. 20.3 mo; P=0.046), and a 20 % redn. in the risk of death.  The most important adverse event was cardiac dysfunction, which occurred in 27 % of the group given an anthracycline, cyclophosphamide, and trastuzumab; 8 % of the group given an anthracycline and cyclophosphamide alone; 13 % of the group given paclitaxel and trastuzumab; and 1 % of the group given paclitaxel alone.  Although the cardiotoxicity was potentially severe and, in some cases, life-threatening, the symptoms generally improved with std. medical management.  Trastuzumab increases the clin. benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGK_4WWRZLKLVg90H21EOLACvtfcHk0li3Sju7CsANaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXisVGktrc%253D&md5=81112f11ffc66fc3a898b61e104322b6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJM200103153441101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200103153441101%26sid%3Dliteratum%253Aachs%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DLeyland-Jones%26aufirst%3DB.%26aulast%3DShak%26aufirst%3DS.%26aulast%3DFuchs%26aufirst%3DH.%26aulast%3DPaton%26aufirst%3DV.%26aulast%3DBajamonde%26aufirst%3DA.%26aulast%3DFleming%26aufirst%3DT.%26aulast%3DEiermann%26aufirst%3DW.%26aulast%3DWolter%26aufirst%3DJ.%26aulast%3DPegram%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DNorton%26aufirst%3DL.%26atitle%3DUse%2520of%2520chemotherapy%2520plus%2520a%2520monoclonal%2520antibody%2520against%2520HER2%2520for%2520metastatic%2520breast%2520cancer%2520that%2520overexpresses%2520HER2%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D783%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Wenle, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spector, N. L.</span><span> </span><span class="NLM_article-title">Anti-tumor activity of GW-572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6255</span><span class="NLM_x">–</span> <span class="NLM_lpage">6263</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=6255-6263&author=X.+Wenleauthor=R.+J.+Mullinauthor=B.+R.+Keithauthor=L.+H.+Liuauthor=H.+Maauthor=D.+W.+Rusnakauthor=G.+Owensauthor=K.+J.+Alligoodauthor=N.+L.+Spector&title=Anti-tumor+activity+of+GW-572016%3A+a+dual+tyrosine+kinase+inhibitor+blocks+EGF+activation+of+EGFR%2FerbB2+and+downstream+Erk1%2F2+and+AKT+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWenle%26aufirst%3DX.%26aulast%3DMullin%26aufirst%3DR.%2BJ.%26aulast%3DKeith%26aufirst%3DB.%2BR.%26aulast%3DLiu%26aufirst%3DL.%2BH.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DOwens%26aufirst%3DG.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DSpector%26aufirst%3DN.%2BL.%26atitle%3DAnti-tumor%2520activity%2520of%2520GW-572016%253A%2520a%2520dual%2520tyrosine%2520kinase%2520inhibitor%2520blocks%2520EGF%2520activation%2520of%2520EGFR%252FerbB2%2520and%2520downstream%2520Erk1%252F2%2520and%2520AKT%2520pathways%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26spage%3D6255%26epage%3D6263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Johnston, S. R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leary, A.</span><span> </span><span class="NLM_article-title">Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">453</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1358%2Fdot.2006.42.7.985637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFamsLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=441-453&author=S.+R.+D.+Johnstonauthor=A.+Leary&title=Lapatinib%3A+a+novel+EGFR%2FHER2+tyrosine+kinase+inhibitor+for+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer</span></div><div class="casAuthors">Johnston, Stephen R. D.; Leary, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of Today</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">441-453</span>CODEN:
                <span class="NLM_cas:coden">MDACAP</span>;
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Lapatinib is an oral dual tyrosine kinase inhibitor that targets epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2), both frequently overexpressed in human cancer.  Preclin. data have shown that lapatinib is a potent and selective inhibitor of the tyrosine kinase domain of EGFR and HER2, and tumor cells that overexpress these receptors are growth inhibited by lapatinib both in vitro and in vivo.  Phase I clin. trials have shown that lapatinib is well tolerated, with mild diarrhea and rash the most frequent toxicities, and early evidence of clin. efficacy has been reported esp. in HER2-pos. breast cancer.  Phase II studies have shown activity for lapatinib in trastuzumab-refractory breast cancer either alone or in combination with trastuzumab.  When used as first-line monotherapy for advanced breast cancer, objective tumor responses have been seen in 28% of patients with untreated HER2-pos. advanced breast cancer.  An extensive phase III program in advanced breast cancer is now in progress both for refractory disease and as first-line therapy in combination with chemotherapy with and without trastuzumab, and with endocrine therapy.  Phase II studies have also been conducted in a variety of other tumors, including renal cell cancer.  Parallel biomarker studies are starting to elucidate predictive mol. phenotypes that may indicate likelihood of response to lapatinib, and these may direct future trials with this oral tyrosine kinase inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC9Obf0OXhBLVg90H21EOLACvtfcHk0li3Sju7CsANaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFamsLzO&md5=a1ebcf51ffa841d1fe058eebcc1e05fa</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1358%2Fdot.2006.42.7.985637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2006.42.7.985637%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DS.%2BR.%2BD.%26aulast%3DLeary%26aufirst%3DA.%26atitle%3DLapatinib%253A%2520a%2520novel%2520EGFR%252FHER2%2520tyrosine%2520kinase%2520inhibitor%2520for%2520cancer%26jtitle%3DDrugs%2520Today%26date%3D2006%26volume%3D42%26spage%3D441%26epage%3D453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Speyer, J.</span><span> </span><span class="NLM_article-title">Cardiac dysfunction in the trastuzumab clinical experience</span> <span class="citation_source-journal">J. Clin.Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1156</span><span class="NLM_x">–</span> <span class="NLM_lpage">1157</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=11870153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A280%3ADC%252BD387jsFShsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=1156-1157&author=J.+Speyer&title=Cardiac+dysfunction+in+the+trastuzumab+clinical+experience"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac dysfunction in the trastuzumab clinical experience</span></div><div class="casAuthors">Speyer James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1156-7</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTVQSbk-JXyK5ggzHGM8X5CfW6udTcc2eaMszV4sFWxprntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387jsFShsA%253D%253D&md5=183c1cd38a341395dc7e419ebc4ca089</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSpeyer%26aufirst%3DJ.%26atitle%3DCardiac%2520dysfunction%2520in%2520the%2520trastuzumab%2520clinical%2520experience%26jtitle%3DJ.%2520Clin.Oncol.%26date%3D2002%26volume%3D20%26spage%3D1156%26epage%3D1157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Abraham, J.</span><span> </span><span class="NLM_article-title">Dual HER1/HER2 inhibitor lapatinib in advanced/metastatic breast cancer</span> <span class="citation_source-journal">Commun. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1016%2FS1548-5315%2811%2970050-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=73-78&author=J.+Abraham&title=Dual+HER1%2FHER2+inhibitor+lapatinib+in+advanced%2Fmetastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS1548-5315%2811%2970050-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1548-5315%252811%252970050-X%26sid%3Dliteratum%253Aachs%26aulast%3DAbraham%26aufirst%3DJ.%26atitle%3DDual%2520HER1%252FHER2%2520inhibitor%2520lapatinib%2520in%2520advanced%252Fmetastatic%2520breast%2520cancer%26jtitle%3DCommun.%2520Oncol.%26date%3D2007%26volume%3D4%26spage%3D73%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Nahta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteva, F. J.</span><span> </span><span class="NLM_article-title">Herceptin: mechanisms of action and resistance</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">232</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">138</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1016%2Fj.canlet.2005.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=16458110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWhurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2006&pages=123-138&author=R.+Nahtaauthor=F.+J.+Esteva&title=Herceptin%3A+mechanisms+of+action+and+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Herceptin: mechanisms of action and resistance</span></div><div class="casAuthors">Nahta, Rita; Esteva, Francisco J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-138</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  HER-2 is overexpressed in 20-25% of invasive breast cancers and is assocd. with an aggressive tumor phenotype and reduced survival rate.  The HER-2 status of a tumor is the crit. determinant of response to the HER-2-targeted antibody Herceptin.  Thus, accurate assessment of HER-2 expression levels is essential for identifying breast cancer patients who will benefit from HER-2-targeted therapy.  Herceptin combined with chemotherapy increases response rates, time to disease progression, and survival.  However, the majority of cancers that initially respond to Herceptin begin to progress again within 1 yr.  This review describes mechanisms by which Herceptin inhibits cell growth in breast cancers that overexpress HER-2 and highlights possible mechanisms contributing to Herceptin resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW9LNMTGjHbLVg90H21EOLACvtfcHk0lgkSM98WjPDNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWhurg%253D&md5=39a03694b92804ff42924c1b85a584b5</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2005.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2005.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DNahta%26aufirst%3DR.%26aulast%3DEsteva%26aufirst%3DF.%2BJ.%26atitle%3DHerceptin%253A%2520mechanisms%2520of%2520action%2520and%2520resistance%26jtitle%3DCancer%2520Lett.%26date%3D2006%26volume%3D232%26spage%3D123%26epage%3D138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">O’Brien, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browne, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginther, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arboleda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffy, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donovan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span> </span><span class="NLM_article-title">Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1489</span><span class="NLM_x">–</span> <span class="NLM_lpage">1502</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1158%2F1535-7163.MCT-09-1171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=20501798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFGgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1489-1502&author=N.+A.+O%E2%80%99Brienauthor=B.+C.+Browneauthor=L.+Chowauthor=Y.+Wangauthor=C.+Gintherauthor=J.+Arboledaauthor=M.+J.+Duffyauthor=J.+Crownauthor=N.+O%E2%80%99Donovanauthor=D.+J.+Slamon&title=Activated+phosphoinositide+3-kinase%2FAKT+signaling+confers+resistance+to+trastuzumab+but+not+lapatinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib</span></div><div class="casAuthors">O'Brien, Neil A.; Browne, Brigid C.; Chow, Lucy; Wang, Yuhua; Ginther, Charles; Arboleda, Jane; Duffy, Michael J.; Crown, John; O'Donovan, Norma; Slamon, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1489-1502</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Trastuzumab and lapatinib provide clin. benefit to women with human epidermal growth factor receptor 2 (HER)-pos. breast cancer.  However, not all patients whose tumors contain the HER2 alteration respond.  Consequently, there is an urgent need to identify new predictive factors for these agents.  The aim of this study was to investigate the role of receptor tyrosine kinase signaling and phosphoinositide 3-kinase (PI3K)/AKT pathway activation in conferring resistance to trastuzumab and lapatinib.  To address this question, we evaluated response to trastuzumab and lapatinib in a panel of 18 HER2-amplified cell lines, using both two- and three-dimensional culture.  The SUM-225, HCC-1419, HCC-1954, UACC-893, HCC-1569, UACC-732, JIMT-1, and MDA-453 cell lines were found to be innately resistant to trastuzumab, whereas the MDA-361, MDA-453, HCC-1569, UACC-732, JIMT-1, HCC-202, and UACC-893 cells are innately lapatinib resistant.  Lapatinib was active in de novo (SUM-225, HCC-1419, and HCC-1954) and in a BT-474 cell line with acquired resistance to trastuzumab.  In these cells, trastuzumab had little effect on AKT phosphorylation, whereas lapatinib retained activity through the dephosphorylation of AKT.  Increased phosphorylation of HER2, epidermal growth factor receptor, HER3, and insulin-like growth factor IR correlated with response to lapatinib but not trastuzumab.  Loss of PTEN or the presence of activating mutations in PI3K marked resistance to trastuzumab, but lapatinib response was independent of these factors.  Thus, increased activation of the PI3K/AKT pathway correlates with resistance to trastuzumab, which can be overcome by lapatinib.  In conclusion, pharmacol. targeting of the PI3K/AKT pathway may provide benefit to HER2-pos. breast cancer patients who are resistant to trastuzumab therapy.  Mol Cancer Ther; 9(6); 1489-502.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDln4KA1Sy-LVg90H21EOLACvtfcHk0lgkSM98WjPDNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFGgsrk%253D&md5=b28273c73db0d89ce83e92827d62bbb7</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-1171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-1171%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DN.%2BA.%26aulast%3DBrowne%26aufirst%3DB.%2BC.%26aulast%3DChow%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DArboleda%26aufirst%3DJ.%26aulast%3DDuffy%26aufirst%3DM.%2BJ.%26aulast%3DCrown%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DN.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26atitle%3DActivated%2520phosphoinositide%25203-kinase%252FAKT%2520signaling%2520confers%2520resistance%2520to%2520trastuzumab%2520but%2520not%2520lapatinib%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1489%26epage%3D1502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Köninki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barok, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitkänen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemmilä, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ilvesaro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isola, J.</span><span> </span><span class="NLM_article-title">Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">294</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1016%2Fj.canlet.2010.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=20193978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A280%3ADC%252BC3cvpt1ylsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2010&pages=211-219&author=K.+K%C3%B6ninkiauthor=M.+Barokauthor=M.+Tannerauthor=S.+Staffauthor=J.+Pitk%C3%A4nenauthor=P.+Hemmil%C3%A4author=J.+Ilvesaroauthor=J.+Isola&title=Multiple+molecular+mechanisms+underlying+trastuzumab+and+lapatinib+resistance+in+JIMT-1+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells</span></div><div class="casAuthors">Koninki Katri; Barok Mark; Tanner Minna; Staff Synnove; Pitkanen Jukka; Hemmila Paivikki; Ilvesaro Joanna; Isola Jorma</div><div class="citationInfo"><span class="NLM_cas:title">Cancer letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Trastuzumab plays an important role in breast cancer therapy.  However, a significant fraction of patients do not respond to therapy or they tend to develop resistance shortly after beginning therapy.  Although some resistance mechanisms have been described, it is unclear whether these mechanisms can coexist.  In this study, we analyzed the resistance mechanisms in the breast cancer cell line JIMT-1, a model of intrinsic trastuzumab resistance.  We compared the JIMT-1 cell line with a panel of eight HER-2 positive breast cancer cell lines.  All cell lines were characterized for the phosphatidylinositol 3-kinase (PIK3CA) mutation status, expression levels of the phosphatase and tensin homolog on chromosome 10 (PTEN) and neuregulin-1 (NRG1) mRNA, HER-2 gene copy number, and protein expression.  The results were correlated to the sensitivity to trastuzumab and lapatinib as well as the potency of trastuzumab-mediated antibody-dependent cellular cytotoxicity (ADCC) evoked by trastuzumab.  JIMT-1 cells showed several co-existing drug resistance mechanisms, including an activating mutation of the PIK3CA gene, low expression of PTEN, high expression of NRG1, and relatively low expression of HER-2 receptor protein (despite gene amplification).  All these features were present at variable levels in other cell lines, whereas JIMT-1 was unique in displaying all these factors at the same time.  Unexpectedly, ADCC reaction by normal lymphocytes was equally strong in all HER-2 positive cell lines, without any correlation to molecular markers or direct sensitivity to the drugs.  Resistance to trastuzumab and lapatinib is probably caused by several co-existing molecular mechanisms.  Direct sensitivity to trastuzumab and lapatinib was not correlated with ADCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR84Wu3NDh-W0loaUqgkFHkfW6udTcc2eZqh9FaMbX8ybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cvpt1ylsQ%253D%253D&md5=ffd542be1a5448568c3ddfcf50f73ccc</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2010.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2010.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6ninki%26aufirst%3DK.%26aulast%3DBarok%26aufirst%3DM.%26aulast%3DTanner%26aufirst%3DM.%26aulast%3DStaff%26aufirst%3DS.%26aulast%3DPitk%25C3%25A4nen%26aufirst%3DJ.%26aulast%3DHemmil%25C3%25A4%26aufirst%3DP.%26aulast%3DIlvesaro%26aufirst%3DJ.%26aulast%3DIsola%26aufirst%3DJ.%26atitle%3DMultiple%2520molecular%2520mechanisms%2520underlying%2520trastuzumab%2520and%2520lapatinib%2520resistance%2520in%2520JIMT-1%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Lett.%26date%3D2010%26volume%3D294%26spage%3D211%26epage%3D219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1087</span><span class="NLM_x">–</span> <span class="NLM_lpage">1092</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1358%2Fdof.2001.026.11.858717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsVyltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2001&pages=1087-1092&author=A.+A.+Adjei&title=Epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy</span></div><div class="casAuthors">Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1087-1092</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases are transmembrane proteins involved in signal transduction.  They propagate growth factor signals from the cell surface to intracellular processes that control crit. functions such as growth, differentiation, angiogenesis and inhibition of apoptosis.  In malignancies, these signaling pathways are often exploited to optimize tumor growth and metastasis.  One such family of receptor tyrosine kinases is the epidermal growth factor receptor (EGFR) tyrosine kinase.  These receptors are overexpressed in a wide variety of epithelial cancers and have been implicated in tumor aggressiveness.  Thus, targeting the EGFR tyrosine kinase has attracted considerable attention.  This review will summarize current preclin. and clin. knowledge of the small-mol. oral inhibitors of the EGFR tyrosine kinase, which include ZD-1839, OSI-774, CI-1033, EKB-569, PKI-166, GW-2016 and BIBX-1382.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfB_TYrS4ANrVg90H21EOLACvtfcHk0lgkSM98WjPDNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsVyltg%253D%253D&md5=1c66b23e86d02cfaa5e719f5c0fcd53e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1358%2Fdof.2001.026.11.858717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2001.026.11.858717%26sid%3Dliteratum%253Aachs%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DDrugs%2520Future%26date%3D2001%26volume%3D26%26spage%3D1087%26epage%3D1092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Renhowe, P. A.</span><span> </span><span class="NLM_article-title">Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy-clinical progress</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">214</span><span class="NLM_x">–</span> <span class="NLM_lpage">224</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2002&pages=214-224&author=P.+A.+Renhowe&title=Inhibitors+of+growth+factor+receptor+kinase-dependent+signaling+pathways+in+anticancer+chemotherapy-clinical+progress"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26atitle%3DInhibitors%2520of%2520growth%2520factor%2520receptor%2520kinase-dependent%2520signaling%2520pathways%2520in%2520anticancer%2520chemotherapy-clinical%2520progress%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2002%26volume%3D5%26spage%3D214%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H.</span><span> </span><span class="NLM_article-title">Synthesis and structure–activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles: the design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020241c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=49-63&author=A.+Wissnerauthor=E.+Overbeekauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=N.+Mamuyaauthor=E.+C.+Rosfjordauthor=C.+Discafaniauthor=R.+Davisauthor=X.+Shiauthor=S.+K.+Rabindranauthor=B.+C.+Gruberauthor=F.+Yeauthor=W.+A.+Hallettauthor=R.+Nilakantanauthor=R.+Shenauthor=Y.+Wangauthor=L.+M.+Greenbergerauthor=H.+Tsou&title=Synthesis+and+structure%E2%80%93activity+relationships+of+6%2C7-disubstituted+4-anilinoquinoline-3-carbonitriles%3A+the+design+of+an+orally+active%2C+irreversible+inhibitor+of+the+tyrosine+kinase+activity+of+the+epidermal+growth+factor+receptor+%28EGFR%29+and+the+human+epidermal+growth+factor+receptor-2+%28HER-2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm020241c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020241c%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DTsou%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%25206%252C7-disubstituted%25204-anilinoquinoline-3-carbonitriles%253A%2520the%2520design%2520of%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520tyrosine%2520kinase%2520activity%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520the%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520%2528HER-2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D49%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Tsou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek-Klumpers, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.+R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Shenauthor=X.+Shiauthor=Y.+F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrogio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himmelsbach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span> </span><span class="NLM_article-title">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4702</span><span class="NLM_x">–</span> <span class="NLM_lpage">4711</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4702-4711&author=D.+Liauthor=L.+Ambrogioauthor=T.+Shimamuraauthor=S.+Kuboauthor=M.+Takahashiauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=G.+I.+Shapiroauthor=A.+Baumauthor=F.+Himmelsbachauthor=W.+J.+Rettigauthor=M.+Meyersonauthor=F.+Solcaauthor=H.+Greulichauthor=K.+K.+Wong&title=BIBW2992%2C+an+irreversible+EGFR%2FHER2+inhibitor+highly+effective+in+preclinical+lung+cancer+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DAmbrogio%26aufirst%3DL.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DBIBW2992%252C%2520an%2520irreversible%2520EGFR%252FHER2%2520inhibitor%2520highly%2520effective%2520in%2520preclinical%2520lung%2520cancer%2520models%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D4702%26epage%3D4711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Kamath, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buolamwini, J. K.</span><span> </span><span class="NLM_article-title">Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=16283677" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=1-26&author=S.+Kamathauthor=J.+K.+Buolamwini&title=Targeting+EGFR+and+HER-2+receptor+tyrosine+kinases+for+cancer+drug+discovery+and+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKamath%26aufirst%3DS.%26aulast%3DBuolamwini%26aufirst%3DJ.%2BK.%26atitle%3DTargeting%2520EGFR%2520and%2520HER-2%2520receptor%2520tyrosine%2520kinases%2520for%2520cancer%2520drug%2520discovery%2520and%2520development%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2006%26spage%3D1%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Shintani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crohin, C. C.</span><span> </span><span class="NLM_article-title">Intragenic mutation analysis of the human epidermal growth factor receptor (EGFR) gene in malignant human oral keratinocytes</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">4142</span><span class="NLM_x">–</span> <span class="NLM_lpage">4147</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=4142-4147&author=S.+Shintaniauthor=K.+Matsuoauthor=C.+C.+Crohin&title=Intragenic+mutation+analysis+of+the+human+epidermal+growth+factor+receptor+%28EGFR%29+gene+in+malignant+human+oral+keratinocytes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShintani%26aufirst%3DS.%26aulast%3DMatsuo%26aufirst%3DK.%26aulast%3DCrohin%26aufirst%3DC.%2BC.%26atitle%3DIntragenic%2520mutation%2520analysis%2520of%2520the%2520human%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520gene%2520in%2520malignant%2520human%2520oral%2520keratinocytes%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D4142%26epage%3D4147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Wildenhain, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackstein, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrulis, I. L.</span><span> </span><span class="NLM_article-title">p185neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">879</span><span class="NLM_x">–</span> <span class="NLM_lpage">883</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1990&pages=879-883&author=Y.+Wildenhainauthor=T.+Pawsonauthor=M.+E.+Blacksteinauthor=I.+L.+Andrulis&title=p185neu+is+phosphorylated+on+tyrosine+in+human+primary+breast+tumors+which+overexpress+neu%2FerbB-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWildenhain%26aufirst%3DY.%26aulast%3DPawson%26aufirst%3DT.%26aulast%3DBlackstein%26aufirst%3DM.%2BE.%26aulast%3DAndrulis%26aufirst%3DI.%2BL.%26atitle%3Dp185neu%2520is%2520phosphorylated%2520on%2520tyrosine%2520in%2520human%2520primary%2520breast%2520tumors%2520which%2520overexpress%2520neu%252FerbB-2%26jtitle%3DOncogene%26date%3D1990%26volume%3D5%26spage%3D879%26epage%3D883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerns, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleintop, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McConnell, O. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huryn, D. M.</span><span> </span><span class="NLM_article-title">Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">453</span><span class="NLM_x">–</span> <span class="NLM_lpage">462</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm201758g&amp;key=10.1177%2F1087057103255988" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=14567798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntlWrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=453-462&author=L.+Diauthor=E.+H.+Kernsauthor=Y.+Hongauthor=T.+A.+Kleintopauthor=O.+J.+McConnellauthor=D.+M.+Huryn&title=Optimization+of+a+higher+throughput+microsomal+stability+screening+assay+for+profiling+drug+discovery+candidates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates</span></div><div class="casAuthors">Di, Li; Kerns, Edward H.; Hong, Yan; Kleintop, Teresa A.; McConnell, Oliver J.; Huryn, Donna M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">453-462</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Metabolic stability plays an important role in the success of drug candidates.  First-pass metab. is one of the major causes of poor oral bioavailability and short half-life.  Traditionally, metabolic stability was evaluated at a later stage of drug discovery and required laborious manual manipulations.  With the advance of high-throughput screening, combinatorial chem., and early profiling of drug-like properties, automated and rapid stability assays are needed to meet the increasing demand of throughput, speed, and reproducibility at earlier stages of drug discovery.  The authors describe optimization of a simple, robust, high-throughput microsomal stability assay developed in a 96-well format.  The assay consists of 2 automated components: robotic sample prepn. for incubation and cleanup and rapid liq. chromatog./mass spectrometry/mass spectrometry (LC/MS/MS) anal. to det. percent remaining of the parent compd.  The reagent solns. and procedural steps were optimized for automation.  Variables affecting assay results were investigated.  The variability introduced by microsome prepns. from different sources (various vendors and batches) was studied and indicates the need for careful control.  Quality control and normalization of the stability results are crit. when applying the screening data, generated at different times or research sites, to discovery projects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZEmYcLkKCtrVg90H21EOLACvtfcHk0lhs82UpAVKKYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntlWrtbo%253D&md5=0a576434f52b90073d67b81aa4dd3b92</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1177%2F1087057103255988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057103255988%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26aulast%3DHong%26aufirst%3DY.%26aulast%3DKleintop%26aufirst%3DT.%2BA.%26aulast%3DMcConnell%26aufirst%3DO.%2BJ.%26aulast%3DHuryn%26aufirst%3DD.%2BM.%26atitle%3DOptimization%2520of%2520a%2520higher%2520throughput%2520microsomal%2520stability%2520screening%2520assay%2520for%2520profiling%2520drug%2520discovery%2520candidates%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2003%26volume%3D8%26spage%3D453%26epage%3D462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1350</span><span class="NLM_x">–</span> <span class="NLM_lpage">1359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm201758g&amp;key=10534321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm201758g&amp;key=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1350-1359&issue=11&author=R.+S.+Obach&title=Prediction+of+human+clearance+of+twenty-nine+drugs+from+hepatic+microsomal+intrinsic+clearance+data%3A+an+examination+of+in+vitro+half-life+approach+and+nonspecific+binding+to+microsomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1350-1359</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Twenty-nine drugs of disparate structures and physicochem. properties were used in an examn. of the capability of human liver microsomal lability data ("in vitro T1/2" approach) to be useful in the prediction of human clearance.  Addnl., the potential importance of nonspecific binding to microsomes in the in vitro incubation milieu for the accurate prediction of human clearance was investigated.  The compds. examd. demonstrated a wide range of microsomal metabolic labilities with scaled intrinsic clearance values ranging from less than 0.5 mL/min/kg to 189 mL/min/kg.  Microsomal binding was detd. at microsomal protein concns. used in the lability incubations.  For the 29 compds. studied, unbound fractions in microsomes ranged from 0.11 to 1.0.  Generally, basic compds. demonstrated the greatest extent of binding and neutral and acidic compds. the least extent of binding.  In the projection of human clearance values, basic and neutral compds. were well predicted when all binding considerations (blood and microsome) were disregarded, however, including both binding considerations also yielded reasonable predictions.  Including only blood binding yielded very poor projections of human clearance for these two types of compds.  However, for acidic compds., disregarding all binding considerations yielded poor predictions of human clearance.  It was generally most difficult to accurately predict clearance for this class of compds.; however the accuracy was best when all binding considerations were included.  Overall, inclusion of both blood and microsome binding values gave the best agreement between in vivo clearance values and clearance values projected from in vitro intrinsic clearance data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWp2hUTOxyubVg90H21EOLACvtfcHk0lhs82UpAVKKYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D&md5=7804cd4dfb131caac45aff9b7a1df901</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DPrediction%2520of%2520human%2520clearance%2520of%2520twenty-nine%2520drugs%2520from%2520hepatic%2520microsomal%2520intrinsic%2520clearance%2520data%253A%2520an%2520examination%2520of%2520in%2520vitro%2520half-life%2520approach%2520and%2520nonspecific%2520binding%2520to%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1999%26volume%3D27%26issue%3D11%26spage%3D1350%26epage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greshock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Annan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halsey, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sathe, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span> </span><span class="NLM_article-title">Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">6871</span><span class="NLM_x">–</span> <span class="NLM_lpage">6878</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=6871-6878&author=L.+Liuauthor=J.+Gregerauthor=H.+Shiauthor=Y.+Liuauthor=J.+Greshockauthor=R.+Annanauthor=W.+Halseyauthor=G.+M.+Satheauthor=A.+Martinauthor=T.+M.+Gilmer&title=Novel+mechanism+of+lapatinib+resistance+in+HER2-positive+breast+tumor+cells%3A+activation+of+AXL"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DGreger%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGreshock%26aufirst%3DJ.%26aulast%3DAnnan%26aufirst%3DR.%26aulast%3DHalsey%26aufirst%3DW.%26aulast%3DSathe%26aufirst%3DG.%2BM.%26aulast%3DMartin%26aufirst%3DA.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26atitle%3DNovel%2520mechanism%2520of%2520lapatinib%2520resistance%2520in%2520HER2-positive%2520breast%2520tumor%2520cells%253A%2520activation%2520of%2520AXL%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D6871%26epage%3D6878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spehar, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arenas-Elliott, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degenhardt, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haws, T. F.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudson-Curtis, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span> </span><span class="NLM_article-title">Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines</span> <span class="citation_source-journal">Cell Proliferation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">580</span><span class="NLM_x">–</span> <span class="NLM_lpage">594</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=580-594&author=D.+W.+Rusnakauthor=K.+J.+Alligoodauthor=R.+J.+Mullinauthor=G.+M.+Speharauthor=C.+Arenas-Elliottauthor=A.+M.+Martinauthor=Y.+Degenhardtauthor=S.+K.+Rudolphauthor=T.+F.+Hawsauthor=B.+L.+Hudson-Curtisauthor=T.+M.+Gilmer&title=Assessment+of+epidermal+growth+factor+receptor+%28EGFR%2C+ErbB1%29+and+HER2+%28ErbB2%29+protein+expression+levels+and+response+to+lapatinib+%28Tykerb%2C+GW572016%29+in+an+expanded+panel+of+human+normal+and+tumour+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DMullin%26aufirst%3DR.%2BJ.%26aulast%3DSpehar%26aufirst%3DG.%2BM.%26aulast%3DArenas-Elliott%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DDegenhardt%26aufirst%3DY.%26aulast%3DRudolph%26aufirst%3DS.%2BK.%26aulast%3DHaws%26aufirst%3DT.%2BF.%26aulast%3DHudson-Curtis%26aufirst%3DB.%2BL.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26atitle%3DAssessment%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%252C%2520ErbB1%2529%2520and%2520HER2%2520%2528ErbB2%2529%2520protein%2520expression%2520levels%2520and%2520response%2520to%2520lapatinib%2520%2528Tykerb%252C%2520GW572016%2529%2520in%2520an%2520expanded%2520panel%2520of%2520human%2520normal%2520and%2520tumour%2520cell%2520lines%26jtitle%3DCell%2520Proliferation%26date%3D2007%26volume%3D40%26spage%3D580%26epage%3D594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Cha, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.-O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. S.</span><span> </span><span class="NLM_article-title">Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6880</span><span class="NLM_x">–</span> <span class="NLM_lpage">6888</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901146p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6880-6888&author=M.+Y.+Chaauthor=K.-O.+Leeauthor=J.+W.+Kimauthor=C.+G.+Leeauthor=J.+Y.+Songauthor=Y.+H.+Kimauthor=G.+S.+Leeauthor=S.+B.+Parkauthor=M.+S.+Kim&title=Discovery+of+a+novel+Her-1%2FHer-2+dual+tyrosine+kinase+inhibitor+for+the+treatment+of+Her-1+selective+inhibitor-resistant+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm901146p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901146p%26sid%3Dliteratum%253Aachs%26aulast%3DCha%26aufirst%3DM.%2BY.%26aulast%3DLee%26aufirst%3DK.-O.%26aulast%3DKim%26aufirst%3DJ.%2BW.%26aulast%3DLee%26aufirst%3DC.%2BG.%26aulast%3DSong%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DLee%26aufirst%3DG.%2BS.%26aulast%3DPark%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DM.%2BS.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520Her-1%252FHer-2%2520dual%2520tyrosine%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520Her-1%2520selective%2520inhibitor-resistant%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6880%26epage%3D6888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK','PDB','1XKK'); return false;">PDB: 1XKK</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i61"><a href="/doi/suppl/10.1021/jm201758g">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_24783"></div></div></div></div></div><hr /></hr><p class="last">Scheme showing the synthesis of compound <b>21</b> and figure showing prolonged inhibitory results on the phosphorylation of EGFR for compound <b>19a</b>. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm201758g/suppl_file/jm201758g_si_001.pdf">jm201758g_si_001.pdf (114.27 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm201758g&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Fjm201758g%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-6" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm201758g" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a7e273e153ce8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
